## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

## Form 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022

OR

□ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

## COMMISSION FILE NUMBER: 1-33901 Oaktree Specialty Lending Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

**DELAWARE** (State or jurisdiction of incorporation or organization)

333 South Grand Avenue, 28th Floor Los Angeles, CA (Address of principal executive office) 26-1219283 (I.R.S. Employer Identification No.)

**90071** (*Zip Code*)

# REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (213) 830-6300

## SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value \$0.01 per share	OCSL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  $\square$  NO  $\square$ 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES  $\square$  NO  $\square$ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	Accelerated filer □	Non-accelerated filer □	Smaller reporting company $\Box$
Emerging growth company $\Box$	If an emerging growth company, ir extended transition period for com- provided pursuant to Section 13(a)	plying with any new or revised	istrant has elected not to use the financial accounting standards □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES  $\Box$  NO  $\square$ 

The registrant had 183,374,250 shares of common stock outstanding as of August 2, 2022.

## OAKTREE SPECIALTY LENDING CORPORATION FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2022

## TABLE OF CONTENTS

## PART I --- FINANCIAL INFORMATION

<u>Item 1.</u>	Consolidated Financial Statements:	
	Consolidated Statements of Assets and Liabilities as of June 30, 2022 (unaudited) and September 30, 2021	<u>2</u>
	Consolidated Statements of Operations (unaudited) for the three and nine months ended June 30, 2022 and 2021	<u>3</u>
	Consolidated Statements of Changes in Net Assets (unaudited) for the three and nine months ended June 30, 2022 and 2021	<u>4</u>
	Consolidated Statements of Cash Flows (unaudited) for the nine months ended June 30, 2022 and 2021	<u>5</u>
	Consolidated Schedule of Investments (unaudited) as of June 30, 2022	<u>6</u>
	Consolidated Schedule of Investments as of September 30, 2021	<u>19</u>
	Notes to Consolidated Financial Statements (unaudited)	<u>31</u>
<u>Item 2.</u>	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>83</u>
<u>Item 3.</u>	Quantitative and Qualitative Disclosures about Market Risk	<u>102</u>
<u>Item 4.</u>	Controls and Procedures	<u>104</u>
	PART II — OTHER INFORMATION	
<u>Item 1.</u>	Legal Proceedings	<u>104</u>
Item 1A.	Risk Factors	<u>104</u>
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds	<u>104</u>
<u>Item 3.</u>	Defaults Upon Senior Securities	<u>104</u>
<u>Item 4.</u>	Mine Safety Disclosures	<u>104</u>
<u>Item 5.</u>	Other Information	<u>105</u>
<u>Item 6.</u>	Exhibits	<u>105</u>
Signatures	3	<u>105</u>

## PART I - FINANCIAL INFORMATION

## Oaktree Specialty Lending Corporation Consolidated Statements of Assets and Liabilities (in thousands, except per share amounts)

		ne 30, 2022 naudited)	Se	ptember 30, 2021
ASSETS				
Investments at fair value:				
Control investments (cost June 30, 2022: \$262,244; cost September 30, 2021: \$283,599)	\$	222,858	\$	270,765
Affiliate investments (cost June 30, 2022: \$24,617; cost September 30, 2021: \$18,763)		23,427		18,289
Non-control/Non-affiliate investments (cost June 30, 2022: \$2,378,626; cost September 30, 2021: \$2,236,759)		2,319,104		2,267,575
Total investments at fair value (cost June 30, 2022: \$2,665,487; cost September 30, 2021: \$2,539,121)	-	2,565,389	-	2,556,629
Cash and cash equivalents		34,306		29,334
Restricted cash		2,009		2,301
Interest, dividends and fees receivable		29,130		22,125
Due from portfolio companies		6,881		1,990
Receivables from unsettled transactions		3,274		8,150
Due from broker		36,340		1,640
Deferred financing costs		7,918		9,274
Deferred offering costs		32		34
Deferred tax asset, net		1,698		714
Derivative assets at fair value		1,134		1,912
Other assets		1,267		2,284
Total assets	\$	2,689,378	\$	2,636,387
LIABILITIES AND NET ASSETS	_			
Liabilities:				
Accounts payable, accrued expenses and other liabilities	\$	2,324	\$	3,024
Base management fee and incentive fee payable		15,563		32,649
Due to affiliate		3,540		4,357
Interest payable		8,356		4,597
Director fees payable		38		_
Payables from unsettled transactions		8,556		8,086
Derivative liability at fair value		30,866		2,108
Credit facilities payable		745,000		630,000
Unsecured notes payable (net of \$5,390 and \$6,501 of unamortized financing costs as of June 30, 2022 and September 30, 2021, respectively)		611,606		638,743
Total liabilities		1,425,849	-	1,323,564
Commitments and contingencies (Note 13)		, ,		, ,
Net assets:				
Common stock, \$0.01 par value per share, 250,000 shares authorized; 183,374 and 180,361 shares issued and outstanding as of June 30, 2022 and September 30, 2021, respectively		1,834		1,804
Additional paid-in-capital		1,826,498		1,804,354
Accumulated overdistributed earnings		(564,803)		(493,335)
Total net assets (equivalent to \$6.89 and \$7.28 per common share as of June 30, 2022 and September 30, 2021, respectively) (Note 11)		1,263,529		1,312,823
Total liabilities and net assets		2,689,378	\$	2,636,387
	_	,, <del>.</del>	_	, <u>,</u>

## Oaktree Specialty Lending Corporation Consolidated Statements of Operations (in thousands, except per share amounts) (unaudited)

(	Three months ended June 30, 2022	Three months ended June 30, 2021	Nine months ended June 30, 2022	Nine months ended June 30, 2021
Interest income:				
Control investments	\$ 3,400	\$ 3,405	\$ 10,214	\$ 8,122
Affiliate investments	470	189	1,170	437
Non-control/Non-affiliate investments	50,707	48,403	155,656	110,720
Interest on cash and cash equivalents	151	2	157	8
Total interest income	54,728	51,999	167,197	119,287
PIK interest income:				
Non-control/Non-affiliate investments	5,178	4,597	14,515	11,487
Total PIK interest income	5,178	4,597	14,515	11,487
Fee income:				
Control investments	12	13	38	46
Affiliate investments	5	5	15	15
Non-control/Non-affiliate investments	2,258	7,805	5,039	13,392
Total fee income	2,275	7,823	5,092	13,453
Dividend income:				
Control investments	875	1,019	5,491	1,358
Non-control/Non-affiliate investments	81	_	81	_
Total dividend income	956	1,019	5,572	1,358
Total investment income	63,137	65,438	192,376	145,585
Expenses:		,		
Base management fee	9,819	8,905	29,853	22,520
Part I incentive fee	6,497	6,990	19,658	15,583
Part II incentive fee	(6,796)		(8,791)	15,986
Professional fees	885	1,059	3,029	2,943
Directors fees	160	147	443	447
Interest expense	11,870	8,823	31,178	21,486
Administrator expense	271	421	968	1,047
General and administrative expenses	811	716	2,217	2,009
Total expenses	23,517	29,898	78,555	82,021
Fees waived	(750)		(2,250)	(858)
Net expenses	22,767	29,148	76,305	81,163
Net investment income before taxes	40,370	36,290	116,071	64,422
(Provision) benefit for taxes on net investment income		(358)	(3,308)	(358)
Net investment income	40,370	35,932	112,763	64,064
Unrealized appreciation (depreciation):	40,570		112,705	04,004
Control investments	(16,991)	) 3,590	(26,552)	30,336
Affiliate investments	(328)		(20,332)	213
Non-control/Non-affiliate investments	(67,806)		× /	83,842
Foreign currency forward contracts	(1,630)		(90,333)	2,226
Net unrealized appreciation (depreciation)	(86,755)	3,917	(118,379)	116,617
Realized gains (losses):			1.0/0	
Control investments Non-control/Non-affiliate investments		0.250	1,868	2( 2(7
	416	9,350	5,888	26,267
Foreign currency forward contracts	8,796	(740)	12,179	(3,586)
Net realized gains (losses)	9,212	8,610	19,935	22,681
(Provision) benefit for taxes on realized and unrealized gains (losses)	(661)		1,696	(2,663)
Net realized and unrealized gains (losses), net of taxes	(78,204)		(96,748)	136,635
Net increase (decrease) in net assets resulting from operations	\$ (37,834) \$ 0.22		<u>\$ 16,015</u>	<u>\$ 200,699</u>
Net investment income per common share — basic and diluted		• • • • •	\$ 0.62	\$ 0.41
Earnings (loss) per common share — basic and diluted (Note 5)	\$ (0.21)		\$ 0.09	\$ 1.29
Weighted average common shares outstanding — basic and diluted	183,370	180,361	181,778	155,970

## Oaktree Specialty Lending Corporation Consolidated Statements of Changes in Net Assets (in thousands, except per share amounts) (unaudited)

	 ree months ended ne 30, 2022	Three months ended June 30, 2021	-	Nine months ended une 30, 2022	ine months ended ne 30, 2021
Operations:					
Net investment income	\$ 40,370	\$ 5 35,932	\$	112,763	\$ 64,064
Net unrealized appreciation (depreciation)	(86,755)	3,917		(118,379)	116,617
Net realized gains (losses)	9,212	8,610		19,935	22,681
(Provision) benefit for taxes on realized and unrealized gains (losses)	(661)	(1,421)		1,696	(2,663)
Net increase (decrease) in net assets resulting from operations	(37,834)	47,038		16,015	 200,699
Stockholder transactions:					
Distributions to stockholders	(30,256)	(23,447)		(87,483)	(55,868)
Net increase (decrease) in net assets from stockholder transactions	 (30,256)	(23,447)		(87,483)	 (55,868)
Capital share transactions:					
Issuance of common stock in connection with the Mergers	_	_		_	242,704
Issuance of common stock under dividend reinvestment plan	874	520		2,426	1,559
Repurchases of common stock under dividend reinvestment plan	(874)	(520)		(874)	(1,559)
Issuance of common stock in connection with the "at the market" offering	1,243	_		20,622	_
Net increase (decrease) in net assets from capital share transactions	 1,243	_		22,174	 242,704
Total increase (decrease) in net assets	(66,847)	23,591		(49,294)	 387,535
Net assets at beginning of period	1,330,376	1,278,823		1,312,823	 914,879
Net assets at end of period	\$ 1,263,529	\$ 5 1,302,414	\$	1,263,529	\$ 1,302,414
Net asset value per common share	\$ 6.89	\$ 5 7.22	\$	6.89	\$ 7.22
Common shares outstanding at end of period	 183,374	180,361		183,374	 180,361

## Oaktree Specialty Lending Corporation Consolidated Statements of Cash Flows (in thousands) (unaudited)

Operating activities.		months ended ine 30, 2022	Nine months ended June 30, 2021		
Operating activities:	¢	16.015	¢	200 (00	
Net increase (decrease) in net assets resulting from operations Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:	\$	16,015	\$	200,699	
Net unrealized (appreciation) depreciation		118,379		(116,617)	
Net realized (gains) losses		(19,935)		(22,681)	
PIK interest income		(14,515)		(11,487)	
Accretion of original issue discount on investments		(22,707)		(18,032)	
Accretion of original issue discount on unsecured notes payable		509		403	
Amortization of deferred financing costs		2,801		3,030	
Deferred taxes		(984)		112	
Purchases of investments		(620,843)		(714,791)	
Proceeds from the sales and repayments of investments		554,933		586,812	
Cash acquired in the Mergers				20,945	
Changes in operating assets and liabilities:				20,745	
		(9,456)		(3,434)	
(Increase) decrease in interest, dividends and fees receivable		(4,891)		1,956	
(Increase) decrease in due from portfolio companies (Increase) decrease in receivables from unsettled transactions		4,876		8,199	
(Increase) decrease in feetvales from unsetted transactions (Increase) decrease in due from broker		(34,700)		(1,640)	
(Increase) decrease in other assets		1,017		(1,444)	
Increase (decrease) in accounts payable, accrued expenses and other liabilities		(700)		476	
Increase (decrease) in accounts payable, accrued expenses and other habitites Increase (decrease) in base management fee and incentive fee payable		(17,086)		17,994	
Increase (decrease) in due to affiliate		(817)		1,773	
Increase (decrease) in interest payable		3,759		1,844	
Increase (decrease) in payables from unsettled transactions		470		10,110	
Increase (decrease) in payables non disected transactions		38		(90)	
Net cash provided by (used in) operating activities		(43,837)		(35,863)	
Financing activities:		(10,007)		(83,000)	
Distributions paid in cash		(85,057)		(54,309)	
Borrowings under credit facilities		290,000		325,000	
Repayments of borrowings under credit facilities		(175,000)		(515,525)	
Issuance of unsecured notes				349,020	
Repayments of secured borrowings		_		(9,341)	
Repurchases of common stock under dividend reinvestment plan		(874)		(1,559)	
Shares issued under the "at the market" offering		20,839			
Deferred financing costs paid		(334)		(7,844)	
Offering costs paid		(215)			
Net cash provided by (used in) financing activities		49,359		85,442	
Effect of exchange rate changes on foreign currency		(842)		(1,146)	
Net increase (decrease) in cash and cash equivalents and restricted cash		4,680		48,433	
Cash and cash equivalents and restricted cash, beginning of period		31,635		39,096	
Cash and cash equivalents and restricted cash, beginning of period	\$	36,315	\$	87,529	
Supplemental information:	<u> </u>		<u> </u>	0.,0-7	
Cash paid for interest	\$	24,109	\$	15,583	
Non-cash financing activities:		,		,	
Issuance of shares of common stock under dividend reinvestment plan	\$	2,426	\$	1,560	
Deferred financing costs				(592)	
Issuance of shares in connection with the Mergers				242,704	
Reconciliation to the Consolidated Statements of Assets and Liabilities	Ju.	ine 30, 2022	Sente	mber 30, 2021	
Cash and cash equivalents	\$	34,306	\$	29,334	
Restricted cash		2,009	•	2,301	
Total cash and cash equivalents and restricted cash	\$	36,315	\$	31,635	
rour oush and oush equivalents and restricted easi		00,010	*	51,000	

		(unauuneu)				
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	<u>Principal (7)</u>	Cost	<u>Fair Value</u>	Notes
		<b>-</b>				
Control Investments						(8)(9)
C5 Technology Holdings, LLC		Data Processing &				
829 Common Units		Outsourced Services		\$	s —	(15)
34,984,460.37 Preferred Units				34,984	27,638	(15)
51,701,100.571100100 01105				34,984	27,638	(15)
Dominion Diagnostics, LLC		Health Care Services		,,		
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	7.26 %		\$ 16,074	16,074	16,074	(6)(15)
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			_	_	_	(6)(15)(19)
30,030.8 Common Units in DD Healthcare Services Holdings,				15.000	0.0(7	(1.5)
LLC				15,222	9,267	(15)
OCSI Glick JV LLC		Multi-Sector Holdings		31,296	25,341	(14)
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	4.94 %	Wulti-Sector Holdings	60,274	50,392	50,606	(6)(11)(15)(19)
87.5% equity interest	F. 70		00,274	50,572		(11)(16)(19)
······································				50,392	50,606	(11)(10)(13)
Senior Loan Fund JV I, LLC		Multi-Sector Holdings		,	,	(14)
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	8.00 %	0	96,250	96,250	96,250	(6)(11)(15)(19)
87.5% LLC equity interest				49,322	23,023	(11)(12)(16)(19)
				145,572	119,273	
Total Control Investments (17.6% of net assets)				\$ 262,244	\$ 222,858	
Affiliate Investments						(17)
Assembled Brands Capital LLC		Specialized Finance				
First Lien Revolver, LIBOR+6.75% cash due 10/17/2023	9.00 %		\$ 21,754	\$ 21,754	\$ 21,260	(6)(15)(19)
1,609,201 Class A Units				764	563	(15)
1,019,168.80 Preferred Units, 6%				1,019	1,203	(15)
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029				_	_	(15)
				23,537	23,026	
Caregiver Services, Inc.		Health Care Services				
1,080,399 shares of Series A Preferred Stock, 10%				1,080	401	(15)
				1,080	401	
Total Affiliate Investments (1.9% of net assets)				\$ 24,617	\$ 23,427	
						(1.0)
Non-Control/Non-Affiliate Investments		D I D I O I				(18)
109 Montgomery Owner LLC		Real Estate Operating Companies				
First Lien Term Loan, LIBOR+7.00% cash due 2/2/2023	8.33 %	1	\$ 2,178	\$ 2,161	\$ 2,306	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+7.00% cash due						
2/2/2023			—	(27)		(6)(15)(19)
AT Holdings II SADI		Distribushas		2,134	2,336	
A.T. Holdings II SÀRL First Lien Term Loan, 9.50% PIK due 12/22/2022		Biotechnology	33,200	33,122	33,283	(11)(15)
First Lien Term Loan, 9.5070 First due 12/22/2022			33,200	33,122	33,283	(11)(15)
Access CIG, LLC		Diversified Support		55,122	55,265	
Querry J. Line Three LIDOD 17 759/ and the 2/27/202/	0.22.0/	Services	20.000	10.001	10 200	
Second Lien Term Loan, LIBOR+7.75% cash due 2/27/2026	9.32 %		20,000	19,921	19,200	(6)
Accupac, Inc.		Personal Products		19,921	19,200	
First Lien Term Loan, SOFR+5.50% cash due 1/16/2026	7.59 %	r ersonar i rouueis	16,017	15,704	15,977	(6)(15)
First Lien Delayed Draw Term Loan, SOFR+5.50% cash due	1.09 10		10,017	15,701	15,711	(0)(15)
1/16/2026			_	_	(8)	(6)(15)(19)
First Lien Revolver, SOFR+5.50% cash due 1/16/2026	7.59 %		91	51	86	(6)(15)(19)
				15,755	16,055	
Acquia Inc.		Application Software				
First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025	8.12 %		27,349	27,012	27,213	(6)(15)
First Lien Revolver, LIBOR+7.00% cash due 10/31/2025	9.08 %		269	243	257	(6)(15)(19)

27,255

27,470

	<u>Cash</u> Interest Rate								
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>(6)</u>	<u>Industry</u>	<u>Pr</u>	incipal (7)		<u>Cost</u>	<u>Fai</u>	r Value	Notes
ADB Companies, LLC		Construction & Engineering							
First Lien Term Loan, LIBOR+6.25% cash due 12/18/2025	8.50 %	Engineering	\$	14,896	\$	14,384	\$	14,650	(6)(15)
				,		14,384		14,650	
Aden & Anais Merger Sub, Inc.		Apparel, Accessories &							
51,645 Common Units in Aden & Anais Holdings, Inc.		Luxury Goods				5,165		_	(15)
s 1,6 12 Common Onno in Adon de Annais Hotanigo, mo.						5,165			(15)
AI Sirona (Luxembourg) Acquisition S.a.r.l.		Pharmaceuticals							
Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026	7.25 %		€	24,838		27,748		23,760	(6)(11)(15)
						27,748		23,760	
AIP RD Buyer Corp.	9.35 %	Distributors	¢	14 414		14 145		12 000	(6)(15)
Second Lien Term Loan, SOFR+7.75% cash due 12/23/2029 14,410 Common Units in RD Holding LP	9.35 %		\$	14,414		14,145 1,352		13,880 1,295	(6)(15) (15)
14,410 Common Onits in RD Holding Er						15,497		15,175	(15)
AirStrip Technologies, Inc.		Application Software				- , -		-, -	
5,715 Common Stock Warrants (exercise price \$139.99)						00			(15)
expiration date 5/11/2025						90 90			(15)
All Web Leads, Inc.		Advertising				90		_	
First Lien Term Loan, LIBOR+6.50% cash due 12/29/2023	8.07 %	. la vortionity		23,124		21,584		22,060	(6)(15)
				,		21,584		22,060	
Altice Financing S.A.		Integrated Telecommunication Services							
Fixed Rate Bond, 5.75% cash due 8/15/2029				300		248		242	(11)
						248		242	
Altice France S.A.		Integrated Telecommunication Services							
Fixed Rate Bond, 5.50% cash due 10/15/2029				3,800		3,309		2,915	(11)
						3,309		2,915	
Alvogen Pharma US, Inc.		Pharmaceuticals							
First Lien Term Loan, LIBOR+5.25% cash due 12/31/2023	7.50 %			13,300		12,981		11,751	(6)
Alvotech Holdings S.A.		Biotechnology				12,981		11,751	(13)
Franche A Fixed Rate Bond 10.00% cash due 6/24/2025		Biotechnology		24,043		23,720		24,043	(13)
Franche B Fixed Rate Bond 10.00% cash due 6/24/2025				23,522		23,240		23,522	(11)(15)
587,930 Common Shares in Alvotech SA				,		5,349		4,827	
124,780 Seller Earn Out Shares in Alvotech SA						444		309	(15)
						52,753		52,701	
American Auto Auction Group, LLC	10.00.01	Consumer Finance		1450				14.01-	(()()))
Second Lien Term Loan, SOFR+8.75% cash due 1/2/2029	10.80 %			14,760		14,481 14,481		14,317 14,317	(6)(15)
American Tire Distributors, Inc.		Distributors				14,481		14,317	
First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	7.00 %	2.50100015		9,920		9,796		9,404	(6)
					-	9,796		9,404	
Amplify Finco Pty Ltd.		Movies & Entertainment							
First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	5.92 %			15,259		13,933		14,890	(6)(11)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 11/26/2027	9.67 %			12,500	_	12,188		12,063	(6)(11)(15)
Anastasia Parent, LLC						26,121		26,953	
snastasia i attiig DDC		Personal Products							
						2.070		2,001	(6)
First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	6.00 %			2,494		2,070		2,001	(*)
	6.00 %			2,494		2,070		2,001	
	6.00 %	Research & Consulting Services		2,494					
First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025 Ankura Consulting Group LLC Second Lien Term Loan, LIBOR+8.00% cash due 3/19/2029	6.00 % 9.18 %	Research & Consulting Services		2,494 5,316					(6)(15)

	<u>Cash</u> Interest Rate							
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>(6)</u>	<b>Industry</b>	<u>Pri</u>	incipal (7)	<u>Cost</u>	<u>Fair Va</u>	lue	Notes
Apptio, Inc.		Application Software						
First Lien Term Loan, LIBOR+6.00% cash due 1/10/2025	7.25 %		\$	34,458	\$ 33,657	\$ 33	,680	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 1/10/2025	7.25 %			892	 859		842	(6)(15)(19)
					34,516	34	,522	
APX Group Inc.		Electrical Components & Equipment						
Fixed Rate Bond, 5.75% cash due 7/15/2029				2,075	1,724	1	,610	(11)
					1,724	1	,610	
Ardonagh Midco 3 PLC		Insurance Brokers						
First Lien Term Loan, EURIBOR+7.00% cash due 7/14/2026	8.00 %		€	1,964	\$ ,		,053	(6)(11)(15)
First Lien Term Loan, SONIA+7.00% cash due 7/14/2026	8.19 %		£	18,636	23,172		,633	(6)(11)(15)
First Lien Term Loan, LIBOR+5.75% cash due 7/14/2026	6.50 %		\$	10,519	10,346	10	,309	(6)(11)(15)
First Lien Delayed Draw Term Loan, SONIA+5.75% cash due 7/14/2026			£	_	(44)		_	(6)(11)(15)(19)
					35,652	34	,995	
ASP Unifrax Holdings, Inc.		Trading Companies & Distributors						
Fixed Rate Bond, 7.50% cash due 9/30/2029			\$	5,500	5,406	3	,828	
Fixed Rate Bond, 5.25% cash due 9/30/2028				2,500	 2,210	2	,000	
					7,616	5	,828	
Associated Asphalt Partners, LLC		Construction Materials						
First Lien Term Loan, LIBOR+5.25% cash due 4/5/2024	6.92 %			2,509	 2,309		,791	(6)
					2,309	1	,791	
Astra Acquisition Corp.		Application Software				_		
First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	6.92 %			8,563	 8,314	-	,485	(6)
athenahealth Group Inc.		Health Care Technology			8,314	1	,485	
18,635 Shares of Series A Preferred Stock in Minerva Holdco,		Treatur Care Technology						
Inc., 10.75%					 18,264	17	,153	(15)
					18,264	17	,153	
Athenex, Inc.		Pharmaceuticals						
First Lien Term Loan, 11.00% cash due 6/19/2026				16,155	15,617	15	,751	(11)(15)
First Lien Delayed Draw Term Loan, 11.00% cash due 6/19/2026				_	(274)		(527)	(11)(15)(19)
First Lien Revenue Interest Financing Term Loan due 5/31/2031				7,926	7,881		,881	(6)(11)(15)
328,149 Common Stock Warrants (exercise price \$0.4955)				, í	,			
expiration date 6/19/2027					 973		43	(11)(15)
					24,197	23	,148	
Aurora Lux Finco S.A.R.L.	7 (2 0/	Airport Services		22 492	22,122	21	226	(()(11)(15)
First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	7.63 %			22,483	 22,123	-	,336	(6)(11)(15)
The Avery		Real Estate Operating Companies			22,123	21	,336	
First Lien Term Loan in T8 Urban Condo Owner, LLC, LIBOR+7.30% cash due 2/17/2023	9.09 %	Companies		15,874	15,757	14	,040	(6)(15)
Subordinated Debt in T8 Senior Mezz LLC, LIBOR+12.50%	9.09 /0			13,074	15,157	10	,040	(0)(15)
cash due 2/17/2023	14.53 %			3,834	 3,808		,865 <b>,905</b>	(6)(15)
BAART Programs, Inc.		Health Care Services			17,505	19	,705	
- <del>-</del>								
First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due					2.226	-	204	(6)(15)(19)
First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	6.60 %			2,269	2,226	2	,204	(0)(13)(19)
6/11/2027 Second Lien Term Loan, LIBOR+8.50% cash due 6/11/2028	6.60 % 10.17 %			2,269 7,166	2,226 7,059		,204 ,059	(6)(13)(19) (6)(15)
6/11/2027				,		7	· · · · ·	

		(unauuncu)				
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
Berner Food & Beverage, LLC		Soft Drinks				
First Lien Term Loan, LIBOR+6.50% cash due 7/30/2027	7.50 %		\$ 33,162	\$ 32,671	\$ 32,034	(6)(15)
First Lien Revolver, PRIME+5.50% cash due 7/30/2026	10.25 %		1,980	1,936	1,884	(6)(15)(19)
				34,607	33,918	
BioXcel Therapeutics, Inc.		Pharmaceuticals				
First Lien Term Loan, 10.25% cash due 4/19/2027			5,322	5,099	5,109	(11)(15)
First Lien Delayed Draw Term Loan, 10.25% cash due 4/19/2027			_	_	_	(11)(15)(19)
First Lien Revenue Interest Financing Delayed Draw Term Loan lue 9/30/2032			_	_	_	(6)(11)(15)(19
21,177 Common Stock Warrants (exercise price \$20.04) expiration date 4/19/2029				125	120	(15)
Blackhawk Network Holdings, Inc.		Data Processing & Outsourced Services		5,224	5,229	
Second Lien Term Loan, LIBOR+7.00% cash due 6/15/2026	8.31 %	Outsourced Services	30,625	30,252	30,038	(6)
	0.51 /0		50,025	30,252	30,038	(0)
Blumenthal Temecula, LLC		Automotive Retail		00,202	20,020	
First Lien Term Loan, 9.00% cash due 9/24/2023		- ratemente recuil	3,979	3,980	3,960	(15)
1,293,324 Preferred Units in Unstoppable Automotive AMV, LLC			5,777	1,293	1,280	(15)
298,460 Preferred Units in Unstoppable Automotive VMV, LLC				298	295	(15)
298,460 Common Units in Unstoppable Automotive AMV, LLC				298	373	(12)(15)
				5,869	5,908	
Cadence Aerospace, LLC		Aerospace & Defense		-,	-,	
First Lien Term Loan, LIBOR+6.50% cash 2.00% PIK due		· · · ·				
11/14/2023	7.74 %		14,256	13,246	13,093	(6)(15)
				13,246	13,093	
Carvana Co.		Automotive Retail				
Fixed Rate Bond, 5.625% cash due 10/1/2025			6,700	5,765	5,155	(11)
				5,765	5,155	
CCO Holdings LLC		Cable & Satellite				
Fixed Rate Bond, 4.50% cash due 5/1/2032			2,097	1,739	1,705	(11)
				1,739	1,705	
CircusTrix Holdings, LLC		Leisure Facilities				
First Lien Term Loan, LIBOR+5.50% cash 1.50% PIK due 7/16/2023	7.17 %		10,739	10,198	9,761	(6)(15)
CITGO Holding, Inc.		Oil & Gas Refining & Marketing		10,198	9,761	
First Lien Term Loan, LIBOR+7.00% cash due 8/1/2023	8.67 %	marketing	8,998	8,940	8,901	(6)
Fixed Rate Bond, 9.25% cash due 8/1/2024	0.07 /0		10,672	10,672	10,345	
· · · · · · · · · · · · · · · · · · ·			10,072	19,612	19,246	
CITGO Petroleum Corp.		Oil & Gas Refining & Marketing				
First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	7.92 %	-	8,268	8,074	8,219	(6)
				8,074	8,219	
Clear Channel Outdoor Holdings Inc.		Advertising				
Fixed Rate Bond, 7.50% cash due 6/1/2029			6,476	6,476	4,676	(11)
Fixed Rate Bond, 5.125% cash due 8/15/2027			1,374	1,223	1,164	(11)
Fixed Rate Bond, 7.75% cash due 4/15/2028			676	647	494	(11)
				8,346	6,334	
CommScope Technologies LLC		Communications Equipment				
Fixed Rate Bond, 5.00% cash due 3/15/2027			1,000	848	741	(11)
Fixed Rate Bond, 6.00% cash due 6/15/2025			3,250	2,926	2,818	(11)
				3,774	3,559	
Condor Merger Sub Inc.		Systems Software				
Fixed Rate Bond, 7.375% cash due 2/15/2030		-	8,420	8,239	6,868	
Tixed Kate Dolid, 7.57576 cash due 2/15/2050			8,420	0,257	0,000	

Portfolio Company/Type of Investment (1)(2)(3)(4)(5) Continental Intermodal Group LP First Lien Term Loan, LIBOR+8.50% cash due 1/28/2025 Common Stock Warrants expiration date 7/28/2025 Convergeone Holdings, Inc. First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026 Conviva Inc. 517,851 Shares of Series D Preferred Stock CorEvitas, LLC	<b>(6)</b> 10.17 % 6.67 %	Industry Oil & Gas Storage & Transportation	Principal (7) \$ 32,188	S         30,771           648         31,419	Fair Value           \$ 27,372           673           28,045	<u>Notes</u> (6)(15) (15)
First Lien Term Loan, LIBOR+8.50% cash due 1/28/2025 Common Stock Warrants expiration date 7/28/2025 Convergeone Holdings, Inc. First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026 Conviva Inc. 517,851 Shares of Series D Preferred Stock		Transportation IT Consulting & Other	\$ 32,188	648	673	()()
Common Stock Warrants expiration date 7/28/2025 Convergeone Holdings, Inc. First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026 Conviva Inc. 517,851 Shares of Series D Preferred Stock		IT Consulting & Other	\$ 32,188	648	673	()()
Convergeone Holdings, Inc. First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026 Conviva Inc. 517,851 Shares of Series D Preferred Stock	6.67 %					(15)
First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026 Conviva Inc. 517,851 Shares of Series D Preferred Stock	6.67 %			31,419	28,045	
First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026 Conviva Inc. 517,851 Shares of Series D Preferred Stock	6.67 %					
Conviva Inc. 517,851 Shares of Series D Preferred Stock	6.67 %	56111665				
517,851 Shares of Series D Preferred Stock			11,944	11,711	10,272	(6)
517,851 Shares of Series D Preferred Stock				11,711	10,272	
		Application Software				
CorEvitas, LLC				605	894	(15)
orevitas, LLC				605	894	
First Lien Term Loan, SOFR+5.75% cash due 12/13/2025	7.38 %	Health Care Technology	13,747	13,581	12 619	(6)(15)
First Lien Revolver, PRIME+4.75% cash due 12/13/2025	9.50 %		305	287	13,618 288	(6)(15) (6)(15)(19)
,099 Class A2 Common Units in CorEvitas Holdings, L.P.	9.50 70		505	690	2,340	(15)
				14,558	16,246	
Coyote Buyer, LLC		Specialty Chemicals				
First Lien Term Loan, LIBOR+6.00% cash due 2/6/2026	7.00 %		18,247	17,814	17,889	(6)(15)
irst Lien Revolver, LIBOR+6.00% cash due 2/6/2025	7.67 %		400	387	374	(6)(15)(19)
				18,201	18,263	
Delivery Hero FinCo LLC		Internet & Direct Marketing Retail				
First Lien Term Loan, SOFR+5.75% cash due 8/12/2027	6.88 %	Ŭ	5,000	4,894	4,713	(6)(11)
				4,894	4,713	
Delta Topco, Inc.		Systems Software				
Second Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	9.34 %		6,680	6,647	5,845	(6)
				6,647	5,845	
Dialyze Holdings, LLC First Lien Term Loan, LIBOR+9.00% cash 2.00% PIK due		Health Care Equipment				
/4/2026	11.25 %		24,272	22,873	22,629	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+9.00% cash 2.00 PIK due 8/4/2026	)%			(144)	(175)	(6)(15)(19)
5,403,823 Class A Warrants (exercise price \$1.00) expiration			_	(144)	(175)	(0)(13)(19)
late 8/4/2028				1,405	1,351	(15)
				24,134	23,805	
Digital.AI Software Holdings, Inc.	0.40.0/	Application Software	0.027	0.000	0.705	(()(15)
First Lien Term Loan, LIBOR+7.00% cash due 2/10/2027 First Lien Revolver, LIBOR+6.50% cash due 2/10/2027	8.40 % 7.90 %		9,927	9,606 227	9,705	(6)(15)
not Elen Revolver, EIBORT0.3076 cash due 2/10/2027	/.90 %		251	9,833	<u> </u>	(6)(15)(19)
DirecTV Financing, LLC		Cable & Satellite		2,000	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	6.67 %		17,718	17,540	16,363	(6)
				17,540	16,363	
OTI Holdco, Inc.		Research & Consulting Services				
First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	6.28 %	501,1005	5,000	4,902	4,695	(6)
				4,902	4,695	
Eagleview Technology Corporation		Application Software				
Second Lien Term Loan, LIBOR+7.50% cash due 8/14/2026	9.17 %		8,974	8,884	8,413	(6)(15)
				8,884	8,413	
COS Fitness Opco Holdings, LLC		Leisure Facilities				
187.5 Class A Preferred Units, 12%				488	966	(15)
2,500 Class B Common Units						(15)
etablishment Labs Heldings Inc.		Health Cana Technel		488	966	
-		Health Care Technology	10 151			(11)(15)
E <b>stablishment Labs Holdings Inc.</b> First Lien Term Loan, 9.00% cash due 4/21/2027 First Lien Delayed Draw Term Loan, 9.00% cash due 4/21/202		Health Care Technology	10,151	<b>488</b> 9,999 3	966 9,998 3	(11)(15) (11)(15)(19)

	Cash					
	<u>Cash</u> Interest Rate	<b>T 1</b> /	<b>D</b> · · 1( <b>D</b> )	<b>C</b>	<b>D</b> • <b>W</b> I	
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>(6)</u>	Industry	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
Fairbridge Strategic Capital Funding LLC		Real Estate Operating Companies				(20)
First Lien Delayed Draw Term Loan, 9.00% cash due 12/24/2028			\$ 17,750	\$ 17,750	\$ 17,750	(15)(19)
2,500 Warrant Units (exercise price \$0.01) expiration date 11/24/2031					2	(11)(12)(15)
11/24/2031				17,750	3	(11)(12)(15)
FINThrive Software Intermediate Holdings, Inc.		Health Care Technology		11,150	11,150	
Second Lien Term Loan, LIBOR+6.75% cash due 12/17/2029	8.42 %		25,061	24,685	22,430	(6)
				24,685	22,430	
Fortress Biotech, Inc.		Biotechnology				
First Lien Term Loan, 11.00% cash due 8/27/2025			9,466	9,037	9,111	(11)(15)
331,200 Common Stock Warrants (exercise price \$3.20) expiration date 8/27/2030				405	56	(11)(15)
oxpitation date 0/2//2000				9,442	9,167	(11)(13)
Frontier Communications Holdings, LLC		Integrated Telecommunication Services		,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Fixed Rate Bond, 6.00% cash due 1/15/2030			4,881	4,408	3,769	(11)
				4,408	3,769	
GKD Index Partners, LLC		Specialized Finance				
First Lien Term Loan, LIBOR+8.00% cash due 6/29/2023	10.25 %		25,436	25,148	25,029	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 6/29/2023	10.10 %		1,280	1,263	1,254	(6)(15)(19)
Clabel Medical Descence Lag				26,411	26,283	
Global Medical Response, Inc.	5.02.0/	Health Care Services	5 507	5 424	5 212	(0)
First Lien Term Loan, LIBOR+4.25% cash due 3/14/2025	5.92 %		5,587	5,434 5,434	5,212 5,212	(6)
Grove Hotel Parcel Owner, LLC		Hotels, Resorts & Cruise		3,434	5,212	
		Lines				
First Lien Term Loan, SOFR+8.00% cash due 6/21/2027 First Lien Delayed Draw Term Loan, SOFR+8.00% cash due	9.45 %		14,311	14,026	14,025	(6)(15)
6/21/2027 First Lien Revolver, SOFR+8.00% cash due 6/21/2027				(57)	(57)	(6)(15)(19) (6)(15)(19)
That Elen Revolver, BOTR (0.007) cash due 0/21/2027				13,941	13,939	(0)(13)(17)
Harbor Purchaser Inc.		Education Services		10,911	10,909	
First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	6.88 %		9,392	9,068	8,541	(6)
				9,068	8,541	
iCIMs, Inc.		Application Software				
First Lien Term Loan, LIBOR+6.50% cash due 9/12/2024	7.72 %		25,635	25,179	25,548	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 9/12/2024					1 1 7 2	(6)(15)
Flist Lien Revolver, LIBOR+0.30% cash due 9/12/2024	7.72 %		1,176	1,154	1,172	(0)(13)
	7.72 %	Hoolth Core Sumpling	1,176	1,154 26,333	26,720	(0)(15)
Immucor, Inc.		Health Care Supplies		26,333	26,720	
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025 Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due	8.00 %	Health Care Supplies	8,591	<b>26,333</b> 8,407	<b>26,720</b> 8,419	(6)(15)
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025		Health Care Supplies		<b>26,333</b> 8,407 21,923	<b>26,720</b> 8,419 22,026	
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025 Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025	8.00 % 10.25 %		8,591	<b>26,333</b> 8,407	<b>26,720</b> 8,419	(6)(15)
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025 Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due	8.00 % 10.25 %	Health Care Supplies	8,591	<b>26,333</b> 8,407 21,923	<b>26,720</b> 8,419 22,026	(6)(15)
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025 Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025 Impel Neuropharma, Inc.	8.00 % 10.25 %		8,591 22,418	26,333 8,407 21,923 30,330	26,720 8,419 22,026 30,445	(6)(15) (6)(15)
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025 Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025 Impel Neuropharma, Inc. First Lien Revenue Interest Financing Term Loan due 2/15/2031 First Lien Term Loan, SOFR+8.75% cash due 3/17/2027	8.00 % 10.25 %		8,591 22,418 12,161	26,333 8,407 21,923 30,330 12,161	26,720 8,419 22,026 30,445 12,161	(6)(15) (6)(15) (6)(15)
Immucor, Inc. First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025 Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025 Impel Neuropharma, Inc. First Lien Revenue Interest Financing Term Loan due 2/15/2031 First Lien Term Loan, SOFR+8.75% cash due 3/17/2027 Innocoll Pharmaceuticals Limited	8.00 % 10.25 % 10.95 %		8,591 22,418 12,161 12,161	26,333 8,407 21,923 30,330 12,161 11,931 24,092	26,720 8,419 22,026 30,445 12,161 11,942 24,103	(6)(15) (6)(15) (6)(15) (6)(15)
Immucor, Inc.         First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025         Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025         Impel Neuropharma, Inc.         First Lien Revenue Interest Financing Term Loan due 2/15/2031         First Lien Term Loan, SOFR+8.75% cash due 3/17/2027         Innocoll Pharmaceuticals Limited         First Lien Term Loan, 11.00% cash due 1/26/2027	8.00 % 10.25 % 10.95 %	Health Care Technology	8,591 22,418 12,161	26,333 8,407 21,923 30,330 12,161 11,931	26,720 8,419 22,026 30,445 12,161 11,942	(6)(15) (6)(15) (6)(15)
Immucor, Inc.         First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025         Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025         Impel Neuropharma, Inc.         First Lien Revenue Interest Financing Term Loan due 2/15/2031         First Lien Term Loan, SOFR+8.75% cash due 3/17/2027	8.00 % 10.25 % 10.95 %	Health Care Technology	8,591 22,418 12,161 12,161	26,333 8,407 21,923 30,330 12,161 11,931 24,092	26,720 8,419 22,026 30,445 12,161 11,942 24,103	(6)(15) (6)(15) (6)(15) (6)(15)
Immucor, Inc.         First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025         Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025         Impel Neuropharma, Inc.         First Lien Revenue Interest Financing Term Loan due 2/15/2031         First Lien Term Loan, SOFR+8.75% cash due 3/17/2027         Innocoll Pharmaceuticals Limited         First Lien Term Loan, 11.00% cash due 1/26/2027         First Lien Delayed Draw Term Loan, 11.00% cash due	8.00 % 10.25 % 10.95 %	Health Care Technology	8,591 22,418 12,161 12,161	26,333 8,407 21,923 30,330 12,161 11,931 24,092	26,720 8,419 22,026 30,445 12,161 11,942 24,103 6,391	(6)(15) (6)(15) (6)(15) (6)(15) (11)(15)

		(unauuneu)				
	<u>Cash</u> Interest Rate			~		
Cortfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>(6)</u>	Industry	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
ntegral Development Corporation		Other Diversified Financial Services				
,078,284 Common Stock Warrants (exercise price \$0.9274)				¢ 112	¢	(15)
xpiration date 7/10/2024				\$ 113 113	<u>\$                                    </u>	(15)
nventus Power, Inc.		Electrical Components &		115		
irst Lien Term Loan, SOFR+5.00% cash due 3/29/2024	7.32 %	Equipment	\$ 18,707	19 509	18 000	(6)(15)
Second Lien Term Loan, LIBOR+8.50% cash due 9/29/2024	10.75 %		\$ 18,707 13,674	18,598 13,494	18,099 13,093	(6)(15) (6)(15)
cond Elen Terri Eleni, Eleor (6.507) casil due 7/27/2024	10.75 %		15,074	32,092	31,192	(0)(13)
NW Manufacturing, LLC		Personal Products		52,672	51,172	
First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	8.00 %	i orsoniur i roductis	36,094	35,217	34,109	(6)(15)
			20,021	35,217	34,109	(*)(-*)
PC Corp.		Application Software			- ,	
First Lien Term Loan, LIBOR+6.50% cash due 10/1/2026	7.50 %	**	34,357	33,565	33,220	(6)(15)
				33,565	33,220	
tafos Inc.		Fertilizers &				
First Lien Term Loan, LIBOR+8.25% cash due 8/25/2024	9.82 %	Agricultural Chemicals	17,017	16,529	16,423	(6)(15)
	7.82 70		17,017	16,529	16,423	(0)(15)
vanti Software, Inc.		Application Software		10,529	10,423	
Second Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	8.85 %	. ppiloution boltware	10,247	10,196	9,410	(6)
	0.00 /0		10,217	10,196	9,410	(*)
azz Acquisition, Inc.		Aerospace & Defense		.,	,	
First Lien Term Loan, LIBOR+7.50% cash due 1/29/2027	9.17 %	I	36,326	35,200	36,411	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 6/18/2027	10.03 %		528	475	483	(6)
				35,675	36,894	
Kings Buyer, LLC		Environmental & Facilities Services				
First Lien Term Loan, LIBOR+6.50% cash due 10/29/2027	8.75 %	Facilities Services	13,658	13,521	13,316	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 10/29/2027	8.75 %		659	640	612	(6)(15)(19)
				14,161	13,928	
aserShip, Inc.		Air Freight & Logistics				
Second Lien Term Loan, LIBOR+7.50% cash due 5/7/2029	10.38 %		4,787	4,739	4,536	(6)(15)
				4,739	4,536	
Lift Brands Holdings, Inc.		Leisure Facilities				
2,000,000 Class A Common Units in Snap Investments, LLC				1,399		(15)
				1,399		
.ightbox Intermediate, L.P.		Real Estate Services				
First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	7.25 %		41,114	40,293	40,086	(6)(15)
		. 10		40,293	40,086	
iquid Environmental Solutions Corporation		Environmental & Facilities Services				
econd Lien Term Loan, LIBOR+8.50% cash due 11/30/2026	10.1-01					(0)(17)
Second Lien Delayed Draw Term Loan, LIBOR+8.50% cash due	10.17 %		4,357	4,280	4,226	(6)(15)
1/30/2026	10.17 %		1,162	1,139	1,057	(6)(15)(19)
				5,419	5,283	
LSL Holdco, LLC		Health Care Distributors				
Sirst Lien Term Loan, LIBOR+6.00% cash due 1/31/2028	7.67 %		19,236	18,878	18,659	(6)(15)
irst Lien Revolver, LIBOR+6.00% cash due 1/31/2028	7.67 %		855	815	791	(6)(15)(19)
TI Holdings, Inc.		Electronic Communest		19,693	19,450	
econd Lien Term Loan, LIBOR+6.75% cash due 9/6/2026	0 40 07	Electronic Components	2 1 40	2 000	1 057	(6)
contraction form coan, Endore 10.7570 cash due 9/0/2020	8.42 %		2,140	2,090 2,090	1,957 1,957	(6)
Aarinus Pharmaceuticals, Inc.		Pharmaceuticals		2,090	1,95/	
First Lien Term Loan, 11.50% cash due 5/11/2026		i numuccuttetto	17,203	16,937	16,558	(11)(15)
irst Lien Delayed Draw Term Loan, 11.50% cash due			,=00			
/11/2026			—			(11)(15)(19
				16,937	16,558	

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	<u>Principal (7)</u>	Cost	Fair Value	Notes
Mesoblast, Inc.	<del>~~</del>	Biotechnology	<b>r</b>			
First Lien Term Loan, 8.00% cash 1.75% PIK due 11/19/2026		8;	\$ 7,183	\$ 6,583	\$ 6,357	(11)(15)
First Lien Delayed Draw Term Loan, 8.00% cash 1.75% PIK due 11/19/2026			_	1	1	(11)(15)(19)
209,588 Warrant Shares (exercise price \$7.26) expiration date				400	120	(11)(15)
11/19/2028				480 7 <b>.064</b>	138 6,496	(11)(15)
MHE Intermediate Holdings, LLC		Diversified Support Services		7,004	0,490	
First Lien Term Loan, LIBOR+6.00% cash due 7/21/2027	7.29 %		18,437	18,120	17,979	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 7/21/2027				(24)	(35)	(6)(15)(19)
				18,096	17,944	
Mindbody, Inc.		Internet Services & Infrastructure				
First Lien Term Loan, LIBOR+7.00% cash 1.50% PIK due 2/14/2025	0 20 0/		15 197	44 407	44 622	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 2/14/2025	8.38 %		45,487	44,407	44,623	(6)(15)
			_	(58) 44,349	(76)	(6)(15)(19)
Mosaic Companies, LLC		Home Improvement Retail		44,349	44,547	
First Lien Term Loan, LIBOR+6.75% cash due 7/2/2026	8.36 %		46,796	46,046	45,907	(6)(15)
,			- ,	46,046	45,907	(-)(-)
MRI Software LLC		Application Software		,	,	
First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	7.75 %	11	28,037	27,574	27,476	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due					(4.9.9)	
2/10/2026			—	(13)	(100)	(6)(15)(19)
First Lien Revolver, LIBOR+5.50% cash due 2/10/2026			_	(13) 27,548	(36)	(6)(15)(19)
Navisite, LLC		Data Processing & Outsourced Services		27,340	27,540	
Second Lien Term Loan, LIBOR+8.50% cash due 12/30/2026	10.75 %		22,560	22,222	21,432	(6)(15)
			,	22,222	21,432	
NeuAG, LLC		Fertilizers & Agricultural Chemicals				
First Lien Term Loan, LIBOR+5.50% cash 7.00% PIK due 0/11/2024	7.75 %		49,572	48,069	48,142	(6)(15)
0/11/2024	1.13 70		49,372	48,009	48,142	(0)(13)
NFP Corp.		Other Diversified Financial Services		40,009	40,142	
Fixed Rate Bond 6.875% cash due 8/15/2028			10,191	9,759	8,437	
				9,759	8,437	
NN, Inc.		Industrial Machinery				
First Lien Term Loan, LIBOR+6.88% cash due 9/19/2026	8.54 %		58,862	57,734	56,802	(6)(11)(15)
				57,734	56,802	
DEConnection LLC		Application Software				
First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	5.67 %		3,332	3,160	3,107	(6)
Second Lien Term Loan, LIBOR+7.00% cash due 9/25/2027	8.60 %		7,519	7,383	7,218	(6)(15)
DTG Management, LLC		A internet Commission		10,543	10,325	
First Lien Term Loan, LIBOR+2.00% cash 8.00% PIK due		Airport Services				
<ul> <li>First Lien Term Loan, LIBOR+2.00% cash 8.00% PIX due</li> <li>V1/2025</li> <li>First Lien Delayed Draw Term Loan, LIBOR+2.00% cash 8.00%</li> </ul>	4.63 %		21,125	20,810	20,703	(6)(15)
PIK due 9/1/2025			_	(33)	(38)	(6)(15)(19)
P & L Development, LLC		Pharmaceuticals		20,777	20,665	
ixed Rate Bond, 7.75% cash due 11/15/2025			7,776	7,823	5,455	
				7,823	5,455	

	<u>Cash</u> Interest Rate					
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>(6)</u>	<u>Industry</u>	<u>Principal (7)</u>	Cost	<u>Fair Value</u>	<u>Notes</u>
Park Place Technologies, LLC		Internet Services & Infrastructure				
First Lien Term Loan, SOFR+5.00% cash due 11/10/2027	6.63 %		\$ 9,875	\$ 9,465	\$ 9,521	(6)
				9,465	9,521	
Performance Health Holdings, Inc.		Health Care Distributors				
First Lien Term Loan, LIBOR+6.00% cash due 7/12/2027	8.88 %		17,976	17,675	17,537	(6)(15)
				17,675	17,537	
PFNY Holdings, LLC		Leisure Facilities				
First Lien Term Loan, LIBOR+7.00% cash due 12/31/2026	8.00 %		26,220	25,750	25,695	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+7.00% cash due 2/31/2026	9.25 %		2,228	2,183	2,178	(6)(15)(19)
irst Lien Revolver, LIBOR+7.00% cash due 12/31/2026				(22)	(25)	(6)(15)(19)
				27,911	27,848	
Planview Parent, Inc.		Application Software				
Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	8.92 %		28,627	28,198	27,482	(6)(15)
				28,198	27,482	
PLNTF Holdings, LLC		Leisure Facilities				
First Lien Term Loan, LIBOR+8.00% cash due 3/22/2026	10.10 %		3,035	2,990	2,944	(6)(15)
Purchight LLC		Application C. C.		2,990	2,944	
Pluralsight, LLC First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	9.00 %	Application Software	48,689	47,910	47,325	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 4/6/2027	9.00 %		48,089	47,910 (56)	(99)	(6)(15) (6)(15)(19)
ist Elen Revolver, Elbort 0.0070 cash dae 4/0/2027				47,854	47,226	(0)(15)(17)
PRGX Global, Inc.		Data Processing &		,001	,	
		Outsourced Services				
First Lien Term Loan, LIBOR+6.75% cash due 3/3/2026	8.95 %		33,861	32,952	33,200	(6)(15)
First Lien Revolver, LIBOR+6.75% cash due 3/3/2026			-	(36)	(49)	(6)(15)(19)
20,515 Class B Common Units				79	89	(15)
				32,995	33,240	
Profrac Holdings II, LLC		Industrial Machinery				(0.4 P)
First Lien Term Loan, SOFR+8.50% cash due 3/4/2025	10.01 %		21,137	20,572	20,714	(6)(15)
Project Boost Purchaser, LLC		Annii setien Cellenan		20,572	20,714	
Second Lien Term Loan, LIBOR+8.00% cash due 5/31/2027	9.67 %	Application Software	5 250	5 164	5.070	(6)(15)
ceolid Elen Term Loan, Elbox (8.0078 cash due 5/51/2027	9.07 %		5,250	5,164 5,164	5,079 5,079	(6)(15)
Juantum Bidco Limited		Food Distributors		5,104	5,079	
First Lien Term Loan, SONIA+6.00% cash due 1/29/2028	7.31 %	1 000 121501000015	£ 3,501	4,643	3,540	(6)(11)(15)
			. 5,501	4,643	3,540	(-)()()
QuorumLabs, Inc.		Application Software		,	- )- 14	
4,887,669 Junior-2 Preferred Stock				375	_	(15)
				375		
Radiology Partners Inc.		Health Care Distributors				
First Lien Term Loan, LIBOR+4.25% cash due 7/9/2025	5.89 %		\$ 3,400	3,200	3,066	(6)
ixed Rate Bond, 9.25% cash due 2/1/2028			4,755	4,718	3,578	
				7,918	6,644	
Relativity ODA LLC		Application Software				
First Lien Term Loan, LIBOR+7.50% PIK due 5/12/2027			24,075	23,626	23,498	(6)(15)
irst Lien Revolver, LIBOR+6.50% cash due 5/12/2027			_	(45)	(53)	(6)(15)(19)
Panaissanaa Halding Com				23,581	23,445	
Renaissance Holding Corp. Second Lien Term Loan, LIBOR+7.00% cash due 5/29/2026	0.68.54	Diversified Banks	0.515		0.010	(6)
econd Lien Term Loan, LIBOK+7.00% cash due 5/29/2026	8.67 %		3,542	3,515	3,310	(6)
RP Escrow Issuer LLC		Health Care Distribute		3,515	3,310	
ixed Rate Bond, 5.25% cash due 12/15/2025		Health Care Distributors	1 2 2 5	1 211	1 1 47	
			1,325	1,211	1,147	
				1,211	1,147	

Carterio Company Crysc of Investment (LDGZ) (VICS)         (b)         Indumotive Residual (VICS)         Sates Kanamotive Residual (VICS)		<u>Cash</u> Interest Rate									
First Late Term Lang, LHBOR + 25% cach due 8/17/006       9.25 %       S       37.71       S       3.77.1       S <th< th=""><th>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</th><th>(6)</th><th>•</th><th>Pri</th><th><u>ncipal (7)</u></th><th></th><th><u>Cost</u></th><th><u>Fair Value</u></th><th><u>Notes</u></th></th<>	Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	(6)	•	Pri	<u>ncipal (7)</u>		<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>		
First Leon Delayed Draw Term Long, LIBOR+6 25% cash due \$1/2020         9.25 %         11.421         10.05 %         10.07 %         6000000000000000000000000000000000000			Automotive Retail								
S321202       9.25 %       11,421       10,585       10,786       60(11)(5)(1)         S3200 exprinted dite 22(2)(2)(2)       7,70       (11)(15)(1)         S3200 exprinted dite 22(2)(2)(2)       7,70       (11)(15)(1)         Sabert Common Stock Warrants (exercise price Size Comported dite 22(2)(2)(2)       1,260       7,764       47,308         First Lien Tern Loan, LIBOR+4 50% cash due 12(10/2026       6.19 %       1,260       1,464       1,464       1,464       1,464       1,464       1,464       1,464       1,464       1,464       1,464       1,465       60       1,665       2,966       2,966       2,966       2,966       2,966       2,966       2,966       2,966       2,966       2,966       2,966       2,966       1,631       1,643       1,643       1,643       1,643       1,643       1,643       1,643       1,643       1,643       1,644       1,645       1,645       1,645       1,645       1,645       1,645       1,645       1		9.25 %		\$	37,751	\$	35,744	\$ 36,275	(6)(11)(15)		
S33.00 expiration date 2/28/2023       77.0       (11)(1)         Sabert Corporation       Metal & Class Containers       47.594       47.138         Sabert Corporation       Metal & Class Containers       1,640       1,645       (6)         Siles Pharmaceuticals Inc.       Pharmaceuticals       2,666       2,296       2,666       2,916       (15)         Share This, Inc.       Application Software       34,625       367        (15)         Share This, Inc.       Application Software       34,625       367        (15)         Share This, Inc.       Metal & Class	8/31/2026	9.25 %			11,421		10,558	10,786	(6)(11)(15)(19)		
Art Comparison       Art Solve       47,594       47,138         Safert Comporation       Metal & Citatas         Containers       47,594       47,138         First Lien Tem Lonn, LIBOR+4,50% cash due 12/10/2026       6 19 %       1,160       1,665       (6)         Softer Pharmaceuticals							1 202	77	(11)(15)		
Saher Corporation         Media         Containers         1.727         1.640         1.645         0           First Len Tem Lon, LIBOR+4 50% cash due 12/10/205         6.19 %         2.060         2.06	\$55.00) expiration date 2/20/2025								(11)(13)		
First Leen Term Loan, LIBOR+4 50% each due 12/10/2026       6.19 %       1,727       1,640       1,645       66         Soller Pharmaceuticals       Pharmaceuticals       2,960       2,666       2,916       (15)         Share This, Inc.       Application Software       367	Sabert Corporation						17,501	1,100			
Select Pharmaceuticals         I.440         I.645           Fixed Rate Zero Corpon Rond due \$152026         2.960         2.666         2.916         (15)           Sharr This, Ine.         Application Software         367	First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	6.19 %			1,727		1,640	1,645	(6)		
First Rate Zero Coupon Bond due &/15/2026       2,960       2,666       2,916       (15)         ShareThis, Inc.       Application Software       367       -       (15)         Stad 53 Software Chrefered Stock Warrans (exercise price S3:095) expiration date 3/4/2024       367       -       (15)         SiO2 Medical Products, Inc.       Metal & Glass Countaineers       681       681       (15)         Common Stock Warrans (exercise price S0:75) expiration date 73/2026       45,140       44,390       44,332       (15)         Stoce Metals Modings, Inc.       Health Care Services       8,972       8,927       (6)(15)         Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029       9.04 %       9,109       8,972       8,927       (6)(15)         SocieWall US Holdings Inc.       Technology Distributors       3,163       3,069       (6)(15)         SocieWall US Holdings Inc.       Technology       9,01 %       3,163       3,069       (6)(15)         SocieWall US Holdings Inc.       Technology Distributors       3,163       3,069       (6)(15)       (11)         SocieWall US Holdings Inc.       Technology       9,01 %       4,546       4,463       4,438       (6)(15)         SocieWall US Holdings Inc.       Technology       197       101       (					,						
Share This, Inc.         Application Software           Share This, Inc.         Application Software           Stare Streker Checkmed Stock Warrants (exercise price         367         —         (15)           Stare This, Inc.         Metal & Glass Containners         367         —         (15)           StO2 Medical Products, Inc.         Metal & Glass Containners         681         681         (15)           StO2 Medical Products, Inc.         Metal & Glass Containners         681         681         (15)           StO2 Medical Products, Inc.         Metal & Glass Containners         681         681         (15)           Store Stock Warrants (exercise price SU 75) expiration date Systema Containners         681         681         (15)           Store Marcine Stock Warrants (exercise price SU 75) expiration date Systema Containners         9,009         8,972         8,927         (6)(15)           Sone Wall US Holdings Inc.         Technology Distributors         3,163         3,009         (6)(15)           Sone Marcine Therapeuties, Inc.         Biotechnology         197         101         (11)           Sprane, LLC         Apparel Retail         (55)         (70)         (6)(15)           Sing Line Term Loan, LIBOR+5.50% cash due 11/18/2027         —         (55)         (70)	Scilex Pharmaceuticals Inc.		Pharmaceuticals								
Share The sine.       Application Software       367	Fixed Rate Zero Coupon Bond due 8/15/2026				2,960		2,666	2,916	(15)		
345       45 $367$ -       (15)         35.093       containers $367$ -       (15)         SiO2       Metal & Glass       Containers       (15)         SiO2       Metal & Glass       (15)       (15)         Grammon Stock Warrants (exercise price S0.75) expiration date $45,140$ $44,390$ $44,332$ (15)         Common Stock Warrants (exercise price S0.75) expiration date $681$ $8927$ $8927$ $8927$ $8927$ $8927$ $89$							2,666	2,916			
S33.0395) expiration date 3/4/2024       367        (15)         S302 Medical Products, Inc.       Metal & Glass Containers       -       (15)         First Lien Term Loan, 5.50% cash 8.50% PIK due 12/21/2026       45,140       44,390       44,332       (15)         Common Slock Warrants (exercise price \$0.75) expiration date 73/12/2028       Health Care Services       681       681       (15)         SSM Wellness Holdings, Inc.       Technology Distributors       8,972       8,927       8,927         SocieWall US Holdings Inc.       Technology Distributors       3,163       3,069       (6)(15)         Sorrento Therapeutics, Inc.       Biotechnology       3,163       3,069       (6)(15)         Sorrento Therapeutics, Inc.       197       101       (11)         Spans, LLC       Apparel Retnil       197       101       (11)         Spans, LLC       Apparel Retnil       197       101       (11)         First Lien Term Loan, LIBOR+5.50% cash due 11/18/2027       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg S.A.R.L       Other Diversified First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026       10.00 %       6       16.911       19.414       17.186         SumUp Holdings Luxembourg S.A.R.L       Other Diversified First Lien Term L	ShareThis, Inc.		Application Software								
$\frac{300}{367}$ $\frac{009}{367}$ SiO2 Medical Products, Inc.       Metal & Glass Containers         Containers         First Lien Term Loan, 5.9% eash 8.59% PIK due 12/21/2026 $45,140$ $44,390$ $44,332$ $(15)$ Common Stock Warrants (exercise price 50.75) expiration date 7/31/2028 $45,071$ $45,075$ $60(15)$ Sone/Wall US Holdings Inc.       Technology Distributors         Sone/Wall LS Holdings Inc.       Technology $107$ $101$ $111$ Sone/Common Stock Units $197$ $101$ $111$ Spanet Loc       Apparel Retail											
SiO2 Medical Products, Inc.         Metal & Glass Containers           First Lien Term Loan, 5.50% cash 8.50% PIK due 12/21/2026         45,140         44,390         44,332         (15)           71/21/2028         681         681         681         (15)           71/21/2028         800         681         681         (15)           71/21/2028         800         681         681         (15)           71/21/2028         904 %         9,109         8.972         8.927         (6)(15)           SonieWall US Holdings Inc.         Technology Distributors         8972         8.927         (6)(15)           SonieWall US Holdings Inc.         Technology         3,163         3,069         (6)(15)           SonieWall US Holdings Inc.         197         101         (11)           SonieWall US Holdings Inc.         197         101         (11)           SonieWall US Holdings Inc.         197         101         (11)           Sonie Chainers         197         101         (11)           Sonie Wall US Holdings Inc.         197         101         (11)           Sonie Wall US Holdings Inc.         197         101         (11)           Sonie Wall US Holdings Inc.         197         101	\$5.0595) expitation date 5/4/2024								(15)		
Containers           Containers           Containers           Single Marnats (exercise price 50.75) expiration date           (All 221/2026           Containers           Single Marnats (exercise price 50.75) expiration date           (All 221/2026           Single Marnats (exercise price 50.75) expiration date           Single Marnats (exercise price 50.75) expiration date           Second Lien Term Loan, LIBOR+8.00% eash due 4/16/2029         9.01 %         8.972         8.927         8.927         (6)(15)           SonieWall US Holdings Inc.         Technology Distributors           Second Lien Term Loan, LIBOR+7.50% eash due 5/18/2026         9.01 %         3.105         3.069         (6)(15)           SonieWall US Holdings Inc.         Technology           SonieWall US Holdings Inc.         197         101           SonieWall IDR +5.0% eash due 11/20/2028         7.10 %         4.546         4.463         4.438         (6)(15)           Sonie Dem Lien Term Loan, LIBOR+5.50% eash due 11/20/2028         7.10 %         Effer Etail         197         101         111 <th cemm<="" colspan="2" dem="" sonie="" td=""><td>S:02 Modical Products Inc</td><td></td><td>Motol &amp; Class</td><td></td><td></td><td></td><td>367</td><td>_</td><td></td></th>	<td>S:02 Modical Products Inc</td> <td></td> <td>Motol &amp; Class</td> <td></td> <td></td> <td></td> <td>367</td> <td>_</td> <td></td>		S:02 Modical Products Inc		Motol & Class				367	_	
Common Stock Warrants (exercise price \$0.75) expiration date $\frac{681}{731/2028}$ $\frac{681}{44,071}$ $\frac{681}{44,017}$ $\frac{17,186}{44,017}$ $\frac{69}{44,017}$ $\frac{17,186}{44,017}$ $\frac{69}{44,017}$ $\frac{17,186}{44,017}$ $\frac{69}{44,017}$ $\frac{17,186}{44,017}$ $\frac{69}{44,017}$ $\frac{17,186}{44,017}$ $\frac{69}{44,017}$ $\frac{17,186}{44,017}$ $17,$	SIO2 menical products, flic.										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	First Lien Term Loan, 5.50% cash 8.50% PIK due 12/21/2026				45,140		44,390	44,332	(15)		
SM Wellness Holdings, Inc.       Health Care Services         Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029       9,04 %       9,109       8,972       8,927       (6)(15)         SonieWall US Holdings Inc.       Technology Distributors       8,972       8,927       8,927         Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026       9,01 %       3,195       3,163       3,069         Sorrento Therapeutics, Inc.       Biotechnology       197       101       (11)         Spans, LLC       Apparel Retail       717       101       (6)(15)         Spans, LLC       Apparel Retail       -       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg S.Å.R.L.       Other Diversified Friancial Services       -       (55)       (70)       (6)(15)(15)         SunUp Holdings Luxembourg S.Å.R.L.       Other Diversified Friancial Services       -       (55)       (70)       (6)(15)(15)         SunUp Holdings Luxembourg S.Å.R.L.       Other Diversified Friancial Services       -       (6)(15)       (6)(15)         SunUp Holdings Luxembourg S.Å.R.L.       Other Diversified Friancial Services       -       (6)(15)       (6)(15)         Sunup Holdings Luxembourg S.Å.R.L.       Other Diversified Friancial Services       -       (6)(15)       (6)(15) <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>(01</td><td>(01</td><td>(1.5)</td></t<>							(01	(01	(1.5)		
SM Wellness Holdings, Inc.       Health Care Services         Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029       9.04 %       9.109       8.972       8.927       (6)(15)         SonicWall US Holdings Inc.       Technology Distributors       3,163       3,069       (6)(15)         Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026       9.01 %       3,195       3,163       3,069       (6)(15)         Sorrento Therapeutics, Inc.       Biotechnology       101       (11)       (11)         Spans, LLC       Apparel Retail       197       101       (11)         Spans, LLC       Apparel Retail       (55)       (70)       (6)(15)(19)         Strip Lien Revolver, LIBOR+5.50% cash due 11/18/2027       —       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg S.A.R.L.       Other Diversified Financial Services       19,414       17,186       (6)(11)(15)         SunLod Asphalt & Construction, LLBOR+6.50% cash due 1/13/2026       8.8 %       \$       4,272       41,686       41,787       (6)(15)         SunLod Asphalt & Construction, LLC       Construction & Engineering       3,121       3,155       (6)(15)         Supermoose Borrower, LLC       Application Software       5       42,77       41,686       41,787       (6)(15)	//31/2028								(15)		
Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029 9.04 % 9,04 % 9,109 8,972 8,927 (6)(15) SonicWall US Holdings Inc. Technology Distributors Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026 9.01 % 3,195 3,163 3,069 (6)(15) Sorrento Therapeutics, Inc. Biotechnology $\frac{197}{101}$ (11) Spans, LLC $\frac{197}{101}$ (11) Spans, LIBOR+5.50% cash due 11/20/2028 7,10 % 4,546 4,463 4,438 (6)(15) First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028 7,10 % 4,546 4,646 4,648 4,648 (6)(15) Supermose Bortower, LIBOR+5.25% cash due 11/20/2028 7,10 % 4,108 4,546 4,648 4,648 4,648 (6)(15) (6)(15)(19) First Lien Term Loan, LIBOR+5.25% cash due 11/20/2028 7,10 % 4,108 4,546 4,648 4,648 (6)(15) (6)(15)(19) Supermose Bortower, LIBOR+5.25% cash due 11/20/2028 7,10 % 4,108 4,546 4,648 4,648 (6)(15) (15) Supermose Bortower, LIBOR+5.25% cash due 11/20/2026 8,88 % 5 42,727 41,686 41,787 (6)(15) Supermose Bortower, LLC Construction & Engineering S Supermose Bortower, LLC Application Software First Lien Term Loan, LIBOR+6,07% cash due 8/29/2025 6,00 % 3,475 3,121 3,155 (6)(15) Supermose Bortower, LLC Application Software First Lien Term Loan, LIBOR+6,75% cash due 8/29/2025 6,00 % 20,819 19,547 18,800 (6)(15) Swordfish Merger Sub LLC Auto Parts & Equipment Second Lien Term Loan, LIBOR+6,75% cash due 2/2/2026 6,75 % 12,500 12,472 11,833 (6)(15)	SM Wellness Holdings Inc		Haalth Cana Samiaaa				45,071	45,015			
Normal		0.04.9/	Health Care Services		0.100		8 07 <b>2</b>	8 027	(6)(15)		
SonicWall US Holdings Inc.       Technology Distributors       3,195       3,163       3,069       60(15)         Second Lien Terrn Loan, LIBOR+7.50% cash due 5/18/2026       9,01 %       3,165       3,163       3,069       60(15)         Sorrento Therapeutics, Inc.       Biotechnology       197       101       (11)         Sono Common Stock Units       197       010       (11)         Spans, LLC       Apparel Retail       197       (615)         First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028       7,10 %       4,546       4,463       4,438       (6)(15)         SumUp Holdings Luxembourg S.Å.R.L.       Other Diversified Financial Services       4,008       4,368       (6)(15)         Strut Lien Term Loan, EURIBOR+8.50% cash due 1/10/2026       10.00 %       €       16,911       19,414       17,186       (6)(15)         SumUp Holdings Luxembourg S.Å.R.L.       Construction & Engineering       194,414       17,186       (6)(11)(15)         Strut Lien Term Loan, LIBOR+8.50% cash due 1/13/2026       8.88 %       \$       4,2727       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       3,155       (6)       3,155       (6)       (11)       (11)       (11)       (11)       (11) <td< td=""><td>Second Elen Term Eoun, ElBOR (0.007) cush due 4/10/2027</td><td>9.04 70</td><td></td><td></td><td>9,109</td><td></td><td><u> </u></td><td></td><td>(0)(13)</td></td<>	Second Elen Term Eoun, ElBOR (0.007) cush due 4/10/2027	9.04 70			9,109		<u> </u>		(0)(13)		
Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026       9.01 %       3,195       3,163       3,069       (6)(15)         Sorrento Therapeutics, Inc.       Biotechnology       197       101       (11)         Spans, LLC       Apparel Retail       197       101       (11)         Spans, LLC       Apparel Retail       -       (55)       (70)       (6)(15)         SumUp Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services       -       (55)       (70)       (6)(15)         SumUp Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services       -       (6)(15)       (6)(15)         Sunland Asphalt & Construction, LLC       Construction & Engineering       -       (6)(15)       (6)(15)         Supermoose Borrower, LLC       Application Software       -       (6)(15)       (6)(15)         Strip Lien Term Loan, LIBOR+5.7% cash due 7/28/2025       6.00 %       3,475       3,121       3,155       (6)(15)         Stypermoose Borrower, LLC       Application Software       -       -       (6)(15)       (6)(15)         Stypermoose Borrower, LLC       Application Software       -       -       3,121       3,155       (6)(15)         Stypermoose Borrower, LLC       Home Furnishings       -       -	SonicWall US Holdings Inc.		Technology Distributors				0,972	0,927			
Minu	•		Technology Distributors		2 105		2 162	2 060	(6)(15)		
Sorrento Therapeutics, Inc.         Biotechnology           50,000 Common Stock Units         197         101           Spanx, LLC         197         101           Spanx, LLC         Apparel Retail	Second Elem Ferni Elem, Elebert (7.5070 cush due 5,76/2020	9.01 /0			5,195	-	,		(0)(13)		
50,000 Common Stock Units       197       101       (11)         Spanx, LLC       Apparel Retail       197       101       (11)         First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028       7.10 %       4,546       4,463       4,438       (6)(15)         First Lien Revolver, LIBOR+5.25% cash due 11/18/2027       —       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services       4,408       4,368         SumUp Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services       19,414       17,186       (6)(11)(15)         Sundand Asphalt & Construction, LLC       Construction & Engineering       197       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       —       3,121       3,155       (6)         Stypermoose Borrower, LLC       Application Software       —       —       —       —       —       —       —       (6)(15)       …	Sorrento Therapeutics, Inc.		Biotechnology				5,105	5,005			
Spanx, LLC       Apparel Retail         First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028       7.10 %       4,546       4,463       4,438       (6)(15)         First Lien Term Loan, LIBOR+5.25% cash due 11/18/2027       -       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg SÅ.R.L.       Other Diversified Financial Services       -       (6)(11)(15)       (6)(11)(15)         Sunland Asphalt & Construction, LLC       Construction & Engineering       19,414       17,186       (6)(11)(15)         Supermoose Borrower, LLC       Application Software       -       3,475       3,121       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       -       -       19,547       18,802       (6)(15)         Swordlish Merger Sub LLC       Auto Parts & Equipment       -       12,500       12,472       11,833       (6)(15)			Bioteennoiogy				197	101	(11)		
First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028       7.10 %       4,546       4,463       4,438 (6)(15)         First Lien Revolver, LIBOR+5.25% cash due 11/18/2027       -       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services       -       (55)       (70)       (6)(15)(19)         First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026       10.00 %       €       16,911       19,414       17,186       (6)(11)(15)         Sunland Asphalt & Construction, LLC       Construction & Engineering       -       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       -       3,121       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       -       19,547       18,802       (6)(15)         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9,00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       -       -       11,833       (6)(15)	,										
First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028       7.10 %       4,546       4,463       4,438 (6)(15)         First Lien Revolver, LIBOR+5.25% cash due 11/18/2027       -       (55)       (70)       (6)(15)(19)         SumUp Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services       -       (55)       (70)       (6)(11)(15)         First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026       10.00 %       €       16,911       19,414       17,186       (6)(11)(15)         Sunland Asphalt & Construction, LLC       Construction & Engineering       -       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       -       3,415       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       -       19,547       18,802       (6)(15)         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9,00 %       20,819       19,547       18,802       (6)(15)         SWordfish Merger Sub LLC       Auto Parts & Equipment       -       -       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       -       -       11,833       (6)(15)	Spanx, LLC		Apparel Retail								
Sum Up Holdings Luxembourg S.À.R.L.       Other Diversified Financial Services $4,408$ $4,368$ First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026       10.00 % $\epsilon$ 16,911       19,414       17,186       (6)(11)(15)         Sunland Asphalt & Construction, LLC       Construction & Engineering       5       42,727       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       7       3,155       (6)       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026       6.75 %       12,500       12,472       11,833       (6)(15)	First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028	7.10 %			4,546		4,463	4,438	(6)(15)		
SumUp Holdings Luxembourg S.À.R.L.Other Diversified Financial ServicesFirst Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026 $10.00\%$ € $16,911$ $19,414$ $17,186$ $(6)(11)(15)$ Sunland Asphalt & Construction, LLCConstruction & Engineering $19,414$ $17,186$ $(6)(11)(15)$ Sunland Asphalt & Construction, LLCConstruction & Engineering $19,414$ $17,186$ $(6)(15)$ Supermoose Borrower, LLCApplication Software $14,686$ $41,787$ $(6)(15)$ First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025 $6.00\%$ $3,475$ $3,121$ $3,155$ $(6)$ SVP-Singer Holdings Inc.Home Furnishings $19,547$ $18,802$ $(6)(15)$ First Lien Term Loan, LIBOR+6.75% cash due 2/2/2026 $6.75\%$ $12,500$ $12,472$ $11,833$ $(6)(15)$	First Lien Revolver, LIBOR+5.25% cash due 11/18/2027				_		(55)	(70)	(6)(15)(19)		
Financial Services       Financial Services         First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026       10.00 %       €       16,911       19,414       17,186       (6)(11)(15)         Sunland Asphalt & Construction, LLC       Construction & Engineering       19,414       17,186       (6)(15)         First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026       8.88 %       \$       42,727       41,686       41,787       (6)(15)         Supermose Borrower, LLC       Application Software       3,475       3,121       3,155       (6)         StyP-Singer Holdings Inc.       Home Furnishings       (6)(15)       (6)(15)       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       500       12,500       12,472       11,833       (6)(15)							4,408	4,368			
10.00 %€16,91119,41417,186(6)(11)(15)In 19,41417,186(6)(11)(15)In 19,41417,186(6)(11)(15)Sunland Asphalt & Construction, LLCConstruction & EngineeringFirst Lien Term Loan, LIBOR+6.00% cash due 1/13/20268.88 %\$42,72741,68641,787(6)(15)Supermoose Borrower, LLCFirst Lien Term Loan, LIBOR+3.75% cash due 8/29/20256.00 %3,4753,1213,155(6)SVP-Singer Holdings Inc.Home FurnishingsFirst Lien Term Loan, LIBOR+6.75% cash due 7/28/20289.00 %20,81919,54718,802(6)(15)Swordfish Merger Sub LLCAuto Parts & EquipmentSecond Lien Term Loan, LIBOR+6.75% cash due 2/2/20266.75 %12,50012,47211,833(6)(15)	SumUp Holdings Luxembourg S.À.R.L.		E: 10 '								
Image: Non-Section of the section	First Lien Term Loan, EURIBOR+8.50% cash due 3/10/2026	10.00.9/		F	16 911		10/11/	17 196	(6)(11)(15)		
Sunland Asphalt & Construction, LLC       Construction & Engineering         First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026       8.88 %       \$ 42,727       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       1       3,155       (6)         First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025       6.00 %       3,475       3,121       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       1       3,155       (6)       (6)(15)         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       1		10.00 %		C	10,911				(0)(11)(13)		
First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026       8.88 %       \$ 42,727       41,686       41,787       (6)(15)         Supermoose Borrower, LLC       Application Software       3,475       3,121       3,155       (6)         First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025       6.00 %       3,475       3,121       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       1 <t< td=""><td>Sunland Asphalt &amp; Construction, LLC</td><td></td><td></td><td></td><td></td><td></td><td>17,717</td><td>17,100</td><td></td></t<>	Sunland Asphalt & Construction, LLC						17,717	17,100			
41,686       41,787         Supermoose Borrower, LLC       Application Software         First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025       6.00 %       3,475       3,121       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings       1       3,155       (6)         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       12,500       12,472       11,833       (6)(15)	First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026	8.88 %	5	\$	42,727		41,686	41,787	(6)(15)		
Supermoose Borrower, LLC       Application Software         First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025       6.00 %       3,475       3,121       3,155       (6)         SVP-Singer Holdings Inc.       Home Furnishings         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       19,547       18,802       (6)(15)         Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026       6.75 %       12,500       12,472       11,833       (6)(15)											
First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025       6.00 %       3,475       3,121       3,155       (6)         SVP-Singer Holdings Inc.         Home Furnishings         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC         Auto Parts & Equipment         Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026         6.75 %       12,500       12,472       11,833       (6)(15)	Supermoose Borrower, LLC		Application Software								
3,121       3,155         SVP-Singer Holdings Inc.       Home Furnishings         First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       Auto Parts & Equipment       (6)(15)       (6)(15)         Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026       6.75 %       12,500       12,472       11,833       (6)(15)	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	6.00 %			3,475		3,121	3,155	(6)		
First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028       9.00 %       20,819       19,547       18,802       (6)(15)         Swordfish Merger Sub LLC       Auto Parts & Equipment       6.75 %       12,500       12,472       11,833       (6)(15)											
Swordfish Merger Sub LLC         Auto Parts & Equipment         19,547         18,802           Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026         6.75 %         12,500         12,472         11,833         (6)(15)	SVP-Singer Holdings Inc.		Home Furnishings								
Swordfish Merger Sub LLC         Auto Parts & Equipment         19,547         18,802           Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026         6.75 %         12,500         12,472         11,833         (6)(15)	First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028	9.00 %			20,819	_	19,547	18,802	(6)(15)		
Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026 6.75 % 12,500 12,472 11,833 (6)(15)							19,547	18,802			
	Swordfish Merger Sub LLC		Auto Parts & Equipment								
12.472 11.833	Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026	6.75 %			12,500		12,472	11,833	(6)(15)		
							12,472	11,833			

	<u>Cash</u> Interest Rate					
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>(6)</u>	<u>Industry</u>	<u>Principal (7)</u>	Cost	<u>Fair Value</u>	<u>Notes</u>
Tacala, LLC		Restaurants				
Second Lien Term Loan, LIBOR+7.50% cash due 2/4/2028	9.17 %		\$ 9,448	\$ 9,333	\$ 8,865	(6)
Tahoe Bidco B.V.		Application Software		9,333	8,865	
First Lien Term Loan, LIBOR+6.00% cash due 9/29/2028	7.12 %	Application Software	23,215	22,799	22,843	(6)(11)(15)
First Lien Revolver, LIBOR+6.00% cash due 10/1/2027	/.12 /0			(31)	(30)	(6)(11)(15)(19)
				22,768	22,813	
Tecta America Corp.		Construction & Engineering				
Second Lien Term Loan, LIBOR+8.50% cash due 4/9/2029	10.17 %	Engineering	5,203	5,125	5,099	(6)(15)
	10.17 /0		3,203	5,125	5,099	(0)(10)
Telestream Holdings Corporation		Application Software		-, -	-,	
First Lien Term Loan, SOFR+9.25% cash due 10/15/2025	10.59 %		18,370	17,971	17,984	(6)(15)
First Lien Revolver, SOFR+9.25% cash due 10/15/2025	10.59 %		703	681	667	(6)(15)(19)
				18,652	18,651	
TerSera Therapeutics LLC		Pharmaceuticals				
Second Lien Term Loan, LIBOR+9.50% cash due 3/30/2026	11.75 %		29,663	29,330	28,912	(6)(15)
668,879 Common Units of TerSera Holdings LLC				2,125	3,487	(15)
TGNR HoldCo LLC		Integrated Oil & Gas		31,455	32,399	
Subordinated Debt, 11.50% cash due 5/14/2026		integrated on & Gas	4,984	4,860	4,859	(10)(11)(15)
			,	4,860	4,859	
Thrasio, LLC		Internet & Direct				
First Lien Term Loan, LIBOR+7.00% cash due 12/18/2026	9.25 %	Marketing Retail	37,590	36,606	36,274	(6)(15)
8,434 Shares of Series C-3 Preferred Stock in Thrasio Holdings,	7.23 70		51,590	50,000	50,271	(0)(10)
Inc.				101	124	(15)
284,650.32 Shares of Series C-2 Preferred Stock in Thrasio Holdings, Inc.				2,409	4,196	(15)
48,352 Shares of Series D Preferred Stock in Thrasio Holdings, Inc.				979	979	(15)
23,201 Shares of Series X Preferred Stock in Thrasio Holdings, Inc.				22,986	26,487	(15)(19)
				63,081	68,060	× /× /
TIBCO Software Inc.		Application Software				
Second Lien Term Loan, LIBOR+7.25% cash due 3/3/2028	8.92 %		14,788	14,695	14,592	(6)
Taughatana Aganisitian Ing				14,695	14,592	
<b>Touchstone Acquisition, Inc.</b> First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	7.67 %	Health Care Supplies	6,031	5,918	5,850	(6)(15)
That Elen Term Elean, Elibore 0.0076 cash due 12/27/2020	1.07 /0		0,051	5,918	5,850	(0)(15)
Uniti Group LP		Specialized REITs		-,	-,	
Fixed Rate Bond, 6.50% cash due 2/15/2029			4,500	4,047	3,309	(11)
Fixed Rate Bond, 4.75% cash due 4/15/2028			300	256	247	(11)
Weither TO Lee				4,303	3,556	
Veritas US Inc. First Lien Term Loan, LIBOR+5.00% cash due 9/1/2025	7.25 %	Application Software	5,876	5 (0)	4 952	(6)
First Elen Tehn Loan, EHBORT 5.0076 cash due 9/1/2025	1.23 70		5,870	5,602 5,602	4,852 4,852	(6)
Win Brands Group LLC		Housewares & Specialties		3,002	4,052	
First Lien Term Loan, LIBOR+9.00% cash 5.00% PIK due		Specialities				
1/22/2026	12.00 %		3,791	3,755	3,753	(6)(15)
181 Class F Warrants in Brand Value Growth LLC (exercise price \$0.01) expiration date 1/25/2027				_	195	(15)
L L				3,755	3,948	()
Windstream Services II, LLC		Integrated Telecommunication Services				
First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	7.92 %	50111005	25,565	24,652	24,018	(6)
18,032 Shares of Common Stock in Windstream Holdings II,				017	200	(15)
LLC 109,420 Warrants in Windstream Holdings II, LLC				216 1,842	328 1,992	(15) (15)
				26,710	26,338	(13)
				20,710	20,000	

	<u>Cash</u> Interest Rate								
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	(6)	<u>Industry</u>	<u>Pri</u>	ncipal (7)		<u>Cost</u>	ŀ	Fair Value	<u>Notes</u>
WP CPP Holdings, LLC		Aerospace & Defense							
First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	4.99 %		\$	10,590	\$	9,849	\$	8,900	(6)
Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	8.99 %			16,000		15,797		13,240	(6)(15)
						25,646		22,140	
WPEngine, Inc.		Application Software							
First Lien Term Loan, LIBOR+6.00% cash due 3/27/2026	7.50 %			40,536		39,905		40,057	(6)(15)
						39,905		40,057	
WWEX Uni Topco Holdings, LLC		Air Freight & Logistics							
Second Lien Term Loan, LIBOR+7.00% cash due 7/26/2029	9.25 %			5,000		4,925		4,538	(6)(15)
					_	4,925	_	4,538	
Zayo Group Holdings Inc		Alternative Carriers							
Fixed Rate Bond, 6.125% cash due 3/1/2028				2,166		1,910		1,570	
Fixed Rate Bond, 4.00% cash due 3/1/2027				250		210		208	
						2,120		1,778	
Zep Inc.		Specialty Chemicals							
Second Lien Term Loan, LIBOR+8.25% cash due 8/11/2025	10.50 %			19,578		19,539		17,130	(6)(15)
						19,539		17,130	
Zephyr Bidco Limited		Specialized Finance							
Second Lien Term Loan, SONIA+7.50% cash due 7/23/2026	8.72 %		£	18,000		23,809		19,547	(6)(11)(15)
					_	23,809	_	19,547	
Total Non-Control/Non-Affiliate Investments (183.5% of net									
assets)					\$	2,378,626	-	2,319,104	
Total Portfolio Investments (203.0% of net assets)					\$	2,665,487	\$	2,565,389	
Cash and Cash Equivalents and Restricted Cash					•	0.657	<i>•</i>	0.657	
JP Morgan Prime Money Market Fund, Institutional Shares					\$	8,657	\$	8,657	
Other cash accounts						27,658		27,658	
Total Cash and Cash Equivalents and Restricted Cash (2.9% of net assets)					\$	36,315	\$	36,315	
Total Portfolio Investments and Cash and Cash Equivalents and Restricted Cash (205.9% of net assets)					\$	2,701,802	\$	2,601,704	
							-		

Derivative Instrument	onal Amount e Purchased		tional Amount to be Sold	Maturity Date	Counterparty	Un App	mulative prealized reciation / preciation)
Foreign currency forward contract	\$ 46,196	e	43,643	8/11/2022	JPMorgan Chase Bank, N.A.	\$	440
Foreign currency forward contract	\$ 49,442	£	40,109	8/11/2022	JPMorgan Chase Bank, N.A.		694
						\$	1,134

Derivative Instrument	Company Receives	Company Pays	Counterparty	Maturity Date	Notional Amount	Fair Value
Interest rate swap	Fixed 2.7%	Floating 3-month LIBOR +1.658%	Royal Bank of Canada	1/15/2027	\$350,000	\$(30,866)

- (1) All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.
- (2) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.
- (3) Equity ownership may be held in shares or units of companies related to the portfolio companies.
- (4) Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.
- (5) Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.
- (6) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to the London Interbank Offered Rate ("LIBOR") and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to the secured overnight financing rate ("SOFR") or the sterling overnight index average ("SONIA"). The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars unless otherwise noted. As of June 30, 2022, the reference rates for the Company's variable rate loans were the 30-day LIBOR at 1.67%, the 90-day LIBOR at 2.25%, the 180-day LIBOR at 2.88%, the 360-day LIBOR at 3.61%, the PRIME at 4.75%, the 30-day SOFR at 1.53%, the 90-day SOFR at 2.05%, the SONIA at 1.19%, the 30-day EURIBOR at (0.54)%, the 90-day EURIBOR at (0.30)% and the 180-day EURIBOR at (0.38)%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.
- (7) Principal includes accumulated payment in kind ("PIK") interest and is net of repayments, if any. "£" signifies the investment is denominated in British Pounds. "€" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars.
- (8) Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.
- (9) As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the nine months ended June 30, 2022 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.
- (10) This investment represents a participation interest in the underlying securities shown.
- (11) Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of June 30, 2022, qualifying assets represented 75.9% of the Company's total assets and non-qualifying assets represented 24.1% of the Company's total assets.
- (12) Income producing through payment of dividends or distributions.
- (13) One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a volume weighted average price ("VWAP") of \$15.00 per share for any ten trading days within any twenty trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any ten trading days within any twenty trading day period.
- (14) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition.
- (15) As of June 30, 2022, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820").
- (16) This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels.
- (17) Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.
- (18) Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.
- (19) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.
- (20) This investment was renamed during the three months ended March 31, 2022. For periods prior to March 31, 2022, this investment was referenced as Realfi Strategic Capital Funding LLC.

## Consolidated Schedule of Investments September 30, 2021

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	Industry	<u>Pr</u>	<u>incipal (7)</u>		<u>Cost</u>	E	<u>air Value</u>	<u>Notes</u>
Control Investments									(8)(9)
C5 Technology Holdings, LLC		Data Processing & Outsourced Services							
829 Common Units					\$	—	\$	_	(15)
34,984,460.37 Preferred Units						34,984		27,638	(15)
						34,984		27,638	
Dominion Diagnostics, LLC		Health Care Services							
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	6.00 %		\$	27,381		27,381		27,381	(6)(15)
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024				_		_		_	(6)(15)(19)
30,030.8 Common Units in DD Healthcare Services Holdings,									
LLC						18,625		18,065	(12)(15)
						46,006		45,446	
First Star Speir Aviation Limited		Airlines							(10)
First Lien Term Loan, 9.00% cash due 12/15/2025				7,500		_		7,500	(11)(15)
100% equity interest						6,332		698	(11)(12)(15)
						6,332		8,198	
OCSI Glick JV LLC		Multi-Sector Holdings							(14)
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	4.60 %			61,709		50,705		55,582	(6)(11)(15)(19)
87.5% equity interest									(11)(16)(19)
						50,705		55,582	
Senior Loan Fund JV I, LLC		Multi-Sector Holdings							(14)
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	8.00 %			96,250		96,250		96,250	(6)(11)(15)(19)
87.5% LLC equity interest						49,322		37,651	(11)(12)(16)(19)
						145,572		133,901	
Total Control Investments (20.6% of net assets)					\$	283,599	\$	270,765	
Affiliate Investments									(17)
Assembled Brands Capital LLC		Specialized Finance							
First Lien Revolver, LIBOR+6.00% cash due 10/17/2023	7.00 %		\$	15,899	\$	15,900	\$	15,712	(6)(15)(19)
1,609,201 Class A Units						764		587	(15)
1,019,168.80 Preferred Units, 6%						1,019		1,152	(15)
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029						_		_	(15)
expiration date style="border: 1px data; background-comparison: comparison; background-comparison: comparison; background-comparison; background-comparis						17,683		17,451	(15)
Caregiver Services, Inc.		Health Care Services				17,005		17,451	
1,080,399 shares of Series A Preferred Stock, 10%		Health Care Bervices				1,080		838	(15)
1,000,577 shales of Series 11 felened Stock, 1070						1,080		838	(15)
Total Affiliate Investments (1.4% of net assets)					\$	18,763	\$	18,289	
					-	10,700	-	10,207	
Non-Control/Non-Affiliate Investments									(18)
4 Over International, LLC		Commercial Printing							()
First Lien Term Loan, LIBOR+6.00% cash due 6/7/2022	7.00 %		\$	10,927	\$	10,524	\$	10,484	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 6/7/2022			*		*	(24)	*	(93)	(6)(15)(19)
						10,500		10,391	(*)(-*)(->)
109 Montgomery Owner LLC		Real Estate Operating Companies				10,000		10,071	
First Lien Delayed Draw Term Loan, LIBOR+7.00% cash due 2/2/2023	7.50 %			3,102		2,984		3,153	(6)(15)(19)
						2,984		3,153	
A.T. Holdings II SÀRL		Biotechnology							
First Lien Term Loan, 9.50% cash due 12/22/2022				37,158		36,930		36,972	(11)(15)
						36,930		36,972	
Access CIG, LLC		Diversified Support Services							
First Lien Term Loan, LIBOR+3.75% cash due 2/27/2025	3.83 %			5,352		5,021		5,332	(6)
Second Lien Term Loan, LIBOR+7.75% cash due 2/27/2026	7.83 %			17,000		16,923		17,028	(6)
						21,944		22,360	

#### Consolidated Schedule of Investments September 30, 2021 (dollar amounts in thousands)

Accupac, Inc.       Personal Products         First Lien Term Loan, LIBOR+6.00% cash due 1/17/2026       7.00 %       \$       16,140       \$       15,758       \$       16,140       (6)(15         First Lien Delayed Draw Term Loan, LIBOR+6.00% cash due 1/17/2026       -       (29)       -       (6)(15         First Lien Revolver, LIBOR+6.00% cash due 1/17/2026       7.00 %       1,838       1,789       1,838       (6)(15         First Lien Revolver, LIBOR+6.00% cash due 1/17/2026       7.00 %       1,838       1,789       1,838       (6)(15         Acquia Inc.       Application Software         First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025       8.00 %       27,349       26,936       27,295       (6)(15	5)(19) 5)(19) 5) 5)(19) 5)(19) 5)
First Lien Term Loan, LIBOR+6.00% cash due 1/17/2026       7.00 %       \$       16,140       \$       15,758       \$       16,140       (6)(15         First Lien Delayed Draw Term Loan, LIBOR+6.00% cash due 1/17/2026	5)(19) 5)(19) 5) 5)(19) 5)(19) 5)
First Lien Delayed Draw Term Loan, LIBOR+6.00% cash due       —       (29)       —       (6)(15)         First Lien Revolver, LIBOR+6.00% cash due 1/17/2026       7.00 %       1,838       1,789       1,838       (6)(15)         First Lien Revolver, LIBOR+6.00% cash due 1/17/2026       7.00 %       27,349       26,936       27,295       (6)(15)         Acquia Inc.       Application Software       —       —       148       175       (6)(15)         First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025       8.00 %       27,349       26,936       27,295       (6)(15)         ADB Companies, LLC       Construction & Engineering       —       148       175       (6)(15)         First Lien Term Loan, LIBOR+6.25% cash due 12/18/2025       7.25 %       15,463       14,817       15,287       (6)(15)         Aden & Anais Merger Sub, Inc.       Apparel, Accessories & Luxury Goods       51,665       —       (15)         51,645 Common Units in Aden & Anais Holdings, Inc.       51,665       —       (15)       (15)         Al Sirona (Luxembourg) Acquisition S.a.r.l.       Pharmaceuticals       27,720       28,738       (6)(11)         Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026       7.25 %       €       24,838       27,720       28,738       (6)(11)     <	5)(19) 5)(19) 5) 5)(19) 5)(19) 5)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	5)(19) 5) 5)(19) 5)(19) 5)
First Lien Revolver, LIBOR+6.00% cash due 1/17/2026       7.00 %       1,838       1,789       1,838       (6)(15         Acquia Inc.       Application Software       17,518       17,978       (6)(15         First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025       8.00 %       27,349       26,936       27,295       (6)(15         First Lien Revolver, LIBOR+7.00% cash due 10/31/2025       8.00 %       27,349       26,936       27,295       (6)(15         ADB Companies, LLC       Construction & Engineering       15,463       14,817       15,287       (6)(15         Aden & Anais Merger Sub, Inc.       Apparel, Accessories & Luxury Goods       15,165        (15)         Stona (Luxembourg) Acquisition S.a.r.l.       Pharmaceuticals       27,720       28,738       (6)(11         AirStrip Technologies, Inc.       Application Software       5,715        (15)         Strip Technologies, Inc.       Application Software        (15)         Strip Technologies, Inc.       Application Software        (15)         Strip Technologies, Inc.       Application Software         (15)         Strip Technologies, Inc.       Application Software        (15)         Strip Technologies, Inc.	5)(19) 5) 5)(19) 5)(19) 5)
Acquia Inc.       Application Software         First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025 $8.00$ % $27,349$ $26,936$ $27,295$ $(6)(15)$ First Lien Revolver, LIBOR+7.00% cash due 10/31/2025 $8.00$ % $179$ $148$ $175$ $(6)(15)$ ADB Companies, LLC       Construction & Engineering $7.25$ % $15,463$ $14,817$ $15,287$ $(6)(15)$ Aden & Anais Merger Sub, Inc.       Apparel, Accessories & Luxury Goods $51,665$ $ (15)$ S1,645 Common Units in Aden & Anais Holdings, Inc. $5,165$ $ (15)$ Al Sirona (Luxembourg) Acquisition S.a.r.l.       Pharmaceuticals $27,720$ $28,738$ $(6)(11)$ AirStrip Technologies, Inc.       Application Software $5,115$ $ (15)$ AirStrip Technologies, Inc.       Application Software $5,115$ $ (15)$ S,715 Common Stock Warrants (exercise price \$139.99)       explication Software $5,715$ $90$ $ (15)$	5) 5)(19) 5)
First Lien Term Loan, LIBOR+7.00% cash due 10/31/2025       8.00 %       27,349       26,936       27,295       (6)(15         First Lien Revolver, LIBOR+7.00% cash due 10/31/2025       8.00 %       179       148       175       (6)(15         ADB Companies, LLC       Construction & Engineering       27,349       26,936       27,295       (6)(15         First Lien Term Loan, LIBOR+6.25% cash due 12/18/2025       7.25 %       15,463       14,817       15,287       (6)(15         Aden & Anais Merger Sub, Inc.       Apparel, Accessories & Luxury Goods       51,645       —       (15)         51,645 Common Units in Aden & Anais Holdings, Inc. $5,165$ —       (15)         AI Sirona (Luxembourg) Acquisition S.a.r.l.       Pharmaceuticals       27,720       28,738       (6)(11)         Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026       7.25 %       €       24,838       27,720       28,738       (6)(11)         AirStrip Technologies, Inc.       Application Software       5,715       —       (15)       (15)         5,715 Common Stock Warrants (exercise price \$139.99) $90$ —       (15)       (15)	5)(19)
First Lien Revolver, LIBOR+7.00% cash due 10/31/2025       8.00 %       179       148       175       (6)(15         ADB Companies, LLC       Construction & Engineering       27,084       27,708       27,708       27,084       28,085       86,011	5)(19)
Z7,084Z7,470ADB Companies, LLCConstruction & EngineeringFirst Lien Term Loan, LIBOR+6.25% cash due 12/18/20257.25 %15,46314,81715,287(6)(15)Aden & Anais Merger Sub, Inc.Apparel, Accessories & Luxury Goods5,165—(15)Aden & Anais Merger Sub, Inc.Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/20267.25 % $€$ 24,83827,72028,738(6)(11)Al Sirona (Luxembourg) Acquisition S.a.r.l.PharmaceuticalsSecond Lien Term Loan, EURIBOR+7.25% cash due 9/28/20267.25 % $€$ 24,83827,72028,738(6)(11)AirStrip Technologies, Inc.Application Software90—(15)5,715 Common Stock Warrants (exercise price \$139.99) expiration date 5/11/202590—(15)	5)
ADB Companies, LLCConstruction & EngineeringFirst Lien Term Loan, LIBOR+6.25% cash due 12/18/2025 $7.25 \%$ $15,463$ $14,817$ $15,287$ $(6)(15)$ Aden & Anais Merger Sub, Inc.Apparel, Accessories & Luxury Goods $14,817$ $15,287$ $(6)(15)$ 51,645 Common Units in Aden & Anais Holdings, Inc. $5,165$ — $(15)$ At Sirona (Luxembourg) Acquisition S.a.r.l.Pharmaceuticals $27,720$ $28,738$ $(6)(11)$ Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026 $7.25 \%$ $€$ $24,838$ $27,720$ $28,738$ $(6)(11)$ AirStrip Technologies, Inc.Application Software $5,115$ — $(15)$ $(5,115)$ $(15)$ $5,155$ $(15)$ $(15)$ $(15)$ $(15)$ $(15)$ $(15)$ $(15)$ $28,738$ $(27,720)$ $28,738$ $(6)(11)$ $(15)$ $(15)$ $25,715$ Common Stock Warrants (exercise price \$139.99) $(15)$ $(15)$ $(15)$ $90$ $(15)$ $(15)$ $(15)$ $(15)$ $90$ $(15)$ $(15)$ $(15)$ $(15)$ $5,115$ $(15)$ $(15)$ $(15)$ $(15)$ $5,115$ $(15)$ $(15)$ $(15)$ $(15)$ $5,115$ $(15)$ $(15)$ $(15)$ $(15)$ $290$ $(15)$ $(15)$ $(15)$ $15,115$ $(15)$ $(15)$ $(15)$ $15,115$ $(15)$ $(15)$ $(15)$ $15,115$ $(15)$ $(15)$ $(15)$ $15,115$ $(15)$ <td></td>	
EngineeringFirst Lien Term Loan, LIBOR+6.25% cash due 12/18/2025 $7.25\%$ $15,463$ $14,817$ $15,287$ $(6)(15)$ Aden & Anais Merger Sub, Inc.Apparel, Accessories & Luxury Goods $5,165$ — $(15)$ Aden & Anais Merger Sub, Inc. $5,165$ — $(15)$ S1,645 Common Units in Aden & Anais Holdings, Inc. $5,165$ $(15)$ AI Sirona (Luxembourg) Acquisition S.a.r.l.PharmaceuticalsSecond Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026 $7.25\%$ $€$ $24,838$ $27,720$ $28,738$ $(6)(11)$ AirStrip Technologies, Inc.Application Software $90$ $ (15)$	
First Lien Term Loan, LIBOR+6.25% cash due 12/18/20257.25 %15,46314,81715,287(6)(15)Aden & Anais Merger Sub, Inc.Apparel, Accessories & Luxury Goods14,81715,287(6)(15)51,645 Common Units in Aden & Anais Holdings, Inc. $5,165$ —(15)Al Sirona (Luxembourg) Acquisition S.a.r.l.Pharmaceuticals $7.25$ % $€$ 24,838 $27,720$ 28,738Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026 $7.25$ % $€$ 24,838 $27,720$ 28,738(6)(11)AirStrip Technologies, Inc.Application Software $5,715$ Common Stock Warrants (exercise price \$139.99) expiration date $5/11/2025$ $90$ —(15)	
Aden & Anais Merger Sub, Inc.Apparel, Accessories & Luxury Goods $51,645$ Common Units in Aden & Anais Holdings, Inc. $5,165$ $ (15)$ 51,645 Common Units in Aden & Anais Holdings, Inc.Pharmaceuticals $5,165$ $ (15)$ AI Sirona (Luxembourg) Acquisition S.a.r.l.Pharmaceuticals $27,720$ $28,738$ $(6)(11)$ Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026 $7.25\%$ $€$ $24,838$ $27,720$ $28,738$ $(6)(11)$ AirStrip Technologies, Inc.Application Software $27,720$ $28,738$ $(6)(11)$ $5,715$ Common Stock Warrants (exercise price \$139.99) expiration date $5/11/2025$ $90$ $ (15)$	1)(15)
Since a strain of the stra	1)(15)
51,645 Common Units in Aden & Anais Holdings, Inc. $5,165$ — (15)AI Sirona (Luxembourg) Acquisition S.a.r.l.PharmaceuticalsSecond Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026 $7.25\%$ $€$ 24,838 $27,720$ $28,738$ $(6)(11)$ AirStrip Technologies, Inc.Application Software $5,715$ Common Stock Warrants (exercise price \$139.99) expiration date $5/11/2025$ $90$ — (15)	1)(15)
5,165 —AI Sirona (Luxembourg) Acquisition S.a.r.l.PharmaceuticalsSecond Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026 $7.25%$ $€$ $24,838$ $27,720$ $28,738$ $(6)(11)$ AirStrip Technologies, Inc. $5,715$ Common Stock Warrants (exercise price \$139.99) expiration date $5/11/2025$ $90$ — $(15)$	1)(15)
Second Lien Term Loan, EURIBOR+7.25% cash due 9/28/2026       7.25 %       €       24,838       27,720       28,738       (6)(11         AirStrip Technologies, Inc.       Application Software       5,715 Common Stock Warrants (exercise price \$139.99)       90       —       (15)	1)(15)
AirStrip Technologies, Inc.     Application Software       5,715 Common Stock Warrants (exercise price \$139.99)     90       expiration date 5/11/2025     90	1)(15)
AirStrip Technologies, Inc.       Application Software         5,715 Common Stock Warrants (exercise price \$139.99)       90 — (15)         90 — (15)	
5,715 Common Stock Warrants (exercise price \$139.99) expiration date 5/11/2025 90 — (15)	
$\frac{90 - (15)}{2}$	
90 —	
AD W/ALT ALT ALT	
All Web Leads, Inc.         Advertising           First Lien Term Loan, LIBOR+6.50% cash due 12/29/2023         7.50 %         \$ 23,899         21,512         22,992         (6)(15)	5)
First Lien Term Loan, LIBOR+6.50% cash due 12/29/2023       7.50 %       \$ 23,899       21,512       22,992       (6)(15)         21,512       22,992       22,992       (6)(15)	3)
Alvogen Pharma US, Inc. Pharmaceuticals	
First Lien Term Loan, LIBOR+5.25% cash due 12/31/2023 6.25 % 13,825 13,329 13,383 (6)	
1000000000000000000000000000000000000	
Alvotech Holdings S.A. Biotechnology (13)	
Fixed Rate Bond 15% PIK Tranche A due 6/24/2025 20,967 20,576 20,967 (11)(1	15)
Fixed Rate Bond 15% PIK Tranche B due 6/24/2025 20,512 20,169 20,512 (11)(1	
6,322 6,322 (15)	,
47,067 47,801	
Amplify Finco Pty Ltd. Movies & Entertainment	
First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026 5.00 % 15,376 13,814 14,985 (6)(11	1)(15)
Second Lien Term Loan, LIBOR+8.00% cash due 11/26/2027         8.75 %         12,500         12,188         12,063         (6)(11)	1)(15)
26,002     27,048       Ankura Consulting Group LLC     Research & Consulting	
Second Lian Term Loan LIPOP+8 00% cash dua 3/10/2020 8 75 % 7.466 7.354 7.666 (6)(15	5)
Second Lien Term Loan, LIBOR+8.00% cash due 3/19/2029 8.75 % 7,466 7,354 7,606 (6)(15	5)
Apptio, Inc. Application Software 7,354 7,606	
Application Software Application Software Sites	5)
	5) 5)(19)
Anst Elen Revolvel, Elboret 7.25 / Cash due 1/10/2025         8.25 / 0         892         843         858         (0)(15           34,269         34,780	
Ardonagh Midco 3 PLC Insurance Brokers	
First Lien Term Loan, EURIBOR+7.25% cash due 7/14/2026	1)(15)
First Lien Term Loan, UK LIBOR+7.25% cash due 7/14/2026	1)(13)
	1)(15)
First Lien Delayed Draw Term Loan, LIBOR+6.00% cash due 7/14/2026 \$ (6)(11	1)(15)(19
First Lien Delayed Draw Term Loan, SONIA+6.00% cash due	
	1)(15)(19
25,515 27,612	

# Consolidated Schedule of Investments September 30, 2021

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	Industry	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
Associated Asphalt Partners, LLC		Construction Materials				
First Lien Term Loan, LIBOR+5.25% cash due 4/5/2024	6.25 %		\$ 2,531	\$ 2,245	\$ 2,350	(6)
				2,245	2,350	
Athenex, Inc.		Pharmaceuticals				
First Lien Term Loan, 11.00% cash due 6/19/2026			42,145	40,475	41,845	(11)(15)
First Lien Delayed Draw Term Loan, 11.00% cash due 5/19/2026			_	(274)	(150)	(11)(15)(19)
328,149 Common Stock Warrants (exercise price \$12.63) expiration date 6/19/2027				973	95	(11)(15)
				41,174	41,790	
Aurora Lux Finco S.À.R.L.		Airport Services				
First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	7.00 %		22,655	22,232	21,318	(6)(11)(15)
The Avery		Real Estate Operating Companies		22,232	21,318	
First Lien Delayed Draw Term Loan in T8 Urban Condo Owner, LLC, LIBOR+7.30% cash due 2/17/2023	7.55 %	1	20,287	19,933	20,490	(6)(15)(19)
Subordinated Delayed Draw Debt in T8 Senior Mezz LLC,						
LIBOR+12.50% cash due 2/17/2023	12.75 %		4,692	4,614	4,698	(6)(15)(19)
				24,547	25,188	
BAART Programs, Inc.	0 <b>-</b> 0 ( )	Health Care Services				(0)(17)
Second Lien Term Loan, LIBOR+8.50% cash due 6/11/2028 Second Lien Delayed Draw Term Loan, LIBOR+8.50% cash due	9.50 %		7,166	7,059	7,130	(6)(15)
5/11/2028			_	(52)	(18)	(6)(15)(19)
				7,007	7,112	
Berner Food & Beverage, LLC	<b>7</b> 50 0/	Soft Drinks	22,412	22.044	22.044	(0)(1.7)
First Lien Term Loan, LIBOR+6.50% cash due 7/30/2027	7.50 %		33,412	32,844	32,844	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 7/30/2027	7.50 %		619	566	566	(6)(15)(19)
				33,410	33,410	
3lackhawk Network Holdings, Inc.		Data Processing & Outsourced Services				
Second Lien Term Loan, LIBOR+7.00% cash due 6/15/2026	7.13 %		30,625	30,181	30,523	(6)
				30,181	30,523	
Blumenthal Temecula, LLC		Automotive Retail				
First Lien Term Loan, 9.00% cash due 9/24/2023			3,979	3,980	3,979	(15)
,293,324 Preferred Units in Unstoppable Automotive AMV,				1,293	1,293	(15)
298,460 Preferred Units in Unstoppable Automotive VMV, LLC				298	298	(15)
298,460 Common Units in Unstoppable Automotive AMV, LLC				298	298	(15)
99,486 Common Units in Unstoppable Automotive MMV, LLC				100	278 99	(15)
				5,969	5,967	(15)
Cadence Aerospace, LLC		Aerospace & Defense		5,505	3,201	
First Lien Term Loan, LIBOR+6.50% cash 2.00% PIK due		- stospace & Detense				
11/14/2023	7.50 %		14,146	12,574	12,992	(6)(15)
				12,574	12,992	
Chief Power Finance II, LLC		Independent Power Producers & Energy Traders				
First Lien Term Loan, LIBOR+6.50% cash due 12/31/2022	7.50 %		23,850	23,458	23,552	(6)(15)
				23,458	23,552	
CircusTrix Holdings, LLC		Leisure Facilities				
First Lien Term Loan, LIBOR+5.50% cash 2.50% PIK due						(0)(1-2)(1-2)
7/16/2023	6.50 %		10,686	9,793	8,816	(6)(15)(19)
				9,793	8,816	
CITGO Holding, Inc.		Oil & Gas Refining & Marketing				
First Lien Term Loan, LIBOR+7.00% cash due 8/1/2023	8.00 %		11,635	11,517	11,512	(6)
Fixed Rate Bond, 9.25% cash due 8/1/2024			10,672	10,672	10,765	

## **Consolidated Schedule of Investments**

September 30, 2021

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	Principal (7)	Cost	<u>Fair Value</u>	Notes
CITGO Petroleum Corp.		Oil & Gas Refining &				
First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	7.25 %	Marketing	\$ 14,221	\$ 13,855	\$ 14,269	(6)
	7.20 70		φ 11,221	13,855	14,269	(0)
Clear Channel Outdoor Holdings Inc.		Advertising		- ,	,	
Fixed Rate Bond, 7.50% cash due 6/1/2029		U	7,137	7,137	7,431	(11)
				7,137	7,431	
Continental Intermodal Group LP		Oil & Gas Storage & Transportation				
irst Lien Term Loan, LIBOR+9.50% PIK due 1/28/2025		×	38,876	36,668	32,628	(6)(15)
Common Stock Warrants expiration date 7/28/2025				648	1,909	(15)
				37,316	34,537	
Convergeone Holdings, Inc.		IT Consulting & Other Services				
irst Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	5.08 %		7,024	6,848	7,003	(6)
				6,848	7,003	
Conviva Inc.		Application Software				
17,851 Shares of Series D Preferred Stock				605	894	(15)
				605	894	
CorEvitas, LLC		Health Care Services				
irst Lien Term Loan, LIBOR+5.50% cash due 12/13/2025	6.50 %		10,196	10,071	10,109	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due 2/13/2025	6.50 %		1,943	1,894	1,912	(6)(15)(19)
irst Lien Revolver, PRIME+4.50% cash due 12/13/2025	7.75 %		305	283	290	(6)(15)(19)
,099 Class A2 Common Units in CorEvitas Holdings, L.P.				1,038	1,177	(15)
				13,286	13,488	
Coty Inc.		Personal Products				
irst Lien Revolver, LIBOR+1.75% cash due 4/5/2023			—	(712)	• `	(6)(11)(15)(19
				(712)	(395)	
Coyote Buyer, LLC	<b>7</b> 00 0/	Specialty Chemicals	10.005	15.005	10.005	(0(17)
First Lien Term Loan, LIBOR+6.00% cash due 2/6/2026	7.00 %		18,387	17,887	18,225	(6)(15)
irst Lien Revolver, LIBOR+6.00% cash due 2/6/2025			_	(13)	(12) 18,213	(6)(15)(19)
Curium Bideo S.à.r.l.		Biotechnology		17,874	18,215	
Second Lien Term Loan, LIBOR+7.75% cash due 10/27/2028	8.50 %	Biotechnology	16,787	16,535	17,070	(6)(11)(15)
ceolid Elen Term Eban, Elbort (7.7576 cash dae 16/27/2626	0.50 /0		10,707	16,535	17,070	(0)(11)(13)
elta Topco, Inc.		Systems Software		10,000	17,070	
econd Lien Term Loan, LIBOR+7.25% cash due 12/1/2028	8.00 %	Systems Sourcare	6,680	6,647	6,769	(6)
			- ,	6,647		()
Dialyze Holdings, LLC		Health Care Equipment		,		
irst Lien Term Loan, LIBOR+7.00% cash 2.00% PIK due /4/2026	8.00 %		24,093	22,439	22,467	(6)(15)
irst Lien Delayed Draw Term Loan, LIBOR+7.00% cash 2.00% IK due 8/4/2026			_	(170)		(6)(15)(19)
403,823 Class A Warrants (exercise price \$1.00) expiration ate 8/4/2028				1,405	1,459	(15)
				23,674	23,763	(10)
Digital.AI Software Holdings, Inc.		Application Software		,-,		
irst Lien Term Loan, LIBOR+7.00% cash due 2/10/2027	8.00 %		10,003	9,627	9,783	(6)(15)
irst Lien Revolver, LIBOR+7.00% cash due 2/10/2027	8.00 %		180	151	156	(6)(15)(19)
				9,778	9,939	
DirecTV Financing, LLC		Cable & Satellite				
irst Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	5.75 %		27,000	26,730	27,048	(6)
				26,730	27,048	
Cagleview Technology Corporation		Application Software				
econd Lien Term Loan, LIBOR+7.50% cash due 8/14/2026	8.50 %		8,974	8,884	8,918	(6)(15)
				8,884	8,918	

# Consolidated Schedule of Investments September 30, 2021

	<u>Cash</u> Interest Rate							
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	(6)	<b>Industry</b>	<u>Principal (7)</u>	<u>Cost</u>		<u>Fai</u>	r Value	<u>Notes</u>
EHR Canada, LLC		Food Retail						
First Lien Term Loan, LIBOR+8.00% cash due 12/31/2021	9.00 %		\$ 3,750		745	\$	3,750	(6)(15)
				3,	745		3,750	
EOS Fitness Opco Holdings, LLC		Leisure Facilities						
487.5 Class A Preferred Units, 12%					488		274	(15)
12,500 Class B Common Units					_			(15)
					488		274	
Firstlight Holdco, Inc.		Alternative Carriers						
First Lien Term Loan, LIBOR+3.50% cash due 7/23/2025	3.58 %		7,012		578		6,939	(6)
				6,	578		6,939	
Fortress Biotech, Inc.		Biotechnology						
First Lien Term Loan, 11.00% cash due 8/27/2025			11,359	10,	722		11,075	(11)(15)
331,200 Common Stock Warrants (exercise price \$3.20) expiration date 8/27/2030					405		341	(11)(15)
				11,	127		11,416	
GI Chill Acquisition LLC		Managed Health Care						
First Lien Term Loan, LIBOR+3.75% cash due 8/6/2025	3.90 %		12,653	12,	442		12,621	(6)(15)
Second Lien Term Loan, LIBOR+7.50% cash due 8/6/2026	7.63 %		6,250	6,	212		6,219	(6)(15)
				18,	654		18,840	
GKD Index Partners, LLC		Specialized Finance						
First Lien Term Loan, LIBOR+8.50% cash due 6/29/2023	9.50 %		26,360	25,	837		25,931	(6)(15)
First Lien Revolver, LIBOR+8.50% cash due 6/29/2023	9.50 %		1,280	1,	251		1,252	(6)(15)(19)
				27,	088		27,183	
Global Medical Response, Inc.		Health Care Services						
First Lien Term Loan, LIBOR+4.25% cash due 3/14/2025	5.25 %		8,630	8,	399		8,674	(6)
				8,	399		8,674	
Gulf Operating, LLC		Oil & Gas Storage & Transportation						
First Lien Revolver, LIBOR+4.00% cash due 12/27/2021			_	(	704)		(75)	(6)(15)(19)
				(	704)		(75)	
Houghton Mifflin Harcourt Publishers Inc.		Education Services						
First Lien Term Loan, LIBOR+6.25% cash due 11/22/2024	7.25 %		1,007		981		1,009	(6)(11)
					981		1,009	
CIMs, Inc.		Application Software						
First Lien Term Loan, LIBOR+6.50% cash due 9/12/2024	7.50 %		25,635	25,	024		25,525	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 9/12/2024	7.50 %		1,176	1,	147		1,171	(6)(15)
				26,	171		26,696	
Immucor, Inc.		Health Care Supplies					_	
First Lien Term Loan, LIBOR+5.75% cash due 7/2/2025	6.75 %		8,657	8,	425		8,570	(6)(15)
Second Lien Term Loan, LIBOR+8.00% cash 3.50% PIK due 10/2/2025	9.00 %		21,834	21.	225		21,616	(6)(15)
			-,	29,			30,186	()(-)
Integral Development Corporation		Other Diversified Financial Services		,				
1,078,284 Common Stock Warrants (exercise price \$0.9274)								
expiration date 7/10/2024					113		_	(15)
					113		_	
Inventus Power, Inc.		Electrical Components & Equipment						
First Lien Term Loan, LIBOR+5.00% cash due 3/29/2024	6.00 %		18,849	18,	693		18,708	(6)(15)
Second Lien Term Loan, LIBOR+8.50% cash due 9/29/2024	9.50 %		13,674	13,	434		13,434	(6)(15)
				32,	127		32,142	

## **Consolidated Schedule of Investments**

September 30, 2021

<u>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</u>	<u>Cash</u> Interest Rate (6)	Industry	Principal (7)		<u>Cost</u>	<u>Fair Value</u>	Notes
INW Manufacturing, LLC		Personal Products					
First Lien Term Loan, LIBOR+5.75% cash due 5/7/2027	6.50 %		\$ 37,031	\$	35,988	\$ 36,291	(6)(15)
Itafos Inc.		Fertilizers &			35,988	36,291	
		Agricultural Chemicals					
First Lien Term Loan, LIBOR+8.25% cash due 8/25/2024	9.25 %		22,506		21,636	21,651	(6)(15)
					21,636	21,651	
Ivanti Software, Inc.	0.50.0/	Application Software	17.246		16064	15.0(0)	(0(15)
Second Lien Term Loan, LIBOR+8.50% cash due 12/1/2028	9.50 %		17,346		16,864	17,368	(6)(15)
Jazz Acquisition, Inc.		Aerospace & Defense			16,864	17,368	
First Lien Term Loan, LIBOR+7.50% cash due 1/29/2027	8.50 %	Actospace & Detense	36,603		35,292	36,531	(6)(15)
·····					35,292	36,531	()()
Latam Airlines Group S.A.		Airlines			,	,	
First Lien Delayed Draw Term Loan, LIBOR+11.00% PIK due			16.000		16005	16056	
3/29/2022			16,239		16,085	16,356	(6)(11)(15)(19)
Lift Brands Holdings, Inc.		Leisure Facilities			16,085	16,356	
2,000,000 Class A Common Units in Snap Investments, LLC		Leisure Facilities			1,399		(15)
, , , <b>1</b> ,					1,399		(10)
Lightbox Intermediate, L.P.		Real Estate Services			,		
First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	5.13 %		41,432		40,445	41,225	(6)(15)
					40,445	41,225	
LogMeIn, Inc.		Application Software					
First Lien Term Loan, LIBOR+4.75% cash due 8/31/2027	4.83 %		3,970		3,720	3,973	(6)
					3,720	3,973	
LTI Holdings, Inc.		Electronic Components					
Second Lien Term Loan, LIBOR+6.75% cash due 9/6/2026	6.83 %		10,140		10,080	10,127	(6)
Marinus Pharmaceuticals, Inc.		Pharmaceuticals			10,080	10,127	
First Lien Term Loan, 11.50% cash due 5/11/2026		Tharmaceuticais	3,441		3,377	3,389	(11)(15)
First Lien Delayed Draw Term Loan, 11.50% cash due					-,- ,	-,	()()
5/11/2026			6,881		6,755	6,778	(11)(15)(19)
					10,132	10,167	
Mayfield Agency Borrower Inc.		Property & Casualty Insurance					
First Lien Term Loan, LIBOR+4.50% cash due 2/28/2025	4.58 %		9,949		9,884	9,949	(6)
					9,884	9,949	
MedAssets Software Intermediate Holdings, Inc.		Health Care Technology					
Second Lien Term Loan, LIBOR+7.75% cash due 1/29/2029	8.50 %		14,137		13,877	13,960	(6)(15)
					13,877	13,960	
MHE Intermediate Holdings, LLC		Diversified Support					
First Lien Term Loan, LIBOR+5.75% cash due 7/21/2027		Services					
	6.75 %		16,429		16,111	16,100	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.75% cash due 7/21/2027	6.75 %		106		84	83	(6)(15)(19)
First Lien Revolver, LIBOR+5.75% cash due 7/21/2027			_	_	(27)	(28)	(6)(15)(19)
					16,168	16,155	
Mindbody, Inc.		Internet Services & Infrastructure					
First Lien Term Loan, LIBOR+7.00% cash 1.50% PIK due		masuuetuie					
2/14/2025	8.00 %		38,774		37,513	38,038	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 2/14/2025			_		(75)	(76)	(6)(15)(19)
					37,438	37,962	

# Consolidated Schedule of Investments September 30, 2021

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	<u>Principal (7)</u>	<u>Cost</u>	<u>Fair Value</u>	<u>Notes</u>
Ainistry Brands, LLC		Application Software				
First Lien Revolver, LIBOR+5.00% cash due 12/2/2022			\$ —	\$ (9)	( )	(6)(15)(19)
Second Lien Term Loan, LIBOR+9.25% cash due 6/2/2023	10.25 %		11,000	10,844	10,906	(6)(15)
		TT T		10,835	10,897	
Aosaic Companies, LLC		Home Improvement Retail				
First Lien Term Loan, LIBOR+6.75% cash due 7/2/2026	7.75 %		47,388	46,487	46,488	(6)(15)
				46,487	46,488	
IRI Software LLC		Application Software				
First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	6.50 %		27,352	26,815	27,335	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due				(25)	_	(6)(15)(19)
First Lien Revolver, LIBOR+5.50% cash due 2/10/2026			_	(13)	(1)	(6)(15)(19)
				26,777	27,334	(0)(13)(17)
Navisite, LLC		Data Processing &				
		Outsourced Services				
Second Lien Term Loan, LIBOR+8.50% cash due 12/30/2026	9.50 %		22,560	22,165	22,176	(6)(15)
				22,165	22,176	
NeuAG, LLC		Fertilizers & Agricultural Chemicals				
First Lien Term Loan, LIBOR+5.50% cash 7.00% PIK due		- Brioundian Chemicals				
/11/2024	7.00 %		47,031	45,279	45,996	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+5.50% cash 7.00% PIK due 9/11/2024	)			(202)	(120)	(6)(15)(10)
IK due 9/11/2024			_	(202) 45,077	(120) <b>45,876</b>	(6)(15)(19)
NN, Inc.		Industrial Machinery		43,077	43,870	
First Lien Term Loan, LIBOR+6.88% cash due 9/19/2026	7.88 %	industrial wideninery	59,309	57,971	58,419	(6)(11)(15)
	1.00 /0		0,000	57,971	58,419	(0)(11)(10)
DEConnection LLC		Application Software		0.,,,,1	00,115	
First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	4.08 %	· · · · · · · · · · · · · · · · · · ·	3,355	3,152	3,351	(6)
				3,152	3,351	
Dlaplex, Inc.		Personal Products				
First Lien Term Loan, LIBOR+6.25% cash due 1/8/2026	7.25 %		52,122	50,906	51,731	(6)(15)
irst Lien Revolver, LIBOR+6.25% cash due 1/8/2025			_	(58)	(75)	(6)(15)(19)
				50,848	51,656	
OmniSYS Acquisition Corporation		Diversified Support				
00.000 Common Units in OSVC Heldings, LLC		Services		1 000	700	(1.5)
00,000 Common Units in OSYS Holdings, LLC				1,000	729	(15)
Dnvoy, LLC		Integrated		1,000	729	
Sirvey, ELC		Telecommunication				
Single Ling Trans Lings LIDOD / 4 500/ seek dos 2/10/2024	5.50.0/	Services	2 (01	2.410	2 (02	(0)
First Lien Term Loan, LIBOR+4.50% cash due 2/10/2024 Second Lien Term Loan, LIBOR+10.50% cash due 2/10/2025	5.50 % 11.50 %		3,601 9,277	3,410	3,603	(6)
9,666.67 Class A Units in GTCR Onvoy Holdings, LLC	11.30 %		9,277	9,277	9,277	(6)(15)
3,664.73 Series 3 Class B Units in GTCR Onvoy Holdings,				1,967	2,372	(15)
LC						(15)
				14,654	15,252	
DTG Management, LLC		Airport Services				
First Lien Term Loan, LIBOR+10.00% cash due 9/1/2025	11.00 %		19,894	19,504	19,496	(6)(15)
First Lien Delayed Draw Term Loan, LIBOR+10.00% cash due //1/2025				(37)	(38)	(6)(15)(19)
				19,467	19,458	(0)(10)(17)
& L Development, LLC		Pharmaceuticals		17,107	17,100	
Fixed Rate Bond, 7.75% cash due 11/15/2025			7,776	7,832	8,089	
			. , •	7,832	8,089	
Park Place Technologies, LLC		Internet Services &				
and have reenhologies, here						
		Infrastructure				(0)
irst Lien Term Loan, LIBOR+5.00% cash due 11/10/2027	6.00 %	Infrastructure	9,950	9,479 9,479	9,961 9,961	(6)

# Consolidated Schedule of Investments September 30, 2021

Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	<u>Cash</u> Interest Rate (6)	Industry	Princ	cipal (7)		Cost	Fair Va	alue	Notes
Performance Health Holdings, Inc.			<u>11110</u>	<u>. ipai (7)</u>	-	<u>cost</u>	<u>ran va</u>	<u>iiuc</u>	<u>riotes</u>
First Lien Term Loan, LIBOR+6.00% cash due 7/12/2027	7.00 %	Health Care Distributors	\$	20,085	\$	19,698	\$ 19	9,683	(6)(15)
First Elen Term Loan, EIBOR (0.0076 cash due 7/12/2027	7.00 %		э	20,085	\$			<u></u>	(0)(13)
Pingora MSR Opportunity Fund I-A, LP		Thrifts & Mortgage				19,698	1	9,683	
r nigora MSK Opportunity Fund I-A, Li		Finance							
1.86% limited partnership interest						752		112	(11)(16)(19)
Dianation Devent Inc		Ann line time Colleman				752		112	
Planview Parent, Inc. Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	8.00 %	Application Software		28,627		20 100	21	2 600	(6)(15)
Second Elen Term Loun, Elbort (7.257) cush due 12/10/2020	8.00 70			28,027		28,198 28,198		8,699 <b>8,699</b>	(6)(15)
PLNTF Holdings, LLC		Leisure Facilities				20,170	20	3,077	
First Lien Term Loan, LIBOR+8.00% cash due 3/22/2026	9.00 %			13,729		13,482	1.	3,798	(6)(15)
						13,482	1.	3,798	
Pluralsight, LLC		Application Software							
First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	9.00 %			48,689		47,788	4	7,763	(6)(15)
First Lien Revolver, LIBOR+8.00% cash due 4/6/2027				_		(65)		(67)	(6)(15)(19)
PRGX Global, Inc.		Data Processing &				47,723	4'	7,696	
i KOA Olubal, Ilic.		Data Processing & Outsourced Services							
First Lien Term Loan, LIBOR+6.75% cash due 3/3/2026	7.75 %			34,118		33,016	33	3,547	(6)(15)
First Lien Revolver, LIBOR+6.75% cash due 3/3/2026				—		(44)		(42)	(6)(15)(19)
80,515 Class B Common Units						79		81	(15)
						33,051	3.	3,586	
ProFrac Services, LLC		Industrial Machinery							
First Lien Term Loan, LIBOR+8.50% cash due 9/15/2023	9.75 %			30,910		29,146	3	0,600	(6)(15)
						29,146	3	0,600	
Project Boost Purchaser, LLC		Application Software							
Second Lien Term Loan, LIBOR+8.00% cash due 5/31/2027	8.08 %			5,250		5,151		5,224	(6)(15)
Ouantum Bidco Limited		Food Distributors				5,151	:	5,224	
First Lien Term Loan, UK LIBOR+6.00% cash due 1/29/2028	6.11 %	Food Distributors	£	3,501		4,625		4,673	(6)(11)
	0.11 /0		2	5,501		4,625		4,673	(0)(11)
QuorumLabs, Inc.		Application Software				1,020		.,	
64,887,669 Junior-2 Preferred Stock		r r				375		_	(15)
						375		_	
Relativity ODA LLC		Application Software							
First Lien Term Loan, LIBOR+7.50% PIK due 5/12/2027			\$	22,856		22,337	22	2,376	(6)(15)
First Lien Revolver, LIBOR+6.50% cash due 5/12/2027				—		(52)		(47)	(6)(15)(19)
						22,285	2	2,329	
Renaissance Holding Corp.		Diversified Banks							
Second Lien Term Loan, LIBOR+7.00% cash due 5/29/2026	7.08 %			3,542		3,515		3,562	(6)
						3,515	i	3,562	
RevSpring, Inc.		Commercial Printing							(0)
First Lien Term Loan, LIBOR+4.25% cash due 10/11/2025	4.38 %			9,725		9,185		9,709	(6)
RumbleOn, Inc.						9,185		9,709	
		Automotive Retail							
First Lien Term Loan, LIBOR+8.25% cash due 8/31/2026	9.25 %			38,036		35,651	3:	5,640	(6)(11)(15)
First Lien Delayed Draw Term Loan, LIBOR+8.25% cash due 8/31/2026				_		(1,022)	(	1,027)	(6)(11)(15)(19
164,660 Class B Common Stock Warrants (exercise price									
\$33.00) expiration date 2/28/2023						1,202		1,553	(15)
						35,831	30	6,166	

# Consolidated Schedule of Investments September 30, 2021

<u>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</u>	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	<u>Prir</u>	<u>1cipal (7)</u>		Cost	<u>Fair V</u>	alue	Notes
Sabert Corporation		Metal & Glass Containers		• • • •					
First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	5.50 %	Containers	\$	1,818	\$	1,711	\$	1,825	(6)
· · · · · · · · · · · · · · · · · · ·	5.50 70		ψ	1,010		1,711	ψ	1,825	(0)
Scilex Pharmaceuticals Inc.		Pharmaceuticals				-,,		1,020	
Fixed Rate Zero Coupon Bond due 8/15/2026				7,692		6,512		7,169	(15)
•				.,		6,512		7,169	
ShareThis, Inc.		Application Software				, í		,	
345,452 Series C Preferred Stock Warrants (exercise price		**							
\$3.0395) expiration date 3/4/2024						367		_	(15)
						367		—	
SIO2 Medical Products, Inc.		Metal & Glass Containers							
Subordinated Debt, 11.25% cash due 2/28/2022				15,896		15,161		15,022	(15)
Subordinated Delayed Draw Debt, 11.25% cash due 2/28/2022						(110)		(119)	(15)(19)
Common Stock Warrants (exercise price \$0.75) expiration date									
7/31/2028						681		685	(15)
N*		D:				15,732		15,588	
Sirva Worldwide, Inc.		Diversified Support Services							
First Lien Term Loan, LIBOR+5.50% cash due 8/4/2025	5.58 %			1,739		1,554		1,644	(6)
				, î		1,554		1,644	
SM Wellness Holdings, Inc.		Health Care Services				, î			
Second Lien Term Loan, LIBOR+8.00% cash due 4/16/2029	8.75 %			9,109		8,972		9,177	(6)(15)
				, î		8,972	-	9,177	
SonicWall US Holdings Inc.		Technology Distributors				, í			
Second Lien Term Loan, LIBOR+7.50% cash due 5/18/2026	7.63 %			3,195		3,163		3,178	(6)
						3,163		3,178	
Sorrento Therapeutics, Inc.		Biotechnology							
50,000 Common Stock Units						197		382	(11)
						197		382	
Star US Bidco LLC		Industrial Machinery							
First Lien Term Loan, LIBOR+4.25% cash due 3/17/2027	5.25 %			1,194		1,114		1,199	(6)
						1,114		1,199	
SumUp Holdings Luxembourg S.À.R.L.		Other Diversified Financial Services							
First Lien Delayed Draw Term Loan, EURIBOR+8.50% cash		Financial Scivices							
due 3/10/2026	10.00 %		€	13,980		15,991		15,908	(6)(11)(15)(1
						15,991		15,908	
Sunland Asphalt & Construction, LLC		Construction & Engineering							
First Lien Term Loan, LIBOR+6.00% cash due 1/13/2026	7.00 %	Lingineering	\$	43,052		41,782		42,450	(6)(15)
First Lien Revolver, LIBOR+6.00% cash due 1/13/2022	7.00 %		*	203		150		169	(6)(15)(19)
,						41,932		42,619	
Supermoose Borrower, LLC		Application Software				, í		,	
First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	3.88 %			8,576		7,581		7,996	(6)
						7,581		7,996	
SVP-Singer Holdings Inc.		Home Furnishings							
First Lien Term Loan, LIBOR+6.75% cash due 7/28/2028	7.50 %			20,976		19,537		19,735	(6)(15)
					-	19,537		19,735	
Swordfish Merger Sub LLC		Auto Parts & Equipment							
Second Lien Term Loan, LIBOR+6.75% cash due 2/2/2026	7.75 %			12,500		12,466		12,365	(6)(15)
						12,466		12,365	
Facala, LLC		Restaurants							
Second Lien Term Loan, LIBOR+7.50% cash due 2/4/2028	8.25 %			9,448		9,317		9,451	(6)
					-	9,317	-	9,451	

## **Consolidated Schedule of Investments**

September 30, 2021

<u>Portfolio Company/Type of Investment (1)(2)(3)(4)(5)</u>	<u>Cash</u> Interest Rate (6)	<u>Industry</u>	<u>Pr</u>	incipal (7)	Cost	Fai	r Value	Notes
Tecta America Corp.		Construction & Engineering						
Second Lien Term Loan, LIBOR+8.50% cash due 4/9/2029	9.25 %	Engineering	\$	5,203	\$ 5,125	\$	5,203	(6)(15)
				,	 5,125		5,203	
Telestream Holdings Corporation		Application Software						
First Lien Term Loan, LIBOR+8.75% cash due 10/15/2025	9.75 %			18,510	18,017		18,250	(6)(15)
First Lien Revolver, LIBOR+8.75% cash due 10/15/2025	9.75 %			492	 464		468	(6)(15)(19)
					18,481		18,718	
TerSera Therapeutics LLC		Pharmaceuticals						
Second Lien Term Loan, LIBOR+9.50% cash due 3/30/2026	10.50 %			29,663	29,359		29,371	(6)(15)
668,879 Common Units of TerSera Holdings LLC					 2,192 31,551		3,487	(15)
TGNR HoldCo LLC		Integrated Oil & Gas			51,551		32,858	
Subordinated Debt, 11.50% cash due 5/14/2026		Integrated On & Gas		4,984	4,842		4,884	(11)(15)(20)
·				· · ·	 4,842		4,884	
Thermacell Repellents, Inc.		Leisure Products						
First Lien Term Loan, LIBOR+5.75% cash due 12/4/2026	6.75 %			6,636	6,603		6,603	(6)(15)
First Lien Revolver, LIBOR+5.75% cash due 12/4/2026				—	 (4)		(4)	(6)(15)(19)
Thrasio, LLC		Internet & Direct			6,599		6,599	
I nrasio, LLC		Marketing Retail						
First Lien Term Loan, LIBOR+7.00% cash due 12/18/2026	8.00 %			37,876	36,736		37,686	(6)(15)
8,434 Shares of Series C-3 Preferred Stock in Thrasio Holdings, Inc.					101		171	(15)
284,650.32 Shares of Series C-2 Preferred Stock in Thrasio Holdings, Inc.					2,410		5,764	(15)
23,201 Shares of Series X Preferred Stock in Thrasio Holdings, Inc.					 22,986 62,233		24,803 68,424	(15)(19)
TIBCO Software Inc.		Application Software			02,233		00,424	
Second Lien Term Loan, LIBOR+7.25% cash due 3/3/2028	7.34 %	rppneuton bonnare		16,788	16,681		17,002	(6)
				- ,	 16,681		17,002	(-)
TigerConnect, Inc.		Application Software						
299,110 Series B Preferred Stock Warrants (exercise price					(0)		595	(15)
\$1.3373) expiration date 12/8/2024					 <u>60</u> 60		525 525	(15)
Transact Holdings Inc.		Application Software			00		525	
First Lien Term Loan, LIBOR+4.75% cash due 4/30/2026	4.83 %	II		6,860	6,757		6,809	(6)(15)
					 6,757		6,809	
Velocity Commercial Capital, LLC		Thrifts & Mortgage						
First Lien Term Loan, LIBOR+8.00% cash due 2/5/2026	9.00 %	Finance		15,909	15,327		15,830	(6)(15)
installer rein Loui, Eldore 6.0070 cash duc 2/3/2020	9.00 70			15,909	 15,327		15,830	(0)(13)
Veritas US Inc.		Application Software			10,017		10,000	
First Lien Term Loan, LIBOR+5.00% cash due 9/1/2025	6.00 %	**		5,940	5,599		5,975	(6)
					5,599		5,975	
Vitalyst Holdings, Inc.		IT Consulting & Other Services						
675 Series A Preferred Stock Units					675		440	(15)
7,500 Class A Common Stock Units					 75			(15)
Win Brands Group LLC		Housewares & Specialties			750		440	
First Lien Term Loan, LIBOR+9.00% cash 5.00% PIK due 1/22/2026	10.00 %	Specialities		1,894	1,875		1,884	(6)(15)
181 Class F Warrants in Brand Value Growth LLC (exercise price \$0.01) expiration date 1/25/2027							119	(15)
r ·····/···					 1,875		2,003	()

# Consolidated Schedule of Investments September 30, 2021

	<u>Cash</u> Interest Rate							
Portfolio Company/Type of Investment (1)(2)(3)(4)(5)	(6)	<b>Industry</b>	<u>Pri</u>	<u>ncipal (7)</u>	<u>Cost</u>	ŀ	Fair Value	<u>Notes</u>
Windstream Services II, LLC		Integrated Telecommunication Services						
First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	7.25 %		\$	31,598	\$ 30,347	\$	31,793	(6)
18,032 Shares of Common Stock in Windstream Holdings II, LLC					216		363	(15)
109,420 Warrants in Windstream Holdings II, LLC					 1,842		2,199	(15)
					 32,405		34,355	
WP CPP Holdings, LLC		Aerospace & Defense						
First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	4.75 %			4,369	4,005		4,264	(6)
Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	8.75 %			16,000	 15,758		15,815	(6)(15)
					19,763		20,079	
WPEngine, Inc.		Application Software						
First Lien Term Loan, LIBOR+6.50% cash due 3/27/2026	7.50 %			40,536	 39,778		40,013	(6)(15)
					39,778		40,013	
WWEX Uni Topco Holdings, LLC		Air Freight & Logistics						
Second Lien Term Loan, LIBOR+7.00% cash due 7/26/2029	7.75 %			5,000	4,925		4,981	(6)
					 4,925	_	4,981	
Zep Inc.		Specialty Chemicals						
First Lien Term Loan, LIBOR+4.00% cash due 8/12/2024	5.00 %			6,495	6,165		6,353	(6)
Second Lien Term Loan, LIBOR+8.25% cash due 8/11/2025	9.25 %			22,748	 22,692		21,993	(6)(15)
					28,857		28,346	
Zephyr Bidco Limited		Specialized Finance						
Second Lien Term Loan, UK LIBOR+7.50% cash due $7/23/2026$	7.55 %		£	18,000	 23,783		24,210	(6)(11)
					23,783		24,210	
Total Non-Control/Non-Affiliate Investments (172.7% of net assets)					\$ 2,236,759	\$	2,267,575	
Total Portfolio Investments (194.7% of net assets)					\$ 2,539,121	\$	2,556,629	
Cash and Cash Equivalents and Restricted Cash								
JP Morgan Prime Money Market Fund, Institutional Shares					\$ 23,600	\$	23,600	
Other cash accounts					8,035		8,035	
Total Cash and Cash Equivalents and Restricted Cash (2.4% of net assets)					\$ 31,635	\$	31,635	

Derivative Instrument	al Amount Purchased		nal Amount be Sold	Maturity Date	Counterparty	Un Appi	nulative realized eciation / reciation)
Foreign currency forward contract	\$ 52,186	£	37,709	11/12/2021	JPMorgan Chase Bank, N.A.	\$	1,339
Foreign currency forward contract	\$ 46,663	e	39,736	11/12/2021	JPMorgan Chase Bank, N.A.	_	573
						\$	1,912

Derivative Instrument	<b>Company Receives</b>	Company Pays	Counterparty	Maturity Date	Notional Amount	Fair Value
Interest rate swap	Fixed 2.7%	Floating 3-month LIBOR +1.658%	Royal Bank of Canada	1/15/2027	\$350,000	\$(2,108)

#### Consolidated Schedule of Investments September 30, 2021 (dollar amounts in thousands)

- (1) All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.
- (2) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.
- (3) Equity ownership may be held in shares or units of companies related to the portfolio companies.
- (4) Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.
- (5) Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.
- (6) The interest rate on the principal balance outstanding for all floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over LIBOR or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars unless otherwise noted. As of September 30, 2021, the reference rates for the Company's variable rate loans were the 30-day LIBOR at 0.08%, the 60-day LIBOR at 0.11%, the 90-day LIBOR at 0.13%, the 180-day LIBOR at 0.16%, the 360-day LIBOR at 0.24%, the PRIME at 3.25%, the 30-day UK LIBOR at 0.05%, the 180-day UK LIBOR at 0.09%, the 30-day EURIBOR at (0.57)%, the 90-day EURIBOR at (0.56)% and the 180-day EURIBOR at (0.53)%. Most loans include an interest floor, which generally ranges from 0% to 1%.
- (7) Principal includes accumulated PIK interest and is net of repayments, if any. "£" signifies the investment is denominated in British Pounds. "€" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars.
- (8) Control Investments generally are defined by the Investment Company Act, as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.
- (9) As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the Company's annual report on Form 10-K for the year ended September 30, 2021 for transactions during the year ended September 30, 2021 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.
- (10) First Star Speir Aviation 1 Limited is a wholly-owned holding company formed by the Company in order to facilitate its investment strategy. In accordance with ASU 2013-08, the Company has deemed the holding company to be an investment company under accounting principles generally accepted in the United States ("GAAP") and therefore deemed it appropriate to consolidate the financial results and financial position of the holding company and to recognize dividend income versus a combination of interest income and dividend income. Accordingly, the debt and equity investments in the wholly-owned holding company are disregarded for accounting purposes since the economic substance of these instruments are equity investments in the operating entities.
- (11) Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of September 30, 2021, qualifying assets represented 75.7% of the Company's total assets and non-qualifying assets represented 24.3% of the Company's total assets.
- (12) Income producing through payment of dividends or distributions.
- (13) PIK interest income for this investment accrues at an annualized rate of 15%, however, the PIK interest is not contractually capitalized on the investment subsequent to a restructure that occurred during the year ended September 30, 2021. As a result, the principal amount of the investment does not increase over time for accumulated PIK interest. As of September 30, 2021, the accumulated PIK interest balance for the A notes and the B notes was \$0.9 million and \$0.8 million, respectively.
- (14) See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition.
- (15) As of September 30, 2021, these investments were categorized as Level 3 within the fair value hierarchy established by FASB guidance under ASC 820.
- (16) This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels.
- (17) Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.
- (18) Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.
- (19) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.
- (20) This investment represents a participation interest in the underlying securities shown.

#### Note 1. Organization

Oaktree Specialty Lending Corporation (together with its consolidated subsidiaries, the "Company") is a specialty finance company that looks to provide customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The Company was formed in late 2007 and operates as a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act. The Company has qualified and elected to be treated as a regulated investment company ("RIC") under the Internal Revenue Code of 1986, as amended (the "Code"), for U.S. federal income tax purposes.

The Company's investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. The Company may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions.

The Company is externally managed by Oaktree Fund Advisors, LLC ("Oaktree"), a subsidiary of Oaktree Capital Group, LLC ("OCG"), pursuant to an investment advisory agreement between the Company and Oaktree (as amended and restated, the "Investment Advisory Agreement"). Oaktree is an affiliate of Oaktree Capital Management, L.P. ("OCM"), the Company's external investment adviser from October 17, 2017 through May 3, 2020 and also a subsidiary of OCG. Oaktree Fund Administration, LLC ("Oaktree Administrator"), a subsidiary of OCM, provides certain administrative and other services necessary for the Company to operate pursuant to an administration agreement between the Company and Oaktree Administration Agreement"). See Note 10. In 2019, Brookfield Asset Management Inc. ("Brookfield") acquired a majority economic interest in OCG. OCG operates as an independent business within Brookfield, with its own product offerings and investment, marketing and support teams.

On March 19, 2021, the Company acquired Oaktree Strategic Income Corporation ("OCSI"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 28, 2020, by and among OCSI, the Company, Lion Merger Sub, Inc., a wholly-owned subsidiary of the Company ("Merger Sub"), and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the Merger Agreement, Merger Sub was first merged with and into OCSI, with OCSI as the surviving corporation (the "Merger"), and, immediately following the Merger, OCSI was then merged with and into the Company, with the Company as the surviving company (together with the Merger, the "Mergers"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of OCSI's common stock was converted into the right to receive 1.3371 shares of the Company's common stock (with OCSI's stockholders receiving cash in lieu of fractional shares of the Company's common stock). As a result of the Mergers, the Company issued an aggregate of 39,400,011 shares of its common stock to former OCSI stockholders.

### Note 2. Significant Accounting Policies

#### **Basis of Presentation:**

The Consolidated Financial Statements of the Company have been prepared in accordance with GAAP and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the Consolidated Financial Statements have been made. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946, *Financial Services - Investment Companies* ("ASC 946").

### Use of Estimates:

The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition.

### **Consolidation:**

The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries.

As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value.

## Fair Value Measurements:

The Company values its investments in accordance with ASC 820, which defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.

Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

- Level 1 Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.
- Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.
- Level 3 Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.

Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.

The Company seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If the Company is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within the Company's set threshold, the Company seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, the Company does not adjust any of the prices received from these sources.

If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, the Company values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its

forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. The Company may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and the Company considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, the Company depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.

In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.

The Company estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.

The Company's Board of Directors undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments:

- The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team in conjunction with Oaktree's portfolio management team and investment professionals responsible for each portfolio investment;
- · Preliminary valuations are then reviewed and discussed with management of Oaktree;
- Separately, independent valuation firms approved by the Board of Directors prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree and the Audit Committee of the Board of Directors;
- Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee;
- The Audit Committee reviews the preliminary valuations with Oaktree, and Oaktree responds and supplements the preliminary valuations to reflect any discussions between Oaktree and the Audit Committee;
- The Audit Committee makes a recommendation to the full Board of Directors regarding the fair value of the investments in the Company's portfolio; and
- The Board of Directors discusses valuations and determines the fair value of each investment in the Company's portfolio.

The fair value of the Company's investments as of June 30, 2022 and September 30, 2021 was determined in good faith by the Board of Directors. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter, and the Board of Directors may reasonably rely on that assistance. However, the Board of Directors is responsible for the ultimate valuation of the portfolio investments at fair value as determined in good faith pursuant to the Company's valuation policy and a consistently applied valuation process.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.

With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax asset, net," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due

from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable," "director fees payable" and "payables from unsettled transactions" approximate fair value due to their short maturities.

### Foreign Currency Translation:

The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

## Derivative Instruments:

## Foreign Currency Forward Contracts

The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts are recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations.

### Interest Rate Swaps

The Company uses an interest rate swap to hedge some of the Company's fixed rate debt. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of the interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swap is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreement are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities.

### Investment Income:

### Interest Income

Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of each of June 30, 2022 and September 30, 2021, there were no investments on non-accrual status.

In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.

#### PIK Interest Income

The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company's debt investments increases the recorded cost bases of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company's stockholders, even though the Company has not yet collected the cash and may never do so.

#### Fee Income

Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered.

The Company has also structured exit fees across certain of its portfolio investments to be received upon the future exit of those investments. These fees are typically paid to the Company upon the earliest to occur of (i) a sale of the borrower or substantially all of the assets of the borrower, (ii) the maturity date of the loan or (iii) the date when full prepayment of the loan occurs. The receipt of such fees is contingent upon the occurrence of one of the events listed above for each of the investments. These fees are included in net investment income over the life of the loan.

#### Dividend Income

The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.

#### Cash and Cash Equivalents and Restricted Cash:

Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts may exceed the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.

As of June 30, 2022 and September 30, 2021, included in restricted cash was \$2.0 million and \$2.3 million, respectively, that was held at Wells Fargo Bank, N.A. in connection with the Citibank Facility (as defined in Note 6. Borrowings). Pursuant to the terms of the Citibank Facility, the Company was restricted in terms of access to \$2.0 million and \$2.3 million as of June 30, 2022 and September 30, 2021, respectively, until the occurrence of the periodic distribution dates and, in connection therewith, the Company's submission of its required periodic reporting schedules and verifications of the Company's compliance with the terms of the Citibank Facility.

### Due from Portfolio Companies:

Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company (*e.g.*, principal payments on the scheduled amortization payment date).

## **Receivables/Payables from Unsettled Transactions:**

Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.

## **Deferred Financing Costs:**

Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Company's Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment.

## **Deferred Offering Costs:**

Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.

## Income Taxes:

The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. The Company did not incur a U.S. federal excise tax for calendar years 2020 and 2021 and does not expect to incur a U.S. federal excise tax for calendar years 2020 and 2021 and does not expect to incur a U.S. federal excise tax for calendar years 2020 and 2021 and does not expect to incur a U.S. federal excise tax for calendar years 2020 and 2021 and does not expect to incur a U.S. federal excise tax for calendar years 2020 and 2021 and does not expect to incur a U.S. federal excise tax for calendar years 2020 and 2021 and does not expect to incur a U.S. federal excis

The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to

offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.

FASB ASC Topic 740, *Accounting for Uncertainty in Income Taxes* ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2019, 2020 and 2021. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months.

## **Recently Adopted Accounting Pronouncements**

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting if certain criteria are met. The guidance is effective from March 12, 2020 through December 31, 2022. As of June 30, 2022, the adoption of this guidance did not have an impact on the Company's Consolidated Financial Statements.

## Note 3. Portfolio Investments

As of June 30, 2022, 203.0% of net assets at fair value, or \$2.6 billion, was invested in 151 portfolio companies, including (i) \$119.3 million in subordinated notes and limited liability company ("LLC") equity interests of Senior Loan Fund JV I, LLC ("SLF JV I"), a joint venture through which the Company and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation ("Kemper"), co-invest in senior secured loans of middle-market companies and other corporate debt securities and (ii) \$50.6 million in subordinated notes and LLC equity interests of OCSI Glick JV LLC ("Glick JV" and, together with SLF JV I, the "JVs"), a joint venture through which the Company and GF Equity Funding 2014 LLC ("GF Equity Funding") co-invest primarily in senior secured loans of middle-market companies. As of June 30, 2022, 2.9% of net assets at fair value, or \$36.3 million, was invested in cash and cash equivalents (including \$2.0 million of restricted cash). In comparison, as of September 30, 2021, 194.7% of net assets at fair value, or \$2.6 billion, was invested in 138 portfolio investments, including (i) \$133.9 million in subordinated notes and LLC equity interests of SLF JV I and (ii) \$55.6 million in subordinated notes and LLC equity interests of SLF JV I and (ii) \$55.6 million, was invested in cash and cash equivalents 30, 2021, 2.4% of net assets at fair value, or \$31.6 million, was invested in cash and cash equivalents and 8.2% consisted of subordinated debt investments, including the debt investments in the JVs. As of September 30, 2021, 86.7% of the Company's portfolio at fair value consisted of senior secured debt investments, including the debt investments in the JVs.

The Company also held equity investments in certain of its portfolio companies consisting of common stock, preferred stock, warrants, limited partnership interests or LLC equity interests. These instruments generally do not produce a current return but are held for potential investment appreciation and capital gain.

During the three and nine months ended June 30, 2022, the Company recorded net realized gains of \$9.2 million and \$19.9 million, respectively. During the three and nine months ended June 30, 2021, the Company recorded net realized gains of \$8.6 million and \$22.7 million, respectively. During the three and nine months ended June 30, 2022, the Company recorded net unrealized depreciation of \$86.8 million and \$118.4 million, respectively. During the three and nine months ended June 30, 2022, the Company recorded net unrealized depreciation of \$86.8 million and \$118.4 million, respectively. During the three and nine months ended June 30, 2021, the Company recorded net unrealized appreciation of \$3.9 million and \$116.6 million, respectively.

The composition of the Company's investments as of June 30, 2022 and September 30, 2021 at cost and fair value was as follows:

		June 3	0, 202	22	 Septembe	r 30,	2021
	Cost Fair Value			Fair Value	Cost		Fair Value
Investments in debt securities	\$	2,342,876	\$	2,285,461	\$ 2,222,223	\$	2,259,924
Investments in equity securities		126,647		110,049	120,621		107,222
Debt investments in the JVs		146,642		146,856	146,955		151,832
Equity investments in the JVs		49,322		23,023	49,322		37,651
Total	\$	2,665,487	\$	2,565,389	\$ 2,539,121	\$	2,556,629

The following table presents the composition of the Company's debt investments as of June 30, 2022 and September 30, 2021 at fixed rates and floating rates:

	 June 3	0, 2022	 Septembe	r 30, 2021
	 Fair Value	% of Debt Portfolio	Fair Value	% of Debt Portfolio
Floating rate debt securities, including the debt investments in the JVs	\$ 2,136,619	87.84 %	\$ 2,205,648	91.45 %
Fixed rate debt securities	295,698	12.16	206,108	8.55
Total	\$ 2,432,317	100.00 %	\$ 2,411,756	100.00 %

The following table presents the financial instruments carried at fair value as of June 30, 2022 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820:

	]	Level 1	Level 2	Level 3	 leasured at Net Asset Value (a)	Total
Investments in debt securities (senior secured)	\$		\$ 290,889	\$ 1,930,714	\$ 	\$ 2,221,603
Investments in debt securities (subordinated, including the debt investments in the JVs)			55,134	155,580		210,714
Investments in equity securities (preferred)		—	—	81,616	—	81,616
Investments in equity securities (common and warrants, including LLC equity interests of the JVs)		4,928		23,505	23,023	51,456
Total investments at fair value		4,928	 346,023	 2,191,415	 23,023	 2,565,389
Cash equivalents		8,657				8,657
Derivative assets			1,134			1,134
Total assets at fair value	\$	13,585	\$ 347,157	\$ 2,191,415	\$ 23,023	\$ 2,575,180
Derivative liability	\$		\$ 30,866	\$ 	\$ 	\$ 30,866
Total liabilities at fair value	\$		\$ 30,866	\$ 	\$ 	\$ 30,866

(a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities.

The following table presents the financial instruments carried at fair value as of September 30, 2021 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820:

				I	easured at Net Asset	
	 Level 1	 Level 2	 Level 3		Value (a)	 Total
Investments in debt securities (senior secured)	\$ 	\$ 338,707	\$ 1,878,536	\$	—	\$ 2,217,243
Investments in debt securities (subordinated, including the debt investments in the JVs)		18,196	176,317		_	194,513
Investments in equity securities (preferred)			63,565			63,565
Investments in equity securities (common and warrants, including LLC equity interests of the						
JVs)	 382	 	 43,163		37,763	 81,308
Total investments at fair value	382	356,903	2,161,581		37,763	2,556,629
Cash equivalents	23,600					23,600
Derivative assets		1,912	_		_	1,912
Total assets at fair value	\$ 23,982	\$ 358,815	\$ 2,161,581	\$	37,763	\$ 2,582,141
Derivative liability	\$ 	\$ 2,108	\$ 	\$		\$ 2,108
Total liabilities at fair value	\$ 	\$ 2,108	\$ 	\$		\$ 2,108

(a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities.

When a determination is made to classify a financial instrument within Level 3 of the valuation hierarchy, the determination is based upon the fact that the unobservable factors are significant to the overall fair value measurement. However, Level 3 financial instruments typically have both unobservable or Level 3 components and observable components (i.e. components that are actively quoted and can be validated by external sources). Accordingly, the appreciation (depreciation) in the tables below includes changes in fair value due in part to observable factors that are part of the valuation methodology. Transfers between levels are recognized at the beginning of the reporting period.

The following table provides a roll-forward in the changes in fair value from March 31, 2022 to June 30, 2022 for all investments for which the Company determined fair value using unobservable (Level 3) factors:

					Inve	stments		
	Se	Senior cured Debt	1	Subordinated Debt (including bt investments in the JVs)		referred Equity	Common Equity and Warrants	Total
Fair value as of March 31, 2022	\$	1,955,858	\$	160,727	\$	84,372	\$ 33,588	\$ 2,234,545
Purchases		60,692		29		_	125	60,846
Sales and repayments		(91,730)		(733)		_	(3,890)	(96,353)
Transfers in (a)		28,475		_		_		28,475
Transfers out (b)		_		_		_	(5,838)	(5,838)
Capitalized PIK interest income		5,537		_		_		5,537
Accretion of OID		5,100		430		_	_	5,530
Net unrealized appreciation (depreciation)		(33,208)		(4,873)		(2,756)	(873)	(41,710)
Net realized gains (losses)		(10)		_			393	383
Fair value as of June 30, 2022	\$	1,930,714	\$	155,580	\$	81,616	\$ 23,505	\$ 2,191,415
Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of June 30, 2022 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2022	\$	(33,199)	\$	(4,873)	\$	(2,756)	\$ (917)	\$ (41,745)

(a) There were transfers into Level 3 from Level 2 for certain investments during the three months ended June 30, 2022 as a result of a change in the number of market quotes available and/or a change in market liquidity.

(b) This transfer out was the result of a transaction in which Level 3 common equity was exchanged for Level 1 common equity.

The following table provides a roll-forward in the changes in fair value from March 31, 2021 to June 30, 2021 for all investments for which the Company determined fair value using unobservable (Level 3) factors:

	Investments									
	Se	Senior cured Debt	I	Subordinated Debt (including bt investments in the JVs)	Preferred Equity			Common Equity and Warrants		Total
Fair value as of March 31, 2021	\$	1,590,290	\$	157,954	\$	51,796	\$	50,339	\$	1,850,379
Purchases		153,259		5,041		_		—		158,300
Sales and repayments		(91,799)		(2,977)				(22,422)		(117,198)
Transfers in (a)		—		—		_		6,322		6,322
Transfers out (a)		(6,322)		—				—		(6,322)
Capitalized PIK interest income		4,243		—		_		—		4,243
Accretion of OID		7,383		297		—		_		7,680
Net unrealized appreciation (depreciation)		4,585		781		664		(2,784)		3,246
Net realized gains (losses)		(52)		344		—		7,093		7,385
Fair value as of June 30, 2021	\$	1,661,587	\$	161,440	\$	52,460	\$	38,548	\$	1,914,035
Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of June 30, 2021 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2021	\$	11,295	\$	1,085	\$	664	\$	656	\$	13,700

(a) There was one transfer from senior secured debt to common equity and warrants during the three months ended June 30, 2021 as a result of an investment restructuring, in which \$6.3 million of senior secured debt was exchanged for \$6.3 million of common equity.

The following table provides a roll-forward in the changes in fair value from September 30, 2021 to June 30, 2022 for all investments for which the Company determined fair value using unobservable (Level 3) factors:

				Inv	estments		Investments										
	Se	Senior cured Debt	Subordinated Debt (including debt investments in the JVs)		Preferred Equity	Common Equity and Warrants		Total									
Fair value as of September 30, 2021	\$	1,878,536	\$ 176,317	\$	63,565	\$ 43,163	\$	2,161,581									
Purchases		437,922	3,777		19,243	2,180		463,122									
Sales and repayments		(391,959)	(21,868)		(163)	(12,836)		(426,826)									
Transfers in (a)		37,042	—			—		37,042									
Transfers out (a)(b)		(17,070)	_		—	(5,838)		(22,908)									
Capitalized PIK interest income		16,653	313		_			16,966									
Accretion of OID		19,048	1,628		_	_		20,676									
Net unrealized appreciation (depreciation)		(57,909)	(4,587)		(517)	(2,520)		(65,533)									
Net realized gains (losses)		8,451	_		(512)	(644)		7,295									
Fair value as of June 30, 2022	\$	1,930,714	\$ 155,580	\$	81,616	\$ 23,505	\$	2,191,415									
Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of June 30, 2022 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2022	\$	(45,187)	\$ (4,734)	\$	(752)	\$ (7,629)	\$	(58,302)									

(a) There were transfers into/out of Level 3 from/to Level 2 for certain investments during the nine months ended June 30, 2022 as a result of a change in the number of market quotes available and/or a change in market liquidity.

(b) This transfer out was the result of a transaction in which Level 3 common equity was exchanged for Level 1 common equity.

The following table provides a roll-forward in the changes in fair value from September 30, 2020 to June 30, 2021 for all investments for which the Company determined fair value using unobservable (Level 3) factors:

				Inve	stments		
	Se	Senior cured Debt	Subordinated Debt (including bt investment in the JVs)	F	Preferred Equity	Common Equity and Warrants	Total
Fair value as of September 30, 2020	\$	904,237	\$ 126,152	\$	29,959	\$ 35,080	\$ 1,095,428
Purchases (a)		923,185	51,327		19,958	2,377	996,847
Sales and repayments		(246,671)	(44,191)		(31)	(28,622)	(319,515)
Transfers in (b)(c)(d)		18,458	_		_	6,759	25,217
Transfers out (d)		(6,322)	_		_	_	(6,322)
Capitalized PIK interest income		10,991	_		_		10,991
Accretion of OID		11,806	1,328		_	_	13,134
Net unrealized appreciation (depreciation)		47,469	18,089		2,543	12,618	80,719
Net realized gains (losses)		(1,566)	8,735		31	10,336	17,536
Fair value as of June 30, 2021	\$	1,661,587	\$ 161,440	\$	52,460	\$ 38,548	\$ 1,914,035
Net unrealized appreciation (depreciation) relating to Level 3 investments still held as of June 30, 2021 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2021	\$	51,977	\$ 4,770	\$	2,543	\$ 12,429	\$ 71,719

(a) Includes the Level 3 investments acquired in connection with the Mergers during the nine months ended June 30, 2021.(b) There were transfers into Level 3 from Level 2 for certain investments during the nine months ended June 30, 2021 as a result of a change in the number of market quotes available and/or a change in market liquidity.

(c) There was a transfer into Level 3 from Level 2 as a result of an investment restructuring in which Level 2 senior secured debt was exchanged for Level 3 senior secured debt and common equity.

(d) There was one transfer from senior secured debt to common equity and warrants during the nine months ended June 30, 2021 as a result of an investment restructuring, in which \$6.3 million of senior secured debt was exchanged for \$6.3 million of common equity.

## Significant Unobservable Inputs for Level 3 Investments

The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of June 30, 2022:

Asset	F	air Value	Valuation Technique	Unobservable Input		Range	Weighted Average (a)
Senior Secured Debt	\$	1,559,851	Market Yield	Market Yield	(b)	7.0% - 25.0%	12.7%
		25,835	Enterprise Value	EBITDA Multiple	(c)	5.0x - 7.0x	6.0x
		23,937	Transaction Precedent	Transaction Price	(d)	N/A - N/A	N/A
		321,091	Broker Quotations	Broker Quoted Price	(e)	N/A - N/A	N/A
Subordinated Debt		8,724	Market Yield	Market Yield	(b)	13.0% - 17.0%	14.8%
Debt Investments in the JVs		146,856	Enterprise Value	N/A	(f)	N/A - N/A	N/A
Preferred & Common Equity		63,662	Enterprise Value	Revenue Multiple	(c)	0.5x - 8.4x	4.5x
		41,336	Enterprise Value	EBITDA Multiple	(c)	3.3x - 17.7x	10.5x
		3	Enterprise Value	Asset Multiple	(c)	0.9x - 1.1x	1.0x
		120	Transaction Precedent	Transaction Price	(d)	N/A - N/A	N/A
Total	\$	2,191,415					

<sup>(</sup>a) Weighted averages are calculated based on fair value of investments.

<sup>(</sup>b) Used when market participants would take into account market yield when pricing the investment.

<sup>(</sup>c) Used when market participants would use such multiples when pricing the investment.

<sup>(</sup>d) Used when there is an observable transaction or pending event for the investment.

<sup>(</sup>e) The Company generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. The Company evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably

estimated. Each quoted price is evaluated by the Audit Committee of the Company's Board of Directors in conjunction with additional information compiled by Oaktree.

(f) The Company determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique.

The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September 30, 2021:

Asset	F	air Value	Valuation Technique	ique Unobservable Input		Range		Weighted Average (a)
Senior Secured Debt	\$	1,413,373	Market Yield	Market Yield	(b)	4.0% -	30.0%	10.4%
		36,197	Enterprise Value	EBITDA Multiple	(c)	3.0x -	9.0x	4.5x
		7,500	Enterprise Value	Asset Multiple	(c)	0.9x -	1.1x	1.0x
		421,466	Broker Quotations	Broker Quoted Price	(e)	N/A -	N/A	N/A
Subordinated Debt		24,485	Market Yield	Market Yield	(b)	12.0% -	14.0%	12.6%
Debt Investments in the JVs		151,832	Enterprise Value	N/A	(f)	N/A -	N/A	N/A
Preferred & Common Equity		6,188	Enterprise Value	Revenue Multiple	(c)	0.9x -	11.2x	2.5x
		93,520	Enterprise Value	EBITDA Multiple	(c)	3.0x -	35.0x	15.9x
		698	Enterprise Value	Asset Multiple	(c)	0.9x -	1.1x	1.0x
		6,322	Transactions Precedent	Transaction Price	(d)	N/A -	N/A	N/A
Total	\$	2,161,581						

(a) Weighted averages are calculated based on fair value of investments.

- (b) Used when market participants would take into account market yield when pricing the investment.
- (c) Used when market participants would use such multiples when pricing the investment.
- (d) Used when there is an observable transaction or pending event for the investment.
- (e) The Company generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. The Company evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Each quoted price is evaluated by the Audit Committee of the Company's Board of Directors in conjunction with additional information compiled by Oaktree.
- (f) The Company determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique.

Under the market yield technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively.

Under the EV technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt or equity securities is the earnings before interest, taxes, depreciation and amortization ("EBITDA"), revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively.

### Financial Instruments Disclosed, But Not Carried, At Fair Value

The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of June 30, 2022 and the level of each financial liability within the fair value hierarchy:

	 Carrying Value	Fair Value	L	evel 1	Level 2	 Level 3
Syndicated Facility payable	\$ 575,000	\$ 575,000	\$	_	\$ —	\$ 575,000
Citibank Facility payable	170,000	170,000		_	_	170,000
2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)	296,678	283,956		_	283,956	_
2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)	 314,928	301,144		_	301,144	_
Total	\$ 1,356,606	\$1,330,100	\$		\$ 585,100	\$ 745,000

The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September 30, 2021 and the level of each financial liability within the fair value hierarchy:

	 Carrying Value	Fair Value	Le	vel 1	Level 2	Level 3
Syndicated Facility payable	\$ 495,000	\$ 495,000	\$		\$ —	\$ 495,000
Citibank Facility payable	135,000	135,000		—	—	135,000
2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)	295,740	314,541		_	314,541	_
2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)	343,003	351,134		_	351,134	_
Total	\$ 1,268,743	\$1,295,675	\$		\$ 665,675	\$ 630,000

The principal values of the credit facilities payable approximate fair value due to their variable interest rates and are included in Level 3 of the hierarchy. The Company used market quotes as of the valuation date to estimate the fair value of its 3.500% notes due 2025 (the "2025 Notes") and 2.700% notes due 2027 (the "2027 Notes"), which are included in Level 2 of the hierarchy.

## Portfolio Composition

Summaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables:

	_	June 3	0, 2022	September 30, 2021		
Cost:			% of Total Investments		% of Total Investments	
Senior secured debt	S	2,269,332	85.14 %	\$ 2,179,907	85.85 %	
Debt investments in the JVs		146,642	5.50 %	146,955	5.79 %	
Preferred equity		84,881	3.18 %	65,939	2.60 %	
Subordinated debt		73,544	2.76 %	42,316	1.67 %	
LLC equity interests of the JVs		49,322	1.85 %	49,322	1.94 %	
Common equity and warrants		41,766	1.57 %	54,682	2.15 %	
Total	\$	2,665,487	100.00 %	\$ 2,539,121	100.00 %	

		June 30, 2022		 S		
Fair Value:		% of Total Investments	% of Net Assets		% of Total Investments	% of Net Assets
Senior secured debt	\$ 2,221,603	86.60 %	175.82 %	\$ 2,217,243	86.72 %	168.89 %
Debt investments in the JVs	146,856	5.72 %	11.63 %	151,832	5.94 %	11.56 %
Preferred equity	81,616	3.18 %	6.46 %	63,565	2.49 %	4.84 %
Subordinated debt	63,858	2.49 %	5.05 %	42,681	1.67 %	3.25 %
LLC equity interests of the JVs	28,433	1.11 %	2.25 %	37,651	1.47 %	2.87 %
Common equity and warrants	23,023	0.90 %	1.82 %	43,657	1.71 %	3.33 %
Total	\$ 2,565,389	100.00 %	203.03 %	\$ 2,556,629	100.00 %	194.74 %

The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets:

	 June 30	September 30, 2021		
Cost:		% of Total Investments		% of Total Investments
Northeast	\$ 736,761	27.65 %	\$ 720,781	28.39 %
Midwest	389,291	14.60 %	385,846	15.20 %
West	363,764	13.65 %	365,471	14.39 %
Southeast	357,164	13.40 %	294,339	11.59 %
International	293,670	11.02 %	268,817	10.59 %
Southwest	240,777	9.03 %	256,227	10.09 %
South	192,806	7.23 %	156,764	6.17 %
Northwest	91,254	3.42 %	90,876	3.58 %
Total	\$ 2,665,487	100.00 %	\$ 2,539,121	100.00 %

		June 30, 2022		382,475 14.96 % 29.13		l
Fair Value:		% of Total Investments	% of Net Assets			
Northeast	\$ 694,038	27.07 %	54.92 %	\$ 721,647	28.24 %	54.97 %
Midwest	372,834	14.53 %	29.51 %	382,475	14.96 %	29.13 %
West	355,367	13.85 %	28.12 %	371,257	14.52 %	28.28 %
Southeast	349,474	13.62 %	27.66 %	299,486	11.71 %	22.81 %
International	280,481	10.93 %	22.20 %	275,904	10.79 %	21.02 %
Southwest	237,561	9.26 %	18.80 %	258,940	10.13 %	19.72 %
South	185,473	7.23 %	14.68 %	155,526	6.08 %	11.85 %
Northwest	90,161	3.51 %	7.14 %	91,394	3.57 %	6.96 %
Total	\$ 2,565,389	100.00 %	203.03 %	\$ 2,556,629	100.00 %	194.74 %

The following tables show the composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of June 30, 2022 and September 30, 2021:

	June	30, 2022	September 3	0, 2021
Cost:		% of Total Investments	×	% of Total Investments
Application Software	\$ 407,964	15.30 % \$	367,265	14.49 %
Multi-Sector Holdings (1)	195,964	7.35	196,277	7.73
Pharmaceuticals	129,031	4.84	138,250	5.44
Data Processing & Outsourced Services	120,453	4.52	120,381	4.74
Biotechnology	102,578	3.85	111,856	4.41
Health Care Technology	98,274	3.69	13,877	0.55
Industrial Machinery	78,306	2.94	88,231	3.47
Aerospace & Defense	74,567	2.80	67,629	2.66
Specialized Finance	73,757	2.77	68,554	2.70
Internet & Direct Marketing Retail	67,975	2.55	62,233	2.45
Fertilizers & Agricultural Chemicals	64,598	2.42	66,713	2.63
Construction & Engineering	61,195	2.30	61,874	2.44
Health Care Services Automotive Retail	59,504 59,138	2.23 2.22	84,750	3.34 1.65
Internet Services & Infrastructure			41,800	
Personal Products	53,814	2.02 1.99	46,917	1.85 4.08
Metal & Glass Containers	53,042		103,642	
	46,711 46,497	1.75	17,443	0.69
Health Care Distributors		1.74	19,698	0.78
Home Improvement Retail Leisure Facilities	46,046	1.73	46,487	1.83 0.99
	42,986	1.61	25,162	
Airport Services Peal Estate Services	42,900 40,293	1.61 1.51	41,699	1.64 1.59
Real Estate Services	40,293 39,449		40,445	1.59
Real Estate Operating Companies Diversified Support Services	39,449 38,017	1.48 1.43	27,531 40,666	1.08
Specialty Chemicals	37,740	1.42	46,731	1.84
Health Care Supplies	36,248	1.36	29,650	1.17
Insurance Brokers	35,652	1.34	25,515	1.00 1.85
Integrated Telecommunication Services Soft Drinks	34,675	1.30	47,059	
	34,607	1.30	33,410	1.32 1.27
Electrical Components & Equipment	33,816	1.27	32,127	1.27
Oil & Gas Storage & Transportation	31,419 29,930	1.18 1.12	36,612	1.44
Advertising			28,649	0.63
Other Diversified Financial Services	29,286	1.10	16,104	1.42
Oil & Gas Refining & Marketing	27,686	1.04	36,044	
Movies & Entertainment Distributors	26,121	0.98 0.95	26,002	1.02
	25,293		22 674	0.93
Health Care Equipment Environmental & Facilities Services	24,134 19,580	0.91 0.73	23,674	0.93
	19,580	0.73	19,537	0.77
Home Furnishings Cable & Satellite		0.73	26,730	1.05
Systems Software	19,279 14,886	0.72	6,647	0.26
Consumer Finance	14,880	0.50	0,047	0.20
Hotels, Resorts & Cruise Lines		0.54	_	
	13,941 12,472	0.32		0.49
Auto Parts & Equipment		0.47	12,466 7,598	0.30
IT Consulting & Other Services	11,711 10,138	0.44	7,354	0.30
Research & Consulting Services	9,664	0.38	4,925	0.19
Air Freight & Logistics Restaurants	9,004	0.30	9,317	0.19
			9,517	0.04
Education Services Trading Companies & Distributors	9,068 7,616	0.34 0.29	981	0.04
			5,165	0.20
Apparel, Accessories & Luxury Goods Integrated Oil & Gas	5,165 4,860	0.19 0.18	4,842	0.20
Food Distributors	4,860 4,643	0.18	4,842 4,625	0.19
Apparel Retail	4,643 4,408	0.17	4,020	0.18
Specialized REITs	4,408 4,303	0.17		
Communications Equipment	4,303 3,774	0.16	_	_
Housewares & Specialties	3,774	0.14	1,875	0.07
Diversified Banks	3,755	0.14	3,515	0.07
Technology Distributors	3,515 3,163	0.13	3,515	0.14
Construction Materials	2,309	0.12	2,245	0.12
Alternative Carriers	2,309 2,120	0.09	2,243 6,578	0.09
Electronic Components	2,120	0.08	10,080	0.26
Independent Power Producers & Energy Traders	2,090	0.08	23,458	0.40
Airlines	_	_	23,438 22,417	0.92
Commercial Printing			19,685	0.88
			19,685	
Managed Health Care			18,654	0.73 0.63
Thrifts & Mortgage Finance Property & Casualty Insurance	—	——————————————————————————————————————		0.63
			9,884	
Leisure Products Food Retail	—	——————————————————————————————————————	6,599 3 745	0.26
roou retaii	e	100.00.0/	3,745	0.15
	\$ 2,665,487	100.00 % \$	2,339,121	100.00 %

	June 30, 2022			September 30, 2021			
Fair Value:		% of Total Investments	% of Net Assets		% of Total Investments	% of Net Assets	
Application Software	\$ 403,073	15.69 %	31.94 %	\$ 372,606	14.58 %	28.39 %	
Multi-Sector Holdings (1)	169,879	6.62	13.44	189,483	7.41	14.43	
Pharmaceuticals	121,216	4.73	9.59	142,194	5.56	10.83	
Data Processing & Outsourced Services	112,348	4.38	8.89	113,923	4.46	8.68	
Biotechnology	101,748	3.97	8.05	113,641	4.44	8.66	
Health Care Technology	96,449	3.76	7.63	13,960	0.55	1.06	
Industrial Machinery	77,516	3.02	6.13	90,218	3.53	6.87	
Internet & Direct Marketing Retail	72,773	2.84	5.76	68,424	2.68	5.21	
Aerospace & Defense	72,127	2.81	5.71	69,602	2.72	5.30	
Specialized Finance	68,856	2.68	5.45	68,844	2.69	5.24	
Fertilizers & Agricultural Chemicals Construction & Engineering	64,565 61,536	2.52 2.40	5.11 4.87	67,527 63,109	2.64 2.47	5.14 4.81	
Automotive Retail	58,201	2.40	4.61	42,133	1.65	3.21	
Internet Services & Infrastructure	54,068	2.11	4.28	47,923	1.87	3.65	
Health Care Services	52,574	2.05	4.16	84,735	3.31	6.45	
Personal Products	52,165	2.03	4.13	105,530	4.13	8.04	
Metal & Glass Containers	46,658	1.82	3.69	17,413	0.68	1.33	
Home Improvement Retail	45,907	1.79	3.63	46,488	1.82	3.54	
Health Care Distributors	44,778	1.75	3.54	19,683	0.77	1.50	
Airport Services	42,001	1.64	3.32	40,776	1.59	3.11	
Leisure Facilities	41,519	1.62	3.29	22,888	0.90	1.74	
Real Estate Services	40,086	1.56	3.17	41,225	1.61	3.14	
Real Estate Operating Companies	39,994	1.56	3.17	28,341	1.11	2.16	
Diversified Support Services	37,144	1.45	2.94	40,888	1.60	3.11	
Health Care Supplies	36,295	1.41	2.87	30,186	1.18	2.30	
Specialty Chemicals	35,393	1.38	2.80	46,559	1.82	3.55	
Insurance Brokers	34,995	1.36	2.77	27,612	1.08	2.10	
Soft Drinks	33,918	1.32	2.68	33,410	1.31	2.54	
Integrated Telecommunication Services	33,264	1.30 1.28	2.63 2.60	49,607	1.94 1.26	3.78 2.45	
Electrical Components & Equipment Advertising	32,802 28,394	1.28	2.00	32,142 30,423	1.19	2.43	
Oil & Gas Storage & Transportation	28,045	1.09	2.23	34,462	1.35	2.63	
Oil & Gas Refining & Marketing	27,465	1.07	2.17	36,546	1.43	2.78	
Movies & Entertainment	26,953	1.05	2.13	27,048	1.06	2.06	
Other Diversified Financial Services	25,623	1.00	2.03	15,908	0.62	1.21	
Distributors	24,579	0.96	1.95	_	_	_	
Health Care Equipment	23,805	0.93	1.88	23,763	0.93	1.81	
Environmental & Facilities Services	19,211	0.75	1.52	—	—	_	
Home Furnishings	18,802	0.73	1.49	19,735	0.77	1.50	
Cable & Satellite	18,068	0.70	1.43	27,048	1.06	2.06	
Consumer Finance	14,317	0.56	1.13	—	—	—	
Hotels, Resorts & Cruise Lines	13,939	0.54	1.10	_	_		
Systems Software	12,713	0.50	1.01	6,769	0.26	0.52	
Auto Parts & Equipment	11,833	0.46	0.94	12,365	0.48	0.94	
IT Consulting & Other Services	10,272	0.40 0.37	0.81 0.75	7,443	0.29 0.30	0.57 0.58	
Research & Consulting Services Air Freight & Logistics	9,479 9,074	0.37	0.73	7,606 4,981	0.30	0.38	
Restaurants	8,865	0.35	0.72	9,451	0.19	0.38	
Education Services	8,541	0.33	0.68	1,009	0.04	0.08	
Trading Companies & Distributors	5,828	0.23	0.46			0.00	
Integrated Oil & Gas	4,859	0.19	0.38	4,884	0.19	0.37	
Apparel Retail	4,368	0.17	0.35		_	_	
Housewares & Specialties	3,948	0.15	0.31	2,003	0.08	0.15	
Communications Equipment	3,559	0.14	0.28	_	_	_	
Specialized REITs	3,556	0.14	0.28	_	_	_	
Food Distributors	3,540	0.14	0.28	4,673	0.18	0.36	
Diversified Banks	3,310	0.13	0.26	3,562	0.14	0.27	
Technology Distributors	3,069	0.12	0.24	3,178	0.12	0.24	
Electronic Components	1,957	0.08	0.15	10,127	0.40	0.77	
Construction Materials	1,791	0.07	0.14	2,350	0.09	0.18	
Alternative Carriers	1,778	0.07	0.14	6,939	0.27	0.53	
Airlines	_	_	_	24,554	0.96	1.87	
Independent Power Producers & Energy Traders	—	—	—	23,552	0.92	1.79	
Commercial Printing Managed Health Care	—			20,100	0.79 0.74	1.53 1.44	
Managed Health Care Thrifts & Mortgage Finance	_		_	18,840 15,942	0.74	1.44	
Property & Casualty Insurance		_	_	9,949	0.39	0.76	
			_	6,599	0.26	0.50	
Leisure Products	_	_		().)99			
Leisure Products Food Retail		_	_	3,750	0.15	0.29	

(1) This industry includes the Company's investments in the JVs and certain limited partnership interests.

As of June 30, 2022 and September 30, 2021, the Company had no single investment that represented greater than 10% of the total investment portfolio at fair value. Income, consisting of interest, dividends, fees, other investment income and realization of gains or losses, may fluctuate and in any given period can be highly concentrated among several investments.

## Senior Loan Fund JV I, LLC

In May 2014, the Company entered into an LLC agreement with Kemper to form SLF JV I. The Company co-invests in senior secured loans of middle-market companies and other corporate debt securities with Kemper through its investment in SLF JV I. SLF JV I is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by Kemper. All portfolio decisions and investment decisions in respect of SLF JV I must be approved by the SLF JV I investment committee, which consists of one representative selected by the Company and one representative selected by Kemper (with approval from a representative of each required). Since the Company does not have a controlling financial interest in SLF JV I, the Company does not consolidate SLF JV I.

SLF JV I is capitalized pro rata with LLC equity interests as transactions are completed and may be capitalized with additional subordinated notes issued to the Company and Kemper by SLF JV I. The subordinated notes issued by SLF JV I (the "SLF JV I Notes") are senior in right of payment to SLF JV I LLC equity interests and subordinated in right of payment to SLF JV I V I's secured debt. As of June 30, 2022 and September 30, 2021, the Company and Kemper owned, in the aggregate, 87.5% and 12.5%, respectively, of the LLC equity interests of SLF JV I and the outstanding SLF JV I Notes. SLF JV I is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act.

SLF JV I has a senior revolving credit facility with Deutsche Bank AG, New York Branch (as amended, the "SLF JV I Deutsche Bank Facility"), which permitted up to \$260.0 million of borrowings (subject to borrowing base and other limitations) as of each of June 30, 2022 and September 30, 2021. Borrowings under the SLF JV I Deutsche Bank Facility are secured by all of the assets of SLF JV I Funding LLC, a special purpose financing subsidiary of SLF JV I. As of June 30, 2022, the reinvestment period of the SLF JV I Deutsche Bank Facility was scheduled to expire May 3, 2023 and the maturity date was May 3, 2028. As of June 30, 2022, borrowings under the SLF JV I Deutsche Bank Facility accrued interest at a rate equal to 3-month LIBOR plus 2.00% per annum during the reinvestment period, 3-month LIBOR plus 2.15% per annum for the first year after the reinvestment period, 3-month LIBOR plus 2.25% for the following year and 3-month LIBOR plus 2.50% thereafter, in each case with a 0.125% LIBOR floor. \$215.0 million and \$215.6 million of borrowings were outstanding under the SLF JV I Deutsche Bank Facility as of June 30, 2022 and September 30, 2021, respectively.

As of June 30, 2022 and September 30, 2021, SLF JV I had total assets of \$365.0 million and \$379.2 million, respectively. SLF JV I's portfolio primarily consisted of senior secured loans to 56 and 55 portfolio companies as of June 30, 2022 and September 30, 2021, respectively. The portfolio companies in SLF JV I are in industries similar to those in which the Company may invest directly. As of June 30, 2022, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$119.3 million in aggregate, at fair value. As of September 30, 2021, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$119.3 million in aggregate, at fair value.

As of each of June 30, 2022 and September 30, 2021, the Company and Kemper had funded approximately \$165.5 million to SLF JV I, of which \$144.8 million was from the Company. As of each of June 30, 2022 and September 30, 2021, the Company had aggregate commitments to fund SLF JV I of \$35.0 million, of which approximately \$26.2 million was to fund additional SLF JV I Notes and approximately \$8.8 million was to fund LLC equity interests in SLF JV I.

Below is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of June 30, 2022 and September 30, 2021:

	June 30, 2022	September 30, 2021
Senior secured loans (1)	\$357,198	\$344,196
Weighted average interest rate on senior secured loans (2)	6.79%	5.60%
Number of borrowers in SLF JV I	56	55
Largest exposure to a single borrower (1)	\$9,650	\$9,875
Total of five largest loan exposures to borrowers (1)	\$47,298	\$46,984

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

# SLF JV I Portfolio as of June 30, 2022

Portfolio Company	Investment Type	<u>Cash</u> <u>Interest</u> <u>Rate (1)(2)</u>	<u>Industry</u>	<u>Principal</u>	Cost	<u>Fair Value</u> (3)	Notes
Access CIG, LLC	First Lien Term Loan, LIBOR+3.75% cash due 2/27/2025	5.32 %	Diversified Support Services	\$ 9,038	\$ 9,017	\$ 8,561	
ADB Companies, LLC	First Lien Term Loan, LIBOR+6.25% cash due 12/18/2025	8.50 %	Construction & Engineering	8,641	8,500	8,498	(4)
Alvogen Pharma US, Inc.	First Lien Term Loan, LIBOR+5.25% cash due 12/31/2023	7.50 %	Pharmaceuticals	9,385	9,273	8,291	(4)
American Tire Distributors, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	7.00 %	Distributors	4,885	4,824	4,631	(4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	5.92 %	Movies & Entertainment	7,820	7,742	7,631	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	6.00 %	Personal Products	1,543	1,206	1,238	(4)
Apptio, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 1/10/2025	7.25 %	Application Software	4,615	4,576	4,511	(4)
Apptio, Inc.	First Lien Revolver, LIBOR+6.00% cash due 1/10/2025	7.25 %	Application Software	154	151	145	(4)(5)
Total Apptio, Inc.				4,769	4,727	4,656	
ASP-R-PAC Acquisition Co LLC	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2027	7.67 %	Paper Packaging	4,187	4,110	4,086	
ASP-R-PAC Acquisition Co LLC	First Lien Revolver, LIBOR+6.00% cash due 12/29/2027		Paper Packaging		(9)	(12)	(5)
Total ASP-R-PAC Acquisition Co LLC				4,187	4,101	4,074	
Astra Acquisition Corp.	First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	6.92 %	Application Software	6,670	6,507	5,831	(4)
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	6.92 %	Property & Casualty Insurance	1,846	1,828	1,579	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	7.63 %	Airport Services	6,353	6,252	6,030	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	6.67 %	Health Care Services	6,386	6,327	6,291	
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	6.60 %	Health Care Services	1,577	1,558	1,533	(4)(5)
Total BAART Programs, Inc.				7,963	7,885	7,824	
Blackhawk Network Holdings, Inc.	First Lien Term Loan, LIBOR+3.00% cash due 6/15/2025	5.05 %	Data Processing & Outsourced Services	9,600	9,590	9,100	
Brazos Delaware II, LLC	First Lien Term Loan, LIBOR+4.00% cash due 5/21/2025	5.60 %	Oil & Gas Equipment & Services	4,203	4,194	4,059	
BYJU's Alpha, Inc.	First Lien Term Loan, LIBOR+5.50% cash due 11/24/2026	7.01 %	Application Software	7,463	7,360	6,380	
C5 Technology Holdings, LLC	171 Common Units		Data Processing & Outsourced Services		_	_	(4)
C5 Technology Holdings, LLC	7,193,539.63 Preferred Units		Data Processing & Outsourced Services		7,194	5,683	(4)
Total C5 Technology Holdings, LLC					7,194	5,683	
Centerline Communications, LLC	First Lien Term Loan, SOFR+5.50% cash due 8/10/2027	7.05 %	Wireless Telecommunication Services	4,368	4,292	4,291	
Centerline Communications, LLC	First Lien Delayed Draw Term Loan, SOFR+5.50% cash due 8/10/2027	7.05 %	Wireless Telecommunication Services	450	428	414	(5)
Centerline Communications, LLC	First Lien Revolver, LIBOR+5.50% cash due 8/10/2027		Wireless Telecommunication Services		(10)	(11)	(5)
Total Centerline							
Communications, LLC CITGO Petroleum Corp.	First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	7.92 %	Oil & Gas Refining & Marketing	<b>4,818</b> 7,056	<b>4,710</b> 6,985	<b>4,694</b> 7,014	(4)
City Football Group Limited	First Lien Term Loan, LIBOR+3.50% cash due 7/21/2028	4.60 %	Movies & Entertainment	6,484	6,451	5,997	()

<u>Portfolio Company</u>	Investment Type	<u>Cash</u> Interest Rate (1)(2)	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value</u> ( <u>3)</u>	<u>Notes</u>
Convergeone Holdings, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	6.67 %	IT Consulting & Other Services	\$ 7,392	\$ 7,211	\$ 6,357	(4)
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+3.75% cash due 7/9/2026	6.00 %	Biotechnology	5,835	5,791	5,525	
Delivery Hero FinCo LLC	First Lien Term Loan, SOFR+5.75% cash due 7/9/2027	6.88 %	Internet & Direct Marketing Retail	5,050	4,948	4,760	(4)
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	6.67 %	Cable & Satellite	5,595	5,539	5,167	(4)
Domtar Corporation	First Lien Term Loan, LIBOR+5.50% cash due 11/30/2028	6.69 %	Paper Products	4,110	4,075	3,967	
DTI Holdco, Inc.	First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	6.28 %	Research & Consulting Services	8,000	7,843	7,511	(4)
Eagle Parent Corp.	First Lien Term Loan, SOFR+4.25% cash due 4/1/2029	6.30 %	Industrial Machinery	4,489	4,380	4,317	
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	6.17 %	Application Software	7,350	7,277	6,809	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	6.41 %	Leisure Products	7,463	7,388	6,380	
Global Medical Response, Inc.	First Lien Term Loan, LIBOR+4.25% cash due 3/14/2025	5.92 %	Health Care Services	1,985	1,985	1,852	(4)
Global Medical Response, Inc.	First Lien Term Loan, LIBOR+4.25% cash due 10/2/2025	5.25 %	Health Care Services	2,198	2,168	2,050	
Total Global Medical Response, Inc.				4,183	4,153	3,902	
Harbor Purchaser Inc.	First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	6.88 %	Education Services	8,000	7,765	7,275	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, SOFR+5.25% cash due 6/30/2026	7.57 %	Pharmaceuticals	7,425	7,304	7,252	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	8.00 %	Personal Products	9,625	9,391	9,096	(4)
Iris Holding, Inc.	First Lien Term Loan, SOFR+4.75% cash due 6/15/2028	5.25 %	Metal & Glass Containers	4,000	3,680	3,663	
LaserAway Intermediate Holdings II, LLC	First Lien Term Loan, LIBOR+5.75% cash due 10/14/2027	6.79 %	Health Care Services	7,463	7,330	7,355	
Lightbox Intermediate, L.P.	First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	7.25 %	Real Estate Services	7,386	7,331	7,201	(4)
LogMeIn, Inc.	First Lien Term Loan, LIBOR+4.75% cash due 8/31/2027	6.35 %	Application Software	7,880	7,766	6,087	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.50% cash due 9/6/2025	5.17 %	Electronic Components	7,385	7,294	6,891	
Mindbody, Inc.	First Lien Term Loan, LIBOR+7.00% cash 1.50% PIK due 2/14/2025	8.38 %	Internet Services & Infrastructure	4,669	4,629	4,580	(4)
Mindbody, Inc.	First Lien Revolver, LIBOR+8.00% cash due 2/14/2025		Internet Services & Infrastructure		(4)	(9)	(4)(5)
Total Mindbody, Inc.	Einst Lion Tome Loon, LIDOD 15 500/		Amplication	4,669	4,625	4,571	
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	7.75 %	Application Software	6,154	6,120	6,031	(4)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software		(3)	(7)	(4)(5)
Total MRI Software LLC				6,154	6,117	6,024	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.50% cash due 3/31/2025	6.55 %	Electrical Components & Equipment	6,703	6,689	6,501	
OEConnection LLC	First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	5.67 %	Application Software	7,797	7,761	7,270	(4)
Park Place Technologies, LLC	First Lien Term Loan, SOFR+5.00% cash due 11/10/2027	6.63 %	Internet Services & Infrastructure	4,938	4,786	4,761	
Peloton Interactive, Inc.	First Lien Term Loan, SOFR+6.50% cash due 5/17/2027	7.00 %	Leisure Products	4,000	3,822	3,823	
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	8.92 %	Application Software	4,503	4,435	4,323	(4)
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	9.00 %	Application Software	6,795	6,687	6,605	
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027		Application Software		(7)		(4)(5)
Total Pluralsight, LLC				6,795	6,680	6,593	

49

<u>Portfolio Company</u>	Investment Type	<u>Cash</u> Interest Rate (1)(2)	<u>Industry</u>	<u>Principal</u>	<u>Cost</u>	<u>Fair Value</u> (3)	<u>Notes</u>
RevSpring, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 10/11/2025	5.67 %	Commercial Printing	\$ 9,650	\$ 9,630	\$ 9,264	
Sabert Corporation	First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	6.19 %	Metal & Glass Containers	2,591	2,565	2,468	(4)
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	6.49 %	Footwear	8,223	8,215	7,483	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	6.47 %	Footwear	138	138	125	
Total SHO Holding I Corporation				8,361	8,353	7,608	
Sorenson Communications, LLC	First Lien Term Loan, LIBOR+5.50% cash due 3/17/2026	7.75 %	Communications Equipment	2,628	2,602	2,578	
Spanx, LLC	First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028	7.10 %	Apparel Retail	8,955	8,792	8,743	(4)
SPX Flow, Inc.	First Lien Term Loan, LIBOR+4.60% cash due 4/5/2029	6.13 %	Industrial Machinery	7,453	7,128	6,965	
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	6.00 %	Application Software	7,763	7,475	7,049	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	4.95 %	Health Care Facilities	3,386	3,374	3,165	
Touchstone Acquisition, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	7.67 %	Health Care Supplies	7,304	7,167	7,085	(4)
Veritas US Inc.	First Lien Term Loan, LIBOR+5.00% cash due 9/1/2025	7.25 %	Application Software	6,365	6,284	5,257	(4)
Windstream Services II, LLC	First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	7.92 %	Integrated Telecommunication Services	7,838	7,604	7,364	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	8.99 %	Aerospace & Defense	6,000	5,970	4,965	(4)
WP CPP Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	4.99 %	Aerospace & Defense	1,990	1,907	1,672	(4)
<b>Total Portfolio Investments</b>				\$ 357,198	\$ 358,578	\$ 339,335	

(1) Represents the interest rate as of June 30, 2022. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All the LIBOR shown above is in U.S. dollars. As of June 30, 2022, the reference rates for SLF JV I's variable rate loans were the 30-day LIBOR at 1.67%, the 90-day LIBOR at 2.25%, the 180-day LIBOR at 2.88%, the 360-day LIBOR at 3.61%, the 30-day SOFR at 1.53% and the 90-day SOFR at 2.05%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of June 30, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the Company's Board of Directors' valuation process described elsewhere herein.

(4) This investment was held by both the Company and SLF JV I as of June 30, 2022.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

# SLF JV I Portfolio as of September 30, 2021

Portfolio Company	Investment Type	<u>Cash</u> Interest Rate (1)(2)	<u>Industry</u>	<u>Principal</u>	Cost	<u>Fair Value</u> ( <u>3)</u>	Notes
Access CIG, LLC	First Lien Term Loan, LIBOR+3.75% cash due 2/27/2025	3.83 %	Diversified Support Services	\$ 9,111	\$ 9,084	\$ 9,078	(4)
ADB Companies, LLC	First Lien Term Loan, LIBOR+6.25% cash due 12/18/2025	7.25 %	Construction & Engineering	7,732	7,566	7,644	(4)
Altice France S.A.	First Lien Term Loan, LIBOR+4.00% cash due 8/14/2026	4.12 %	Integrated Telecommunication Services	2,596	2,468	2,591	
Alvogen Pharma US, Inc.	First Lien Term Loan, LIBOR+5.25% cash due 12/31/2023	6.25 %	Pharmaceuticals	9,755	9,580	9,443	(4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	5.00 %	Movies & Entertainment	7,880	7,801	7,680	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	3.88 %	Personal Products	2,799	2,211	2,378	
Apptio, Inc.	First Lien Term Loan, LIBOR+7.25% cash due 1/10/2025	8.25 %	Application Software	4,615	4,565	4,544	(4)
Apptio, Inc.	First Lien Revolver, LIBOR+7.25% cash due 1/10/2025	8.25 %	Application Software	154	150	148	(4)(5)
Total Apptio, Inc.				4,769	4,715	4,692	
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	5.33 %	Property & Casualty Insurance	6,000	5,940	5,980	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	7.00 %	Airport Services	6,403	6,283	6,025	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	6.00 %	Health Care Services	5,985	5,925	5,970	
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	6.00 %	Health Care Services	450	436	446	(5)
Total BAART Programs, Inc.				6,435	6,361	6,416	
Blackhawk Network Holdings, Inc.	First Lien Term Loan, LIBOR+3.00% cash due 6/15/2025	3.08 %	Data Processing & Outsourced Services	9,675	9,662	9,615	
Boxer Parent Company Inc.	First Lien Term Loan, LIBOR+3.75% cash due 10/2/2025	3.88 %	Systems Software	6,643	6,570	6,615	
Brazos Delaware II, LLC	First Lien Term Loan, LIBOR+4.00% cash due 5/21/2025	4.08 %	Oil & Gas Equipment & Services	7,253	7,234	7,158	
C5 Technology Holdings, LLC	171 Common Units		Data Processing & Outsourced Services		_	_	(4)
C5 Technology Holdings, LLC	7,193,539.63 Preferred Units		Data Processing & Outsourced Services		7,194	5,683	(4)
Total C5 Technology Holdings, LLC					7,194	5,683	
Centerline Communications, LLC	First Lien Term Loan, LIBOR+5.50% cash due 8/10/2027	6.50 %	Wireless Telecommunication Services	2,000	1,961	1,960	
Centerline Communications, LLC	First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due 8/10/2023	6.50 %	Wireless Telecommunication Services	1,920	1,890	1,889	(5)
Centerline Communications, LLC	First Lien Revolver, LIBOR+5.50% cash due 8/10/2027		Wireless Telecommunication Services	_	(12)	(12)	(5)
Total Centerline Communications, LLC				3,920	3,839	3,837	•
CITGO Petroleum Corp.	First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	7.25 %	Oil & Gas Refining & Marketing	7,111	7,040	7,134	(4)
City Football Group Limited	First Lien Term Loan, LIBOR+3.50% cash due 7/21/2028	4.00 %	Movies & Entertainment	6,500	6,468	6,492	
Connect U.S. Finco LLC	First Lien Term Loan, LIBOR+3.50% cash due 12/11/2026		Alternative Carriers	7,362	7,204	7,376	
Convergeone Holdings, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 1/4/2026	5.08 %	IT Consulting & Other Services	7,449	7,229	7,427	(4)
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.00% cash due 7/9/2026	4.13 %	Biotechnology	5,880	5,836	5,884	
Dcert Buyer, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 10/16/2026	4.08 %	Internet Services & Infrastructure	5,885	5,870	5,893	
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	5.75 %	Cable & Satellite	6,000	5,940	6,011	(4)
Enviva Holdings, LP	First Lien Term Loan, LIBOR+5.50% cash due 2/17/2026	6.50 %	Forest Products	5,878	5,819	5,893	

Portfolio Company	Investment Type	<u>Cash</u> Interest Rate (1)(2)	<u>Industry</u>	<u>Principal</u>	Cost	<u>Fair Value</u> (3)	Notes
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	5.50 %	Application Software	\$ 7,406	\$ 7,332	\$ 7,451	
GI Chill Acquisition LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/6/2025	3.90 %	Managed Health Care	3,721	3,737	3,712	(4)
GI Chill Acquisition LLC	Second Lien Term Loan, LIBOR+7.50% cash due 8/6/2026	7.63 %	Managed Health Care	3,750	3,674	3,731	(4)
Total GI Chill Acquisition				7,471	7,411	7,443	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	5.75 %	Leisure Products	7,500	7,425	7,463	
Global Medical Response, Inc.	First Lien Term Loan, LIBOR+4.75% cash due 10/2/2025	5.75 %	Health Care Services	2,214	2,178	2,226	
Global Medical Response, Inc. Total Global Medical	First Lien Term Loan, LIBOR+4.25% cash due 3/14/2025	5.25 %	Health Care Services	1,995	1,995	2,004	(4)
Response, Inc. Grab Holdings Inc.	First Lien Term Loan, LIBOR+4.50% cash due 1/29/2026	5.50 %	Interactive Media & Services	<b>4,209</b> 2,985	<b>4,173</b> 2,907	<b>4,230</b> 3,025	
Indivior Finance S.À.R.L.	First Lien Term Loan, LIBOR+5.25% cash due 6/30/2026	6.00 %	Pharmaceuticals	7,481	7,336	7,456	
Intelsat Jackson Holdings S.A.	First Lien Term Loan, PRIME+4.75% cash due 11/27/2023		Alternative Carriers	3,568	3,550	3,622	
Intelsat Jackson Holdings S.A.	First Lien Term Loan, LIBOR+4.75% cash due 7/13/2022	5.75 %	Alternative Carriers	5,000	4,935	5,044	
Intelsat Jackson Holdings S.A.	First Lien Delayed Draw Term Loan, LIBOR+4.75% cash due 7/13/2022		Alternative Carriers		(13)	9	(5)
Total Intelsat Jackson Holdings S.A.				8,568	8,472	8,675	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 5/7/2027	6.50 %	Personal Products	9,875	9,597	9,678	(4)
Lightbox Intermediate, L.P.	First Lien Term Loan, LIBOR+5.00% cash due 5/9/2026	5.13 %	Real Estate Services	7,443	7,377	7,405	(4)
LogMeIn, Inc.	First Lien Term Loan, LIBOR+4.75% cash due 8/31/2027	4.83 %	Application Software	7,940	7,812	7,946	(4)
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.50% cash due 9/6/2025	3.58 %	Electronic Components	7,442	7,329	7,354	
Maravai Intermediate Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 10/19/2027	4.75 %	Biotechnology	6,819	6,751	6,846	
Mindbody, Inc.	First Lien Term Loan, LIBOR+7.00% cash 1.50% PIK due 2/14/2025	8.00 %	Internet Services & Infrastructure	4,616	4,565	4,528	(4)
Mindbody, Inc.	First Lien Revolver, LIBOR+8.00% cash due 2/14/2025		Internet Services & Infrastructure		(6)	(9)	(4)(5)
Total Mindbody, Inc.			4 11 11	4,616	4,559	4,519	
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	6.50 %	Application Software	3,877	3,843	3,875	(4)
MRI Software LLC	First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due 2/10/2026		Application Software	-	(6)	(1)	(4)(5)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software		(3)		(4)(5)
Total MRI Software LLC				3,877	3,834	3,874	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.50% cash due 3/31/2025	5.50 %	Electrical Components & Equipment	6,755	6,738	6,738	
OEConnection LLC	First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	4.08 %	Application Software	7,852	7,816	7,842	(4)
Olaplex, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 1/8/2026	7.25 %	Personal Products	6,273	6,189	6,226	(4)
Olaplex, Inc.	First Lien Revolver, LIBOR+6.25% cash due 1/8/2025		Personal Products		(7)	(8)	(4)(5)
Total Olaplex, Inc.				6,273	6,182	6,218	
Park Place Technologies, LLC	First Lien Term Loan, LIBOR+5.00% cash due 11/10/2027	6.00 %	Internet Services & Infrastructure	4,975	4,801	4,981	(4)
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	8.00 %	Application Software	4,503	4,435	4,514	(4)

<u>Portfolio Company</u>	<u>Investment Type</u>	<u>Cash</u> Interest Rate (1)(2)	<u>Industry</u>	<u>Principal</u>	Cost	<u>Fair Value</u> (3) Notes
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	9.00 %	Application Software	\$ 6,796	\$ 6,669	\$ 6,667 (4)
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027		Application Software	_	(8)	(8) (4)(5)
Total Pluralsight, LLC				6,796	6,661	6,659
Sabert Corporation	First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	5.50 %	Metal & Glass Containers	2,728	2,700	2,738 (4)
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	6.25 %	Footwear	8,288	8,277	7,874
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	6.23 %	Footwear	138	138	131
Total SHO Holding I Corporation				8,426	8,415	8,005
Sirva Worldwide, Inc.	First Lien Term Loan, LIBOR+5.50% cash due 8/4/2025	5.58 %	Diversified Support Services	1,087	1,071	1,027 (4)
Sorenson Communications, LLC	First Lien Term Loan, LIBOR+5.50% cash due 3/17/2026	6.25 %	Communications Equipment	2,854	2,825	2,877
Star US Bidco LLC	First Lien Term Loan, LIBOR+4.25% cash due 3/17/2027	5.25 %	Industrial Machinery	8,255	8,075	8,289 (4)
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	3.88 %	Application Software	7,823	7,465	7,294 (4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	4.50 %	Health Care Facilities	4,911	4,895	4,925
Trench Plate Rental, Co.	First Lien Term Loan, LIBOR+4.75% cash due 12/3/2026	5.75 %	Construction Materials	3,942	3,882	3,881
Trench Plate Rental, Co.	First Lien Delayed Draw Term Loan, LIBOR+4.75% cash due 12/3/2026		Construction Materials	_	(11)	(12) (5)
Trench Plate Rental, Co.	First Lien Revolver, LIBOR+4.75% cash due 12/3/2026	5.75 %	Construction Materials	24	15	15 (5)
Total Trench Plate Rental, Co.				3,966	3,886	3,884
Veritas US Inc.	First Lien Term Loan, LIBOR+5.00% cash due 9/1/2025	6.00 %	Application Software	6,435	6,333	6,473 (4)
Verscend Holding Corp.	First Lien Term Loan, LIBOR+4.00% cash due 8/27/2025	4.08 %	Health Care Technology	4,080	4,052	4,091
Waystar Technologies, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 10/22/2026	4.08 %	Health Care Technology	5,910	5,880	5,921
Windstream Services II, LLC	First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	7.25 %	Integrated Telecommunication Services	7,899	7,629	7,948 (4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	8.75 %	Aerospace & Defense	6,000	5,964	5,931 (4)
Total Portfolio Investments				\$ 344,196	\$ 346,052	\$ 346,665

(1) Represents the interest rate as of September 30, 2021. All interest rates are payable in cash, unless otherwise noted.

(4) This investment was held by both the Company and SLF JV I as of September 30, 2021.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

<sup>(2)</sup> The interest rate on the principal balance outstanding for all floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over LIBOR or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. All the LIBOR shown above is in U.S. dollars. As of September 30, 2021, the reference rates for SLF JV I's variable rate loans were the 30-day LIBOR at 0.08%, the 60-day LIBOR at 0.11%, the 90-day LIBOR at 0.13%, the 180-day LIBOR at 0.16%, the 360-day LIBOR at 0.24% and the PRIME at 3.25%. Most loans include an interest floor, which generally ranges from 0% to 1%.

<sup>(3)</sup> Represents the current determination of fair value as of September 30, 2021 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the Company's Board of Directors' valuation process described elsewhere herein.

Both the cost and fair value of the Company's SLF JV I Notes were \$96.3 million as of each of June 30, 2022 and September 30, 2021. The Company earned interest income of \$1.9 million and \$5.8 million on the SLF JV I Notes for the three and nine months ended June 30, 2022, respectively. The Company earned interest income of \$1.9 million and \$5.4 million on the SLF JV I Notes for the three and nine months ended June 30, 2021, respectively. As of June 30, 2022, the SLF JV I Notes bore interest at a rate of one-month LIBOR plus 7.00% per annum with a LIBOR floor of 1.00% and will mature on December 29, 2028.

The cost and fair value of the LLC equity interests in SLF JV I held by the Company were \$49.3 million and \$23.0 million, respectively, as of June 30, 2022, and \$49.3 million and \$37.7 million, respectively, as of September 30, 2021. The Company earned \$0.9 million and \$2.0 million in dividend income for the three and nine months ended June 30, 2022, respectively, with respect to its investment in the LLC equity interests of SLF JV I. The Company earned \$0.5 million in dividend income for the three and nine months ended June 30, 2021 with respect to its investment in the LLC equity interests of SLF JV I. The LLC equity interests of SLF JV I. The LLC equity interests of SLF JV I are generally dividend producing to the extent SLF JV I has residual cash to be distributed on a quarterly basis.

Below is certain summarized financial information for SLF JV I as of June 30, 2022 and September 30, 2021 and for the three and nine months ended June 30, 2022 and 2021:

	June 30, 2022	Sept	ember 30, 2021
Selected Balance Sheet Information:			
Investments at fair value (cost June 30, 2022: \$358,578; cost September 30, 2021: \$346,052)	\$ 339,335	\$	346,665
Cash and cash equivalents	14,904		23,446
Restricted cash	4,156		4,517
Other assets	 6,653		4,529
Total assets	\$ 365,048	\$	379,157
		-	
Senior credit facility payable	\$ 215,000	\$	215,620
SLF JV I Notes payable at fair value (proceeds June 30, 2022: \$110,000; proceeds September 30, 2021: \$110,000)	110,000		110,000
Other liabilities	13,718		10,507
Total liabilities	\$ 338,718	\$	336,127
Members' equity	 26,330		43,030
Total liabilities and members' equity	\$ 365,048	\$	379,157

	Three months ended June 30, 2022	Three months ended June 30, 2021	Nine months ended June 30, 2022	Nine months ended June 30, 2021
Selected Statements of Operations Information:				
Interest income	\$ 5,796	\$ 5,247	\$ 16,664	\$ 14,535
Other income	32	19	105	546
Total investment income	5,828	5,266	16,769	15,081
Senior credit facility interest expense	1,929	1,430	4,995	4,222
SLF JV I Notes interest expense	2,224	2,224	6,673	6,195
Other expenses	77	56	198	193
Total expenses (1)	4,230	3,710	11,866	10,610
Net unrealized appreciation (depreciation)	(16,411)	1,407	(19,856)	13,334
Net realized gains (losses)	165	426	568	427
Net income (loss)	\$ (14,648)	\$ 3,389	\$ (14,385)	\$ 18,232

(1) There are no management fees or incentive fees charged at SLF JV I.

SLF JV I has elected to fair value the SLF JV I Notes issued to the Company and Kemper under FASB ASC Topic 825, *Financial Instruments - Fair Value Option*. The SLF JV I Notes are valued based on the total assets less the total liabilities senior to the SLF JV I Notes in an amount not exceeding par under the EV technique.

During the nine months ended June 30, 2022, the Company sold \$9.7 million of senior secured debt investments to SLF JV I for \$9.7 million cash consideration, which represented the fair value at the time of sale. A gain of \$0.5 million was recognized by the Company on these transactions. The Company did not sell any senior secured debt investments to SLF JV I during the three months ended June 30, 2022. During the three and nine months ended June 30, 2021, the Company sold \$10.5 million and \$45.5 million, respectively, of senior secured debt investments to SLF JV I, for \$10.3 million and \$44.8 million cash consideration, respectively, which represented the fair value at the time of sale.

### OCSI Glick JV LLC

On March 19, 2021, as a result of the consummation of the Mergers, the Company became party to the LLC agreement of Glick JV. The Company co-invests primarily in senior secured loans of middle-market companies with GF Equity Funding through the Glick JV. The Glick JV is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by GF Equity Funding. The Glick JV is capitalized as transactions are completed, and portfolio decisions and investment decisions in respect of the Glick JV must be approved by the Glick JV investment committee, which consists of one representative selected by the Company and one representative selected by GF Equity Funding (with approval from a representative of each required). Since the Company does not have a controlling financial interest in the Glick JV, the Company does not consolidate the Glick JV.

The members provide capital to the Glick JV in exchange for LLC equity interests, and the Company and GF Debt Funding 2014 LLC ("GF Debt Funding"), an entity advised by affiliates of GF Equity Funding, provide capital to the Glick JV in exchange for subordinated notes issued by the Glick JV (the "Glick JV Notes"). As of June 30, 2022 and September 30, 2021, the Company and GF Equity Funding owned 87.5% and 12.5%, respectively, of the outstanding LLC equity interests, and the Company and GF Debt Funding owned 87.5% and 12.5%, respectively, of the Glick JV Notes. The Glick JV is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act.

The Glick JV has a senior revolving credit facility with Deutsche Bank AG, New York Branch (the "Glick JV Deutsche Bank Facility"), which, as of June 30, 2022, had a reinvestment period end date and maturity date of May 3, 2023 and May 3, 2028, respectively, and permitted borrowings of up to \$90.0 million (subject to borrowing base and other limitations). Borrowings under the Glick JV Deutsche Bank Facility are secured by all of the assets of the Glick JV and all of the equity interests in the Glick JV and, as of June 30, 2022, bore interest at a rate equal to 3-month LIBOR plus 2.25% per annum during the reinvestment period, 3-month LIBOR plus 2.40% for the first year after the end of the reinvestment period, 3-month LIBOR plus 2.50% for the following year and 3-month LIBOR plus 2.75% thereafter, in each case with a 0.125% LIBOR floor. \$80.1 million and \$71.9 million of borrowings were outstanding under the Glick JV Deutsche Bank Facility as of June 30, 2022 and September 30, 2021, respectively.

As of June 30, 2022 and September 30, 2021, the Glick JV had total assets of \$141.5 million and \$141.0 million, respectively. The Glick JV's portfolio consisted of middle-market and other corporate debt securities of 43 and 37 portfolio companies as of June 30, 2022 and September 30, 2021, respectively. The portfolio companies in the Glick JV are in industries similar to those in which the Company may invest directly. The Company's investment in the Glick JV consisted of LLC equity interests and Glick JV Notes of \$50.6 million and \$55.6 million in the aggregate at fair value as of June 30, 2022 and September 30, 2021, respectively. The Glick JV Notes are junior in right of payment to the repayment of temporary contributions made by the Company to fund investments of the Glick JV that are repaid when GF Equity Funding and GF Debt Funding make their capital contributions and fund their Glick JV Notes, respectively.

As of each of June 30, 2022 and September 30, 2021, the Glick JV had total capital commitments of \$100.0 million, \$87.5 million of which was from the Company and the remaining \$12.5 million of which was from GF Equity Funding and GF Debt Funding. Approximately \$84.0 million in aggregate commitments were funded as of each of June 30, 2022 and September 30, 2021, of which \$73.5 million was from the Company. As of each of June 30, 2022 and September 30, 2021, the Company had commitments to fund Glick JV Notes of \$78.8 million, of which \$12.4 million were unfunded. As of each of June 30, 2022 and September 30, 2021, the Company had commitments to fund LLC equity interests in the Glick JV of \$8.7 million, of which \$1.6 million were unfunded.

Below is a summary of the Glick JV's portfolio, followed by a listing of the individual loans in the Glick JV's portfolio as of June 30, 2022 and September 30, 2021:

	June 30, 2022	September 30, 2021
Senior secured loans (1)	\$141,783	\$126,512
Weighted average current interest rate on senior secured loans (2)	6.85%	5.86%
Number of borrowers in the Glick JV	43	37
Largest loan exposure to a single borrower (1)	\$6,645	\$6,907
Total of five largest loan exposures to borrowers (1)	\$28,564	\$28,324

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

## Glick JV Portfolio as of June 30, 2022

	<b>1 . .</b>	<u>Cash</u> Interest				<u>Fair Value</u>
<u>Portfolio Company</u>	Investment Type	<u>Rate (1)(2)</u>	Industry	<b>Principal</b>	<u>Cost</u>	<u>(3) Notes</u>
ADB Companies, LLC	First Lien Term Loan, LIBOR+6.25% cash due 12/18/2025	8.50%	Construction & Engineering	\$ 4,714	\$ 4,640	\$ 4,636 (4)
Alvogen Pharma US, Inc.	First Lien Term Loan, LIBOR+5.25% cash due 12/31/2023	7.50%	Pharmaceuticals	6,645	6,564	5,871 (4)
American Tire Distributors, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 10/20/2028	7.00%	Distributors	2,897	2,861	2,746 (4)
Amplify Finco Pty Ltd.	First Lien Term Loan, LIBOR+4.25% cash due 11/26/2026	5.92%	Movies & Entertainment	2,933	2,903	2,862 (4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	6.00%	Personal Products	919	714	738 (4)
ASP-R-PAC Acquisition Co LLC	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2027	7.67%	Paper Packaging	1,738	1,706	1,696
ASP-R-PAC Acquisition Co LLC	First Lien Revolver, LIBOR+6.00% cash due 12/29/2027		Paper Packaging	_	(4)	(5) (5)
Total ASP-R-PAC Acquisition Co LLC				1,738	1,702	1,691
Astra Acquisition Corp.	First Lien Term Loan, LIBOR+5.25% cash due 10/25/2028	6.92%	Application Software	3,155	3,084	2,758 (4)
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	6.92%	Property & Casualty Insurance	923	914	789
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	7.63%	Airport Services	3,666	3,607	3,478 (4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	6.67%	Health Care Services	3,406	3,375	3,355
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	6.60%	Health Care Services		712	699 (4)(5)
Total BAART Programs, Inc.				4,126	4,087	4,054
			Oil & Gas	.,	1,007	.,
Brazos Delaware II, LLC	First Lien Term Loan, LIBOR+4.00% cash due 5/21/2025	5.60%	Equipment & Services	2,802	2,796	2,706
BYJU's Alpha, Inc.	First Lien Term Loan, LIBOR+5.50% cash due 11/24/2026	7.01%	Application Software	3,980	3,925	3,403
CITGO Petroleum Corp.	First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	7.92%	Oil & Gas Refining & Marketing	3,528	3,493	3,507 (4)
City Football Group Limited	First Lien Term Loan, LIBOR+3.50% cash due 7/21/2028	4.60%	Movies & Entertainment	2,494	2,481	2,307
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+3.75% cash due 7/9/2026	6.00%	Biotechnology	2,878	2,856	2,725
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	6.67%	Cable & Satellite	2,798	2,770	2,583 (4)
Domtar Corporation	First Lien Term Loan, LIBOR+5.50% cash due 11/30/2028	6.69%	Paper Products	2,509	2,484	2,421
DTI Holdco, Inc.	First Lien Term Loan, SOFR+4.75% cash due 4/26/2029	6.28%	Research & Consulting Services	3,000	2,941	2,817 (4)
Eagle Parent Corp.	First Lien Term Loan, SOFR+4.25% cash due 4/1/2029	4.75%	Industrial Machinery	2,494	2,433	2,398
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	6.17%	Application Software	2,450	2,426	2,270

Portfolio Company	Investment Type	<u>Cash</u> <u>Interest</u> <u>Rate (1)(2)</u>	<u>Industry</u>	<b>Principal</b>	<u>Cost</u>	<u>Fair Value</u> (3)	<u>Notes</u>
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	6.41%	Leisure Products	\$ 3,980	\$ 3,940	\$ 3,403	
Harbor Purchaser Inc.	First Lien Term Loan, SOFR+5.25% cash due 4/9/2029	6.88%	Education Services	4,000	3,883	3,638	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, LIBOR+5.51% cash due 6/30/2026	7.57%	Pharmaceuticals	3,960	3,895	3,868	
Integro Parent, Inc.	First Lien Term Loan, LIBOR+2.50% cash due 10/31/2022	4.00%	Insurance Brokers	3,217	3,221	3,041	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 3/25/2027	8.00%	Personal Products	2,406	2,348	2,274	(4)
Iris Holding, Inc.	First Lien Term Loan, SOFR+4.75% cash due 6/15/2028	6.86%	Metal & Glass Containers	2,000	1,840	1,832	
LaserAway Intermediate Holdings II, LLC	First Lien Term Loan, LIBOR+5.75% cash due 10/14/2027	6.79%	Health Care Services	3,980	3,909	3,923	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.50% cash due 9/6/2025	5.17%	Electronic Components	1,362	1,180	1,271	
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	7.75%	Application Software	1,651	1,636	1,618	(4)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software	_	(1)	(3)	(4)(5)
Total MRI Software LLC				1,651	1,635	1,615	•
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.50% cash due 3/31/2025	6.55%	Electrical Components & Equipment	5,266	5,256	5,108	
OEConnection LLC	First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	5.67%	Application Software	3,898	3,880	3,635	(4)
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	8.92%	Application Software	2,842	2,799	2,728	(4)
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	9.00%	Application Software	4,465	4,394	4,340	(4)
N. L'IL II G	First Lien Revolver, LIBOR+8.00% cash		Application		(5)	(0)	(1) (7)
Pluralsight, LLC	due 4/6/2027		Software	4,465	(5) 4,389		(4)(5)
Total Pluralsight, LLC	First Lien Term Loan, LIBOR+4.50%		Metal & Glass	4,405	4,389	4,331	
Sabert Corporation	cash due 12/10/2026	6.19%	Containers	1,728	1,710	1,645	(4)
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	6.49%	Footwear	6,110	6,097	5,560	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	6.47%	Footwear	102	102	93	-
Total SHO Holding I Corporation				6,212	6,199	5,653	
Spanx, LLC	First Lien Term Loan, LIBOR+5.50% cash due 11/20/2028	7.10%	Apparel Retail	4,975	4,884	4,857	(4)
SPX Flow, Inc.	First Lien Term Loan, LIBOR+4.60% cash due 4/5/2029	6.13%	Industrial Machinery	5,466	5,222	5,108	
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	6.00%	Application Software	2,828	2,710	2,567	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	4.95%	Health Care Facilities	3,386	3,374	3,165	
Touchstone Acquisition, Inc.	First Lien Term Loan, LIBOR+6.00% cash due 12/29/2028	7.67%	Health Care Supplies	3,031	2,975	2,940	(4)
Tribe Buyer LLC	First Lien Term Loan, LIBOR+4.50% cash due 2/16/2024	6.17%	Human Resource & Employment Services	1,587	1,586	1,326	
Windstream Services II, LLC	First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	7.92%	Integrated Telecommunication Services	4,899	4,753	4,603	(4)
WP CPP Holdings, LLC	First Lien Term Loan, LIBOR+3.75% cash due 4/30/2025	4.99%	Aerospace & Defense	995	954	836	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	8.99%	Aerospace & Defense	3,000	2,985	2,482	(4)
Total WP CPP Holdings, LLC				3,995	3,939	3,318	
				0,110		0,010	

(1) Represents the interest rate as of June 30, 2022. All interest rates are payable in cash, unless otherwise noted.

<sup>(2)</sup> The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. Certain loans may also be indexed to SOFR. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. All

LIBOR shown above is in U.S. dollars. As of June 30, 2022, the reference rates for the Glick JV's variable rate loans were the 30-day LIBOR at 1.67%, the 90-day LIBOR at 2.25%, the 180-day LIBOR at 2.88% and the 360-day LIBOR at 3.61%, the 30-day SOFR at 1.53% and the 90-day SOFR at 2.05%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of June 30, 2022 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the Company's Board of Directors' valuation process described elsewhere herein.

(4) This investment was held by both the Company and the Glick JV as of June 30, 2022.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

Portfolio Company	Investment Type	<u>Cash</u> <u>Interest</u> Rate (1)(2)	Industry	Principal	Cost	Fair Value (3)	Notes
	First Lien Term Loan, LIBOR+6.25%		Construction &	*			
ADB Companies, LLC	cash due 12/18/2025 First Lien Term Loan, LIBOR+5.25%	7.25%	Engineering	\$ 3,866	, ,	\$ 3,822	. /
Alvogen Pharma US, Inc.	cash due 12/31/2023 First Lien Term Loan, LIBOR+4.25%	6.25%	Pharmaceuticals Movies &	6,907	6,780	6,687	(4)
Amplify Finco Pty Ltd.	cash due 11/26/2026	5.00%	Entertainment	2,955	2,925	2,880	(4)
Anastasia Parent, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/11/2025	3.88%	Personal Products	1,667	1,310	1,416	
Asurion, LLC	Second Lien Term Loan, LIBOR+5.25% cash due 1/20/2029	5.33%	Property & Casualty Insurance	3,000	2,970	2,990	
Aurora Lux Finco S.À.R.L.	First Lien Term Loan, LIBOR+6.00% cash due 12/24/2026	7.00%	Airport Services	3,694	3,625	3,476	(4)
BAART Programs, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 6/11/2027	6.00%	Health Care Services	3,192	3,160	3,184	
BAART Programs, Inc.	First Lien Delayed Draw Term Loan, LIBOR+5.00% cash due 6/11/2027	6.00%	Health Care Services	240	232	238	(5)
Total BAART Programs, Inc.				3,432	3,392	3,422	
Brazos Delaware II, LLC	First Lien Term Loan, LIBOR+4.00% cash due 5/21/2025	4.08%	Oil & Gas Equipment & Services	4,835	4,823	4,772	
CITGO Petroleum Corp.	First Lien Term Loan, LIBOR+6.25% cash due 3/28/2024	7.25%	Oil & Gas Refining & Marketing	3,555	3,520	3,567	(4)
City Football Group Limited	First Lien Term Loan, LIBOR+3.50% cash due 7/21/2028	4.00%	Movies & Entertainment	2,500	2,488	2,497	
Curium Bidco S.à.r.l.	First Lien Term Loan, LIBOR+4.00% cash due 7/9/2026	4.13%	Biotechnology	4,900	4,863	4,903	
DirecTV Financing, LLC	First Lien Term Loan, LIBOR+5.00% cash due 8/2/2027	5.75%	Cable & Satellite	3,000	2,970	3,005	(4)
Enviva Holdings, LP	First Lien Term Loan, LIBOR+5.50% cash due 2/17/2026	6.50%	Forest Products	3,919	3,879	3,928	
eResearch Technology, Inc.	First Lien Term Loan, LIBOR+4.50% cash due 2/4/2027	5.50%	Application Software	2,469	2,444	2,484	
Gibson Brands, Inc.	First Lien Term Loan, LIBOR+5.00% cash due 8/11/2028	5.75%	Leisure Products	4,000	3,960	3,981	
Houghton Mifflin Harcourt Publishers Inc.	First Lien Term Loan, LIBOR+6.25% cash due 11/22/2024	7.25%	Education Services	431	420	433	(4)
Indivior Finance S.À.R.L.	First Lien Term Loan, LIBOR+5.25% cash due 6/30/2026	6.00%	Pharmaceuticals	3,990	3,913	3,977	
Integro Parent, Inc.	First Lien Term Loan, LIBOR+5.75% cash due 10/31/2022	6.75%	Insurance Brokers	3,229	3,221	3,173	
Intelsat Jackson Holdings S.A.	First Lien Term Loan, LIBOR+4.75% cash due 7/13/2022	5.75%	Alternative Carriers	4,167	4,112	4,203	
Intelsat Jackson Holdings S.A.	First Lien Delayed Draw Term Loan, LIBOR+4.75% cash due 7/13/2022		Alternative Carriers		(11)	7	(5)
Total Intelsat Jackson Holdings S.A.				4,167	4,101	4,210	
INW Manufacturing, LLC	First Lien Term Loan, LIBOR+5.75% cash due 5/7/2027	6.50%	Personal Products	2,469	2,399	2,419	(4)
Lightstone Holdco LLC	First Lien Term Loan, LIBOR+3.75% cash due 1/30/2024	4.75%	Electric Utilities	3,439	3,115	2,855	
LTI Holdings, Inc.	First Lien Term Loan, LIBOR+3.50% cash due 9/6/2025	3.58%	Electronic Components	1,372	1,147	1,356	

## Glick JV Portfolio as of September 30, 2021

<u>Portfolio Company</u>	Investment Type	<u>Cash</u> Interest Rate (1)(2)	Industry	<b>Principal</b>	<u>Cost</u>	<u>Fair Value</u> (3)	<u>Notes</u>
MRI Software LLC	First Lien Term Loan, LIBOR+5.50% cash due 2/10/2026	6.50%	Application Software	\$ 1,635	\$ 1,621	\$ 1,634	(4)
MRI Software LLC	First Lien Delayed Draw Term Loan, LIBOR+5.50% cash due 2/10/2026		Application Software	_	(1)	_	(4)(5)
MRI Software LLC	First Lien Revolver, LIBOR+5.50% cash due 2/10/2026		Application Software		(1)		(4)(5)
Total MRI Software LLC				1,635	1,619	1,634	
Northern Star Industries Inc.	First Lien Term Loan, LIBOR+4.50% cash due 3/31/2025	5.50%	Electrical Components & Equipment	5,308	5,294	5,294	
OEConnection LLC	First Lien Term Loan, LIBOR+4.00% cash due 9/25/2026	4.08%	Application Software	3,926	3,908	3,921	(4)
Olaplex, Inc.	First Lien Term Loan, LIBOR+6.25% cash due 1/8/2026	7.25%	Personal Products	3,502	3,454	3,475	(4)
Olaplex, Inc.	First Lien Revolver, LIBOR+6.25% cash due 1/8/2025		Personal Products		(4)	(5)	(4)(5)
Total Olaplex, Inc.				3,502	3,450	3,470	
Planview Parent, Inc.	Second Lien Term Loan, LIBOR+7.25% cash due 12/18/2028	8.00%	Application Software	2,842	2,799	2,849	(4)
Pluralsight, LLC	First Lien Term Loan, LIBOR+8.00% cash due 4/6/2027	9.00%	Application Software	4,465	4,383	4,380	(4)
Pluralsight, LLC	First Lien Revolver, LIBOR+8.00% cash due 4/6/2027		Application Software		(6)	(6)	(4)(5)
Total Pluralsight, LLC				4,465	4,377	4,374	
Sabert Corporation	First Lien Term Loan, LIBOR+4.50% cash due 12/10/2026	5.50%	Metal & Glass Containers	1,819	1,800	1,825	(4)
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.25% cash due 4/27/2024	6.25%	Footwear	6,159	6,140	5,851	
SHO Holding I Corporation	First Lien Term Loan, LIBOR+5.23% cash due 4/27/2024	6.23%	Footwear	102	102		
Total SHO Holding I Corporation				6,261	6,242	5,948	
Supermoose Borrower, LLC	First Lien Term Loan, LIBOR+3.75% cash due 8/29/2025	3.88%	Application Software	2,850	2,703	2,657	(4)
Surgery Center Holdings, Inc.	First Lien Term Loan, LIBOR+3.75% cash due 8/31/2026	4.50%	Health Care Facilities	4,911	4,895	4,925	
Tribe Buyer LLC	First Lien Term Loan, LIBOR+4.50% cash due 2/16/2024	5.50%	Human Resource & Employment Services	1,599	1,598	1,354	
Verscend Holding Corp.	First Lien Term Loan, LIBOR+4.00% cash due 8/27/2025	4.08%	Health Care Technology	1,721	1,709	1,725	
Waystar Technologies, Inc.	First Lien Term Loan, LIBOR+4.00% cash due 10/22/2026	4.08%	Health Care Technology	3,940	3,920	3,947	
Windstream Services II, LLC	First Lien Term Loan, LIBOR+6.25% cash due 9/21/2027	7.25%	Integrated Telecommunication Services	4,937	4,768	4,967	(4)
WP CPP Holdings, LLC	Second Lien Term Loan, LIBOR+7.75% cash due 4/30/2026	8.75%	Aerospace & Defense	3,000	2,982	2,965	(4)
<b>Total Portfolio Investments</b>				\$ 126,512	\$ 124,112	\$ 124,108	

(1) Represents the interest rate as of September 30, 2021. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for all floating rate loans is indexed to LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over LIBOR or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR shown above is in U.S. dollars. As of September 30, 2021, the reference rates for the Glick JV's variable rate loans were the 30-day LIBOR at 0.08%, the 60-day LIBOR at 0.11%, the 90-day LIBOR at 0.13%, the 180-day LIBOR at 0.16% and the 360-day LIBOR at 0.24%. Most loans include an interest floor, which generally ranges from 0% to 1%.

(3) Represents the current determination of fair value as of September 30, 2021 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the Company's Board of Directors' valuation process described elsewhere herein.

(4) This investment was held by both the Company and the Glick JV as of September 30, 2021.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

The cost and fair value of the Company's aggregate investment in the Glick JV was \$50.4 million and \$50.6 million, respectively, as of June 30, 2022. The cost and fair value of the Company's aggregate investment in the Glick JV was

\$50.7 million and \$55.6 million, respectively, as of September 30, 2021. For the three and nine months ended June 30, 2022, the Company's investment in the Glick JV Notes earned interest income of \$1.2 million and \$3.3 million, respectively. For the three months ended June 30, 2021, the Company's investment in the Glick JV Notes earned interest income of \$1.0 million. For the period from March 19, 2021 to June 30, 2021, the Company's investment in the Glick JV Notes earned interest income of \$1.1 million. The Company did not earn dividend income for the three and nine months ended June 30, 2022 and for the period from March 19, 2021 to June 30, 2021 with respect to its investment in the LLC equity interest of the Glick JV. The LLC equity interests of the Glick JV are income producing to the extent there is residual cash to be distributed on a quarterly basis. As of June 30, 2022, the Glick JV Notes bore interest at a rate of one-month LIBOR plus 4.50% per annum and will mature on October 20, 2028.

Below is certain summarized financial information for the Glick JV as of June 30, 2022 and September 30, 2021 and for the three and nine months ended June 30, 2022 and for the three months ended June 30, 2021 and for the period from March 19, 2021 to June 30, 2021:

					June 30, 2022	Se	September 30, 2021		
Selected Balance Sheet Information:									
Investments at fair value (cost June 30, 2022: \$139,2	208; Septe	ember 30, 202	1: \$124,112)	\$	132,609	\$	124,108		
Cash and cash equivalents					2,677		14,087		
Restricted cash					1,387		1,055		
Other assets					4,792	_	1,750		
Total assets				\$	141,465	\$	141,000		
Senior credit facility payable				\$	80,082	\$	71,882		
Glick JV Notes payable at fair value (proceeds June	30 2022.	\$68 885. San	tember 30, 2021		80,082	φ	/1,002		
\$70,525)	50, 2022.	\$00,005, 5 <b>c</b> p	tember 50, 2021.		57,837		63,522		
Other liabilities					3,546		5,596		
Total liabilities				\$	141,465	\$	141,000		
Members' equity					—		—		
Total liabilities and members' equity				\$	141,465	\$	141,000		
·····						_			
	(	ee months ended e 30, 2022	Three month ended June 30, 202		Nine months ended June 30, 2022		For the period from March 19, 2021 to June 30, 2021		
Selected Statements of Operations Information:	(	ended	ended		ended		from March 19, 2021 to June 30,		
	(	ended	ended June 30, 202		ended	5 9	from March 19, 2021 to June 30, 2021		
Selected Statements of Operations Information:	Jun	ended e 30, 2022	ended June 30, 202	1	ended June 30, 2022		from March 19, 2021 to June 30, 2021		
Selected Statements of Operations Information: Interest income	Jun	ended e 30, 2022 2,416	ended June 30, 202 \$ 2,	<b>1</b> 161	ended June 30, 2022 \$ 6,796	2	from March 19, 2021 to June 30, 2021		
Selected Statements of Operations Information: Interest income Fee income	Jun	ended e 30, 2022 2,416 47	ended June 30, 202 \$ 2, 2,	<b>1</b> 161 56	ended June 30, 2022 \$ 6,796 82	2 	from March 19, 2021 to June 30, 2021 \$ 2,465 59		
Selected Statements of Operations Information: Interest income Fee income Total investment income	Jun	ended e 30, 2022 2,416 47 2,463	ended June 30, 202 \$ 2, 2,	<b>1</b> 161 56 <b>217</b>	ended June 30, 2022 \$ 6,796 82 6,878	2 3 2	from March 19, 2021 to June 30, 2021 \$ 2,465 59 2,524		
Selected Statements of Operations Information: Interest income Fee income Total investment income Senior credit facility interest expense	Jun	ended e 30, 2022 2,416 47 2,463 694	ended June 30, 202 \$ 2, 2,	<b>1</b> 161 56 <b>217</b> 557	ended June 30, 2022 \$ 6,796 82 6,878 1,742	2 3 2	from March 19, 2021 to June 30, 2021 5 2,465 59 2,524 646		
Selected Statements of Operations Information: Interest income Fee income Total investment income Senior credit facility interest expense Glick JV Notes interest expense	Jun	ended e 30, 2022 2,416 47 2,463 694 860	ended June 30, 202 \$ 2, 2,	<b>1</b> 161 56 <b>217</b> 557 830	ended June 30, 2022 \$ 6,796 82 6,876 1,742 2,479	2 3 2 9 7	from March 19, 2021 to June 30, 2021 5 2,465 59 2,524 646 950		
Selected Statements of Operations Information: Interest income Fee income Total investment income Senior credit facility interest expense Glick JV Notes interest expense Other expenses Other expenses (1) Net unrealized appreciation (depreciation)	Jun	ended e 30, 2022 2,416 47 2,463 694 860 59	ended June 30, 202 \$ 2, 2, 2, 1,	1 161 56 217 557 830 48	ended June 30, 2022 \$ 6,796 82 6,878 1,742 2,479 127	2 3 2 3 7 3 	from March 19, 2021 to June 30, 2021 5 2,465 59 2,524 646 950 54		
Selected Statements of Operations Information: Interest income Fee income Total investment income Senior credit facility interest expense Glick JV Notes interest expense Other expenses Total expenses (1)	Jun	ended e 30, 2022 2,416 47 2,463 694 860 59 1,613	ended June 30, 202 \$ 2, 2, 2, 1,	1 161 56 217 557 830 48 435	ended June 30, 2022 \$ 6,796 82 6,878 1,742 2,479 127 4,348	2 3 2 3 7 3 	from March 19, 2021 to June 30, 2021 5 2,465 59 2,524 646 950 54 1,650		

(1) There are no management fees or incentive fees charged at the Glick JV.

The Glick JV has elected to fair value the Glick JV Notes issued to the Company and GF Debt Funding under FASB ASC Topic 825, *Financial Instruments - Fair Value Option*. The Glick JV Notes are valued based on the total assets less the liabilities senior to the Glick JV Notes in an amount not exceeding par under the EV technique.

During the three and nine months ended June 30, 2022 and the period from March 19, 2021 to June 30, 2021, the Company did not sell any debt investments to the Glick JV.

## Note 4. Fee Income

For the three and nine months ended June 30, 2022, the Company recorded total fee income of \$2.3 million and \$5.1 million, respectively, of which \$0.2 million and \$0.7 million, respectively, was recurring in nature. For the three and nine

months ended June 30, 2021, the Company recorded total fee income of \$7.8 million and \$13.5 million, respectively, of which \$0.1 million and \$0.3 million, respectively, was recurring in nature. Recurring fee income primarily consisted of servicing fees and exit fees.

## Note 5. Share Data and Net Assets

## Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share, pursuant to ASC Topic 260-10, *Earnings per Share*, for the three and nine months ended June 30, 2022 and 2021:

(Share amounts in thousands)		ree months ended ne 30, 2022	-	hree months ended une 30, 2021	-	vine months ended une 30, 2022	-	vine months ended une 30, 2021
Earnings (loss) per common share — basic and diluted:								
Net increase (decrease) in net assets resulting from operations	\$	(37,834)	\$	47,038	\$	16,015	\$	200,699
Weighted average common shares outstanding — basic and diluted		183,370		180,361		181,778		155,970
Earnings (loss) per common share — basic and diluted	\$	(0.21)	\$	0.26	\$	0.09	\$	1.29

## Changes in Net Assets

The following table presents the changes in net assets for the three and nine months ended June 30, 2022:

	Common Stock						
(Share amounts in thousands)	Shares	Pa	ır Value	A	Additional paid-in- capital	Accumulated Overdistributed Earnings	 Total Net Assets
Balance as of September 30, 2021	180,361	\$	1,804	\$	1,804,354	\$ (493,335)	\$ 1,312,823
Net investment income	—				_	32,295	32,295
Net unrealized appreciation (depreciation)	—				_	(4,586)	(4,586)
Net realized gains (losses)	—				_	9,321	9,321
(Provision) benefit for taxes on realized and unrealized gains (losses)	_		—		_	2,378	2,378
Distributions to stockholders	_		—		_	(27,956)	(27,956)
Issuance of common stock under dividend reinvestment plan	108		1		785		786
Balance as of December 31, 2021	180,469	\$	1,805	\$	1,805,139	\$ (481,883)	\$ 1,325,061
Net investment income	_		_		_	40,098	40,098
Net unrealized appreciation (depreciation)	_		—		_	(27,038)	(27,038)
Net realized gains (losses)	_		_		_	1,402	1,402
(Provision) benefit for taxes on realized and unrealized gains (losses)	_		_		_	(21)	(21)
Distributions to stockholders	_		_		_	(29,271)	(29,271)
Issuance of common stock in connection with the "at the market" offering	2,632		26		19,353	_	19,379
Issuance of common stock under dividend reinvestment plan	104		1		765		766
Balance as of March 31, 2022	183,205	\$	1,832	\$	1,825,257	\$ (496,713)	\$ 1,330,376
Net investment income	_		_		_	40,370	40,370
Net unrealized appreciation (depreciation)	_		_		_	(86,755)	(86,755)
Net realized gains (losses)	_		_		_	9,212	9,212
(Provision) benefit for taxes on realized and unrealized gains (losses)	_		_		_	(661)	(661)
Distributions to stockholders	_		_		_	(30,256)	(30,256)
Issuance of common stock in connection with the "at the market" offering	169		2		1,241	_	1,243
Issuance of common stock under dividend reinvestment plan	131		1		873	_	874
Repurchases of common stock under dividend reinvestment plan	(131)		(1)		(873)		(874)
Balance as of June 30, 2022	183,374	\$	1,834	\$	1,826,498	\$ (564,803)	\$ 1,263,529

The following table presents the changes in net assets for the three and nine months ended June 30, 2021:

	Common Stock						
(Share amounts in thousands)	Shares	Par	r Value	1	Additional paid-in- capital	Accumulated verdistributed Earnings	 Total Net Assets
Balance as of September 30, 2020	140,961	\$	1,409	\$	1,487,774	\$ (574,304)	\$ 914,879
Net investment income	—				—	10,018	10,018
Net unrealized appreciation (depreciation)	—		_			47,556	47,556
Net realized gains (losses)	—				—	8,215	8,215
Provision for income tax (expense) benefit	—		_			(245)	(245)
Distributions to stockholders	—				—	(15,506)	(15,506)
Issuance of common stock under dividend reinvestment plan	94		1		527		528
Repurchases of common stock under dividend reinvestment plan	(94)		(1)		(527)	 	(528)
Balance as of December 31, 2020	140,961	\$	1,409	\$	1,487,774	\$ (524,266)	\$ 964,917
Net investment income	—				—	18,114	18,114
Net unrealized appreciation (depreciation)	—				—	65,144	65,144
Net realized gains (losses)	—				—	5,856	5,856
Provision for income tax (expense) benefit	—				—	(997)	(997)
Distributions to stockholders	—				—	(16,915)	(16,915)
Issuance of common stock in connection with the Mergers	39,400		395		242,309		242,704
Issuance of common stock under dividend reinvestment plan	82		1		510	—	511
Repurchases of common stock under dividend reinvestment plan	(82)		(1)		(510)	 	(511)
Balance as of March 31, 2021	180,361	\$	1,804	\$	1,730,083	\$ (453,064)	\$ 1,278,823
Net investment income	—		_			35,932	35,932
Net unrealized appreciation (depreciation)	—				—	3,917	3,917
Net realized gains (losses)	—		_			8,610	8,610
(Provision) benefit for taxes on realized and unrealized gains (losses)	—				—	(1,421)	(1,421)
Distributions to stockholders	—		_			(23,447)	(23,447)
Issuance of common stock under dividend reinvestment plan	77		1		519		520
Repurchases of common stock under dividend reinvestment plan	(77)		(1)		(519)		(520)
Balance as of June 30, 2021	180,361	\$	1,804	\$	1,730,083	\$ (429,473)	\$ 1,302,414

### Distributions

Distributions to common stockholders are recorded on the ex-dividend date. The amount to be paid out as a dividend is determined by the Board of Directors and is based on management's estimate of the Company's annual taxable income. Net realized capital gains, if any, may be distributed to stockholders or retained for reinvestment.

The Company has adopted a dividend reinvestment plan ("DRIP") that provides for reinvestment of any distributions the Company declares in cash on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Company's Board of Directors declares a cash distribution, then the Company's stockholders who have not "opted out" of the Company's DRIP will have their cash distribution automatically reinvested in additional shares of the Company's common stock, rather than receiving the cash distribution. If the Company's shares are trading at a premium to net asset value, the Company typically issues new shares to implement the DRIP with such shares issued at the greater of the most recently computed net asset value per share of common stock or 95% of the current market price per share of common stock on the payment date for such distribution. If the Company's shares are trading at a discount to net asset value, the Company typically purchases shares in the open market in connection with the Company's obligations under the DRIP.

For income tax purposes, the Company has reported its distributions for the 2021 calendar year as ordinary income. The character of such distributions was appropriately reported to the Internal Revenue Service and stockholders for the 2021 calendar year. To the extent the Company's taxable earnings for a fiscal and taxable year fall below the amount of distributions paid for the fiscal and taxable year, a portion of the total amount of the Company's distributions for the fiscal and taxable year is deemed a return of capital for U.S. federal income tax purposes to the Company's stockholders.

The following table reflects the distributions per share that the Company has paid, including shares issued under the DRIP, on its common stock during the nine months ended June 30, 2022 and 2021:

Date Declared	<b>Record Date</b>	Payment Date	 Amount per Share	Di	Cash stribution	DRIP Shares Issued	DRIP Shares Value (3)
October 13, 2021	December 15, 2021	December 31, 2021	\$ 0.155	\$	27.2 million	107,971 (1)	\$ 0.8 million
January 28, 2022	March 15, 2022	March 31, 2022	0.16		28.5 million	104,411 (1)	0.8 million
April 29, 2022	June 15, 2022	June 30, 2022	 0.165		29.4 million	131,028 (2)	0.9 million
Total for the nine	months ended June 30	), 2022	\$ 0.48	\$	85.1 million	343,410	\$ 2.4 million
Date Declared	Record Date	Payment Date	Amount per Share	Cash Distribution		DRIP Shares Issued (2)	DRIP Shares Value (3)
November 13, 2020							
1000011001 15, 2020	December 15, 2020	December 31, 2020	\$ 0.11	\$	15.0 million	93,964	\$ 0.5 million
January 29, 2021	December 15, 2020 March 15, 2021	December 31, 2020 March 31, 2021	\$ 0.11 0.12	\$	15.0 million 16.4 million	93,964 81,702	\$ 0.5 million 0.5 million
	,	,	\$	\$		,	• • • • •

(1) New shares were issued and distributed.

(2) Shares were purchased on the open market and distributed.

(3) Total may not sum due to rounding.

### Common Stock Issuances

During the nine months ended June 30, 2022, the Company issued an aggregate of 212,382 shares of common stock as part of the DRIP.

On February 7, 2022, the Company entered into an equity distribution agreement by and among the Company, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by the Company of shares of common stock, having an aggregate offering price of up to \$125.0 million. Sales of the common stock may be made in negotiated transactions or transactions that are deemed to be "at the market," as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

In connection with the "at the market" offering, the Company issued and sold the following shares of common stock during the nine months ended June 30, 2022:

	Number of Shares Issued	Gross Proceeds	Pla	acement Agent Fees	 Net Proceeds (1)	Av	verage Sales Price per Share (2)
"At the market" offering	2,801,206	\$ 21,049	\$	210	\$ 20,839	\$	7.51

(1) Net proceeds excludes offering costs of \$0.2 million.

(2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses.

On March 19, 2021, in connection with the Mergers, the Company issued an aggregate of 39,400,011 shares of common stock to former OCSI stockholders. There were no other common stock issuances during the nine months ended June 30, 2021.

# Note 6. Borrowings

# Syndicated Facility

On November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the "Syndicated Facility") pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans,

mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank.

On December 10, 2021, the Company entered into an incremental commitment and assumption agreement pursuant to which a new lender provided additional commitments of \$50 million under the Syndicated Facility. As of June 30, 2022, the size of the Syndicated Facility was \$1.0 billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of \$1.25 billion and the Company's net worth, as defined in the facility, under certain circumstances.

As of June 30, 2022, (i) the period during which the Company may make drawings will expire on May 4, 2025 and the maturity date is May 4, 2026 and (ii) the interest rate margin for (a) LIBOR loans (which may be 1-, 2-, 3- or 6-month, at the Company's option) was 2.00% and (b) alternate base rate loans was 1.00%.

The Syndicated Facility is secured by substantially all of the Company's assets (excluding, among other things, investments held in and by certain subsidiaries of the Company (including OCSL Senior Funding II LLC) or investments in certain portfolio companies of the Company) and guaranteed by certain subsidiaries of the Company. As of June 30, 2022, except for assets that were held by OCSL Senior Funding II LLC and certain immaterial subsidiaries, substantially all of the Company's assets are pledged as collateral under the Syndicated Facility.

The Syndicated Facility requires the Company to, among other things, (i) make representations and warranties regarding the collateral as well as each of the Company's portfolio companies' businesses, (ii) agree to certain indemnification obligations, and (iii) comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A) limitations on the incurrence of additional indebtedness and liens, (B) limitations on certain investments, (C) limitations on certain asset transfers and restricted payments, (D) maintaining a certain minimum stockholders' equity, (E) maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F) maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G) maintaining a minimum liquidity and net worth, and (H) limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of June 30, 2022, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company's portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions.

As of June 30, 2022 and September 30, 2021, the Company had \$575.0 million and \$495.0 million of borrowings outstanding under the Syndicated Facility, respectively, which had a fair value of \$575.0 million and \$495.0 million, respectively. The Company's borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 2.406% and 2.202% for the nine months ended June 30, 2022 and 2021, respectively. For the three and nine months ended June 30, 2022, the Company recorded interest expense (inclusive of fees) of \$4.8 million and \$12.6 million, respectively, related to the Syndicated Facility. For the three and nine months ended June 30, 2021, the Company recorded interest expense (inclusive of fees) of \$4.0 million and \$10.5 million, respectively, related to the Syndicated Facility.

### Citibank Facility

On March 19, 2021, as a result of the consummation of the Mergers, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the "Citibank Facility") with OCSL Senior Funding II LLC (formerly OCSI Senior Funding II LLC), the Company's wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian.

On November 18, 2021, the Company entered into an amendment to the Citibank Facility that, among other things, increased the size of the facility by \$50 million and extended the reinvestment period and final maturity date. As of June 30, 2022, the Company was able to borrow up to \$200 million under the Citibank Facility (subject to borrowing base and other limitations). As of June 30, 2022, the reinvestment period under the Citibank Facility was scheduled to expire on November 18, 2023 and the maturity date for the Citibank Facility was November 18, 2024.

As of June 30, 2022, borrowings under the Citibank Facility are subject to certain customary advance rates and accrue interest at a rate equal to LIBOR plus between 1.25% and 2.20% per annum on broadly syndicated loans, subject to observable market depth and pricing, and LIBOR plus 2.25% per annum on all other eligible loans during the reinvestment period. In addition, as of June 30, 2022, for the duration of the reinvestment period there is a non-usage fee payable of 0.50% per annum on the undrawn amount under the Citibank Facility. The minimum asset coverage ratio applicable to the Company under the Citibank Facility is 150% as determined in accordance with the requirements of the Investment Company Act. Borrowings under the Citibank Facility are secured by all of the assets of OCSL Senior Funding II LLC and all of the Company's equity interests in OCSL Senior Funding II LLC. The Company may use the Citibank Facility to fund a portion of its loan origination activities and for general corporate purposes. Each loan origination under the Citibank Facility is subject to the satisfaction of certain conditions.

As of June 30, 2022 and September 30, 2021, the Company had \$170.0 million and \$135.0 million outstanding under the Citibank Facility, respectively, which had a fair value of \$170.0 million and \$135.0 million, respectively. The Company's borrowings under the Citibank Facility bore interest at a weighted average interest rate of 2.563% and 2.198% for the nine months ended June 30, 2022 and the period from March 19, 2021 to June 30, 2021, respectively. For the three and nine months ended June 30, 2022, the Company recorded interest expense (inclusive of fees) of \$1.6 million and \$3.5 million related to the Citibank Facility. For three months ended June 30, 2021 and the period from March 19, 2021 to June 30, 2021, the Company recorded interest expense (inclusive of fees) of \$1.6 million, respectively, related to the Citibank Facility.

### 2025 Notes

On February 25, 2020, the Company issued \$300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes.

The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.

Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the nine months ended June 30, 2022, the Company did not repurchase any of the 2025 Notes in the open market.

The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture.

### 2027 Notes

On May 18, 2021, the Company issued \$350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8 million after deducting OID of \$1.0 million, underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes.

The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027

Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.

Interest on the 2027 Notes is paid semi-annually on January 15 and July 15, beginning on January 15, 2022, at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the nine months ended June 30, 2022, the Company did not repurchase any of the 2027 Notes in the open market.

The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture.

In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month LIBOR plus 1.658% on a notional amount of \$350 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.

The below table presents the components of the carrying value of the 2025 Notes and the 2027 Notes as of June 30, 2022 and September 30, 2021:

	As of June 30, 2022					As of September 30, 2021			
(\$ in millions)	20	25 Notes		2027 Notes		2025 Notes		2027 Notes	
Principal	\$	300.0	\$	350.0	\$	300.0	\$	350.0	
Unamortized financing costs		(2.0)		(3.4)		(2.6)		(4.0)	
Unaccreted discount		(1.3)		(0.8)		(1.7)		(0.9)	
Interest rate swap fair value adjustment		_		(30.9)				(2.1)	
Net carrying value	\$	296.7	\$	314.9	\$	295.7	\$	343.0	
Fair Value	\$	284.0	\$	301.1	\$	314.5	\$	351.1	

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended June 30, 2022:

	2025 Notes					2027 Notes				
(\$ in millions)		e months ended ine 30, 2022		e months ended une 30, 2022		ee months ended June 30, 2022		months ended ne 30, 2022		
Coupon interest	\$	2.6	\$	7.9	\$	2.4	\$	7.1		
Amortization of financing costs and discount		0.3		0.9		0.2		0.7		
Effect of interest rate swap		_				(0.1)		(1.6)		
Total interest expense	\$	2.9	\$	8.8	\$	2.5	\$	6.2		
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)		3.500 %		3.500 %		2.572 %		2.069 %		

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended June 30, 2021:

	2025 Notes					2027 Notes				
(\$ in millions)		onths ended a 30, 2021		months ended ne 30, 2021		months ended ne 30, 2021	Nine months ended June 30, 2021			
Coupon interest	\$	2.6	\$	7.9	\$	1.1	\$	1.1		
Amortization of financing costs and discount		0.3		0.9		0.1		0.1		
Effect of interest rate swap				_		(0.3)		(0.3)		
Total interest expense	\$	2.9	\$	8.8	\$	0.9	\$	0.9		
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)		3.500 %		3.500 %		1.813 %		1.813 %		

## Note 7. Taxable/Distributable Income and Dividend Distributions

Taxable income differs from net increase (decrease) in net assets resulting from operations primarily due to: (1) unrealized appreciation (depreciation) on investments and foreign currency, as gains and losses are not included in taxable income until they are realized; (2) origination and exit fees received in connection with investments in portfolio companies; (3) organizational costs; (4) income or loss recognition on exited investments; and (5) recognition of interest income on certain loans.

As of September 30, 2021, the Company had net capital loss carryforwards of \$547.9 million to offset net capital gains that will not expire, to the extent available and permitted by U.S. federal income tax law, of which \$69.1 million are available to offset future short-term capital gains and \$478.8 million are available to offset future long-term capital gains. A portion of such net capital loss carryfowards represented a realized loss under sections 382 and 383 of the Code, which is carried forward to future years to offset future gains subject to certain limitations.

Listed below is a reconciliation of "net increase (decrease) in net assets resulting from operations" to taxable income for the three and nine months ended June 30, 2022 and 2021.

	 ree months ended ne 30, 2022	-	hree months ended une 30, 2021	-	vine months ended une 30, 2022	 ine months ended ne 30, 2021
Net increase (decrease) in net assets resulting from operations	\$ (37,834)	\$	47,038	\$	16,015	\$ 200,699
Net unrealized (appreciation) depreciation	86,755		(3,917)		118,379	(116,617)
Book/tax difference due to organizational costs	(21)		_		(65)	(22)
Book/tax difference due to interest income on certain loans	_		339		_	—
Book/tax difference due to capital losses utilized	(3,736)		(12,728)		(19,183)	(34,625)
Other book/tax differences	 (8,819)		(3,785)		(18,597)	 13,847
Taxable/Distributable Income (1)	\$ 36,345	\$	26,947	\$	96,549	\$ 63,282

(1) The Company's taxable income for the three and nine months ended June 30, 2022 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2022. Therefore, the final taxable income may be different than the estimate.

The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.

When assessing the realizability of deferred tax assets, the Company considers whether it is probable that some or all of the deferred tax assets will not be realized. In determining whether the deferred tax assets are realizable, the Company considers the period of expiration of the tax asset, historical and projected taxable income and tax liabilities for the tax jurisdiction in which the tax asset is located. The deferred tax asset recognized by the Company, as it relates to the higher tax basis in the carrying value of certain assets compared to the book basis of those assets, will be recognized in future years by these taxable

entities. Deferred tax assets are based on the amount of the tax benefit that the Company's management has determined is more likely than not to be realized in future periods. In determining the realizability of this tax benefit, management considered numerous factors that will give rise to pre-tax income in future periods. Among these are the historical and expected future book and tax basis pre-tax income of the Company and unrealized gains in the Company's assets at the determination date. Based on these and other factors, the Company determined that, as of June 30, 2022, \$3.3 million of the \$5.0 million deferred tax assets would not more likely than not be realized in future periods. As of June 30, 2022, the Company recorded a net deferred tax asset of \$1.7 million on the Consolidated Statements of Assets and Liabilities.

For the three months ended June 30, 2022, the Company recognized a total provision for income tax related to realized and unrealized gains (losses) of \$0.7 million, which was primarily composed of current income tax expense. For the three months ended June 30, 2021, the Company recognized a provision for income tax related to realized and unrealized gains of \$1.4 million, which was comprised of (i) a current income tax expense of approximately \$1.6 million, and (ii) a deferred income tax benefit of approximately \$0.2 million, which resulted from unrealized depreciation on investments held by the Company's wholly-owned taxable subsidiaries.

For the nine months ended June 30, 2022, the Company recognized a provision for income tax related to net investment income of \$3.3 million, which was all current income tax expense. For the nine months ended June 30, 2022, the Company also recognized a total benefit for income taxes related to realized and unrealized gains (losses) of \$1.7 million, which was composed of (i) a current income tax benefit of approximately \$0.7 million, and (ii) a deferred income tax benefit of approximately \$1.0 million, which resulted from unrealized depreciation of investments held by the Company's wholly-owned taxable subsidiaries. For the nine months ended June 30, 2021, the Company recognized a total provision for income tax related to realized and unrealized gains of \$2.7 million, which was comprised of (i) a current income tax expense of approximately \$0.1 million, which resulted from unrealized appreciation of investments held by the Company's wholly-owned taxable subsidiaries. For the nine months ended June 30, 2021, the Company recognized a total provision for income tax related to realized and unrealized gains of \$2.7 million, which was comprised of (i) a current income tax expense of approximately \$0.1 million, which resulted from unrealized appreciation on investments held by the Company's wholly-owned taxable subsidiaries.

As of September 30, 2021, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows:

Undistributed ordinary income, net	\$ (20,260)
Net realized capital losses	497,255
Unrealized losses, net	16,340
Accumulated overdistributed earnings	\$ 493,335

The aggregate cost of investments for U.S. federal income tax purposes was \$2.6 billion as of September 30, 2021. As of September 30, 2021, the aggregate gross unrealized appreciation for all investments in which there was an excess of value over cost for U.S. federal income tax purposes was \$409.5 million. As of September 30, 2021, the aggregate gross unrealized depreciation for all investments in which there was an excess of cost for U.S. federal income tax purposes over value was \$425.8 million. Net unrealized depreciation based on the aggregate cost of investments for U.S. federal income tax purposes was \$16.3 million.

## Note 8. Realized Gains or Losses and Net Unrealized Appreciation or Depreciation

## Realized Gains or Losses

Realized gains or losses are measured by the difference between the net proceeds from the sale or redemption and the cost basis of the investment without regard to unrealized appreciation or depreciation previously recognized, and include investments written-off during the period, net of recoveries. Realized losses may also be recorded in connection with the Company's determination that certain investments are considered worthless securities and/or meet the conditions for loss recognition per the applicable tax rules.

During the three months ended June 30, 2022, the Company recorded an aggregate net realized gain of \$9.2 million, which consisted of the following:

(\$ in millions)	
Portfolio Company	Net Realized Gain (Loss)
Foreign currency forward contracts	8.8
Other, net	0.4
Total, net	\$ 9.2

During the three months ended June 30, 2021, the Company recorded an aggregate net realized gain of \$8.6 million, which consisted of the following:

(\$ in millions)		
Portfolio Company	Net Realized Gain	ı (Loss)
Keypath Education Holdings, LLC	\$	6.8
Signify Health, LLC		0.6
Other, net		1.2
Total, net	\$	8.6

During the nine months ended June 30, 2022, the Company recorded an aggregate net realized gain of \$19.9 million, which consisted of the following:

(\$ in millions)					
Portfolio Company	Net Realized Gain (Loss)				
Foreign currency forward contracts	\$	12.2			
OmniSYS Acquisition Corporation		2.2			
First Star Speir Aviation Limited		1.9			
TigerConnect Inc.		1.8			
Other, net		1.8			
Total, net	\$	19.9			

During the nine months ended June 30, 2021, the Company recorded an aggregate net realized gain of \$22.7 million, which consisted of the following:

(\$ in millions)		
Portfolio Company	Net Realized	Gain (Loss)
PLATO Learning Inc.	\$	7.8
Keypath Education Holdings, LLC		6.8
L Squared Capital Partners LLC		3.4
LTI Holdings, Inc.		2.6
BX Commercial Mortgage Trust 2020-VIVA		2.6
California Pizza Kitchen Inc.		(1.8)
Other, net		1.3
Total, net	\$	22.7

## Net Unrealized Appreciation or Depreciation

Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation.

During the three months ended June 30, 2022 and 2021, the Company recorded net unrealized appreciation (depreciation) of \$(86.8) million and \$3.9 million, respectively. For the three months ended June 30, 2022, this consisted of \$66.8 million of net unrealized depreciation on debt investments, \$17.9 million of net unrealized depreciation on equity investments, \$1.6 million of net unrealized depreciation of foreign currency forward contracts and \$0.4 million of net unrealized depreciation

related to exited investments (a portion of which resulted in a reclassification to realized gains). For the three months ended June 30, 2021, this consisted of \$12.3 million of net unrealized appreciation on debt investments, \$3.8 million of net unrealized appreciation of foreign currency forward contracts, partially offset by \$13.3 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains).

During the nine months ended June 30, 2022 and 2021, the Company recorded net unrealized appreciation (depreciation) of \$(118.4) million and \$116.6 million, respectively. For the nine months ended June 30, 2022, this consisted of \$84.6 million of net unrealized depreciation on debt investments, \$23.8 million of net unrealized depreciation on equity investments, \$9.2 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains) and \$0.8 million of net unrealized depreciation of foreign currency forward contracts. For the nine months ended June 30, 2021, this consisted of \$79.7 million of net unrealized appreciation related to exited investments, \$4.0 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized appreciation on equity investments, \$4.0 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$2.2 million of net unrealized appreciation of foreign currency forward contracts.

### Note 9. Concentration of Credit Risks

The Company deposits its cash with financial institutions and at times such balances may be in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability.

#### Note 10. Related Party Transactions

As of June 30, 2022 and September 30, 2021, the Company had a liability on its Consolidated Statements of Assets and Liabilities in the amount of \$15.6 million and \$32.6 million, respectively, reflecting the unpaid portion of the base management fees and incentive fees payable to Oaktree.

#### Investment Advisory Agreement

The Company is party to the Investment Advisory Agreement. Under the Investment Advisory Agreement, the Company pays Oaktree a fee for its services under the Investment Advisory Agreement consisting of two components: a base management fee and an incentive fee. The cost of both the base management fee payable to Oaktree and any incentive fees earned by Oaktree is ultimately borne by common stockholders of the Company.

From October 17, 2017 through May 3, 2020, the Company was externally managed by OCM pursuant to an investment advisory agreement. On May 4, 2020, OCM effected the novation of such investment advisory agreement to Oaktree. Immediately following such novation, the Company and Oaktree entered into a new investment advisory agreement with the same terms, including fee structure, as the investment advisory agreement with OCM. The investment advisory agreement with Oaktree was subsequently amended and restated on March 19, 2021 in connection with the closing of the Mergers. The term "Investment Advisory Agreement" refers collectively to the agreements with Oaktree and, prior to its novation, with OCM.

Unless earlier terminated as described below, the Investment Advisory Agreement will remain in effect from year-toyear if approved annually by the Board of Directors of the Company or by the affirmative vote of the holders of a majority of the Company's outstanding voting securities, including, in either case, approval by a majority of the directors of the Company who are not interested persons. The Investment Advisory Agreement will automatically terminate in the event of its assignment. The Investment Advisory Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Investment Advisory Agreement may also be terminated, without penalty, upon the vote of a majority of the outstanding voting securities of the Company.

#### Base Management Fee

Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of total gross assets, including any investment made with borrowings, but excluding cash and cash equivalents. The base management fee is payable quarterly in arrears and the fee for any partial month or quarter is appropriately prorated. Effective May 3, 2019, the

base management fee on the Company's gross assets, including any investments made with borrowings, but excluding any cash and cash equivalents, that exceed the product of (A) 200% and (B) the Company's net asset value will be 1.00%. For the avoidance of doubt, the 200% will be calculated in accordance with the Investment Company Act and will give effect to exemptive relief the Company received from the SEC with respect to debentures issued by a small business investment company subsidiary. In connection with the Mergers, the Company and Oaktree entered into an amended and restated investment advisory agreement, which among other items, waived an aggregate of \$6 million of base management fees otherwise payable to Oaktree in the two years following the closing of the Mergers on March 19, 2021 at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter).

For the three and nine months ended June 30, 2022, the base management fee incurred under the Investment Advisory Agreement was \$9.1 million (net of waiver) and \$27.6 million (net of waiver), respectively. For the three and nine months ended June 30, 2021, the base management fee incurred under the Investment Advisory Agreement was \$8.2 million (net of waiver) and \$21.7 million (net of waiver), respectively.

### Incentive Fee

The incentive fee consists of two parts. Under the Investment Advisory Agreement, the first part of the incentive fee (the "incentive fee on income" or "Part I incentive fee") is calculated and payable quarterly in arrears based upon the "pre-incentive fee net investment income" of the Company for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a "hurdle rate"), expressed as a rate of return on the value of the Company's net assets at the end of the most recently completed quarter, of 1.50%, subject to a "catch up" feature.

For this purpose, "pre-incentive fee net investment income" means interest income, dividend income and any other income (including any other fees such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies, other than fees for providing managerial assistance) accrued during the fiscal quarter, minus the Company's operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID debt, instruments with PIK interest and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the Mergers, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments in an increase in pre-incentive fee net investment income.

Under the Investment Advisory Agreement, the calculation of the incentive fee on income for each quarter is as follows:

- No incentive fee is payable to Oaktree in any quarter in which the Company's pre-incentive fee net investment income does not exceed the preferred return rate of 1.50% (the "preferred return") on net assets;
- 100% of the Company's pre-incentive fee net investment income, if any, that exceeds the preferred return but is less than or equal to 1.8182% in any fiscal quarter is payable to Oaktree. This portion of the incentive fee on income is referred to as the "catch-up" provision, and it is intended to provide Oaktree with an incentive fee of 17.5% on all of the Company's pre-incentive fee net investment income when the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets in any fiscal quarter; and
- For any quarter in which the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets, the incentive fee on income is equal to 17.5% of the amount of the Company's pre-incentive fee net investment income, as the preferred return and catch-up will have been achieved.

There is no accumulation of amounts on the hurdle rate from quarter to quarter and accordingly there is no clawback of amounts previously paid if subsequent quarters are below the quarterly hurdle.

For the three and nine months ended June 30, 2022, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$6.5 million and \$19.7 million, respectively. For the three and nine months ended June 30, 2021, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$7.0 million and \$15.6 million, respectively.

Under the Investment Advisory Agreement, the second part of the incentive fee (the "capital gains incentive fee") is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of the Company's realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each subsequent fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees under the Investment Advisory Agreement. Any realized capital gains, realized capital losses, unrealized capital appreciation and unrealized capital depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the Mergers, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee and (2) include any such amounts associated with the investments acquired in the Mergers for the period from October 1, 2018 to the date of closing of the Mergers, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. As of June 30, 2022, the Company paid \$9.6 million of capital gains incentive fees cumulatively under the Investment Advisory Agreement (net of waivers). For the three and nine months ended June 30, 2022, the Company did not incur any capital gains incentive fees under the Investment Advisory Agreement.

GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized capital appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized capital appreciation were realized on a theoretical "liquidation basis." A fee so calculated and accrued would not be payable under applicable law and may never be paid based upon the computation of capital gains incentive fees in subsequent periods. Amounts ultimately paid under the Investment Advisory Agreement will be consistent with the formula reflected in the Investment Advisory Agreement. This GAAP accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital depreciation included in the calculation of the capital gains incentive fee plus the aggregate cumulative unrealized capital appreciation. Any realized capital gains and losses and cumulative unrealized capital appreciation and depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the GAAP accrual. If such amount is positive at the end of a period, then GAAP requires the Company to record a capital gains incentive fee equal to 17.5% of such cumulative amount, less the aggregate amount of actual capital gains incentive fees payable or capital gains incentive fees accrued under GAAP in all prior periods. The resulting accrual for any capital gains incentive fee under GAAP in a given period may result in an additional expense if such cumulative amount is greater than in the prior period or a reversal of previously recorded expense if such cumulative amount is less than in the prior period. If such cumulative amount is negative, then there is no accrual. There can be no assurance that such unrealized capital appreciation will be realized in the future or any accrued capital gains incentive fee will become payable under the Investment Advisory Agreement. For the three and nine months ended June 30, 2022, \$6.8 million and \$8.8 million of accrued capital gains incentive fees were reversed, respectively. For the three and nine months ended June 30, 2021, \$2.8 million and \$16.0 million of accrued capital gains incentive fees were expensed, respectively. As of June 30, 2022, the total accrued capital gains incentive fee liability was zero. Part II incentive fees are contractually calculated and paid at the end of the fiscal year in accordance with the Investment Advisory Agreement, which, as described above, differs from Part II incentive fees accrued under GAAP. Hypothetically, if Part II incentive fees were calculated as of June 30, 2022 under the Investment Advisory Agreement, there would be no amounts payable.

# Indemnification

The Investment Advisory Agreement provides that, absent willful misfeasance, bad faith or gross negligence in the performance of their respective duties or by reason of the reckless disregard of their respective duties and obligations, Oaktree and its officers, managers, partners, members (and their members, including the owners of their members), agents, employees, controlling persons and any other person or entity affiliated with it, are entitled to indemnification from the Company for any damages, liabilities, costs and expenses (including reasonable attorneys' fees and amounts reasonably paid in settlement) arising from the rendering of Oaktree's services under the Investment Advisory Agreement or otherwise as investment adviser.

#### Administrative Services

The Company is party to the Administration Agreement with Oaktree Administrator. Pursuant to the Administration Agreement, Oaktree Administrator provides administrative services to the Company necessary for the operations of the Company, which include providing office facilities, equipment, clerical, bookkeeping and record keeping services at such facilities and such other services as Oaktree Administrator, subject to review by the Company's Board of Directors, shall from time to time deem to be necessary or useful to perform its obligations under the Administration Agreement. Oaktree

Administrator may, on behalf of the Company, conduct relations and negotiate agreements with custodians, trustees, depositories, attorneys, underwriters, brokers and dealers, corporate fiduciaries, insurers, banks and such other persons in any such other capacity deemed to be necessary or desirable. Oaktree Administrator makes reports to the Company's Board of Directors of its performance of obligations under the Administration Agreement and furnishes advice and recommendations with respect to such other aspects of the Company's business and affairs, in each case, as it shall determine to be desirable or as reasonably required by the Company's Board of Directors; provided that Oaktree Administrator shall not provide any investment advice or recommendation.

Oaktree Administrator also provides portfolio collection functions for interest income, fees and warrants and is responsible for the financial and other records that the Company is required to maintain and prepares, prints and disseminates reports to the Company's stockholders and all other materials filed with the SEC. In addition, Oaktree Administrator assists the Company in determining and publishing the Company's net asset value, overseeing the preparation and filing of the Company's tax returns, and generally overseeing the payment of the Company's expenses and the performance of administrative and professional services rendered to the Company by others. Oaktree Administrator may also offer to provide, on the Company's behalf, managerial assistance to the Company's portfolio companies.

For providing these services, facilities and personnel, the Company reimburses Oaktree Administrator the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including the Company's allocable portion of the rent of the Company's principal executive offices (which are located in a building owned by a Brookfield affiliate) at market rates and the Company's allocable portion of the costs of compensation and related expenses of its Chief Financial Officer, Chief Compliance Officer, their staffs and other non-investment professionals at Oaktree that perform duties for the Company. Such reimbursement is at cost, with no profit to, or markup by, Oaktree Administrator. The Administration Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Administration Agreement may also be terminated, without penalty, upon the vote of a majority of the Company's outstanding voting securities.

For the three months ended June 30, 2022 and 2021, the Company accrued administrative expenses of \$0.3 million and \$0.5 million, respectively, including \$0.1 million and \$0.1 million of general and administrative expenses, respectively. For the nine months ended June 30, 2022 and 2021, the Company accrued administrative expenses of \$1.2 million and \$1.2 million, respectively, including \$0.1 million of general and administrative expenses, respectively.

As of June 30, 2022 and September 30, 2021, \$3.5 million and \$4.4 million, respectively, was included in "Due to affiliate" in the Consolidated Statements of Assets and Liabilities, reflecting the unpaid portion of administrative expenses and other reimbursable expenses payable to Oaktree Administrator.

# Note 11. Financial Highlights

(Share amounts in thousands)	Three months ended June 30, 2022	Three months ended June 30, 2021	Nine months ended June 30, 2022	Nine months ended June 30, 2021
Net asset value per share at beginning of period	\$7.26	\$7.09	\$7.28	\$6.49
Net investment income (1)	0.22	0.20	0.62	0.41
Net unrealized appreciation (depreciation) (1)	(0.47)	0.02	(0.65)	0.74
Net realized gains (losses) (1)	0.05	0.05	0.11	0.15
(Provision) benefit for taxes on realized and unrealized gains (losses) (1)	—	(0.01)	0.01	(0.02)
Distributions of net investment income to stockholders	(0.17)	(0.13)	(0.48)	(0.36)
Issuance of common stock				(0.19)
Net asset value per share at end of period	6.89	7.22	6.89	7.22
Per share market value at beginning of period	\$7.37	\$6.20	\$7.06	\$4.84
Per share market value at end of period	6.55	6.69	6.55	\$6.69
Total return (2)	(8.93)%	9.98%	(0.79)%	46.39%
Common shares outstanding at beginning of period	183,205	180,361	180,361	140,961
Common shares outstanding at end of period	183,374	180,361	183,374	180,361
Net assets at beginning of period	\$1,330,376	\$1,278,823	\$1,312,823	\$914,879
Net assets at end of period	\$1,263,529	\$1,302,414	\$1,263,529	\$1,302,414
Average net assets (3)	\$1,306,727	\$1,298,995	\$1,323,232	\$1,094,761
Ratio of net investment income to average net assets (4)	12.39%	11.09%	11.39%	7.82%
Ratio of total expenses to average net assets (4)	7.22%	9.23%	7.94%	10.02%
Ratio of net expenses to average net assets (4)	6.99%	9.00%	7.71%	9.91%
Ratio of portfolio turnover to average investments at fair value	4.73%	7.43%	21.44%	31.59%
Weighted average outstanding debt (5)	\$1,369,615	\$1,140,774	\$1,358,150	\$884,525
Average debt per share (1)	\$7.47	\$6.32	\$7.47	\$5.67
Asset coverage ratio at end of period (6)	187.82%	216.01%	187.82%	216.01%

(1) Calculated based upon weighted average shares outstanding for the period.

(3) Calculated based upon the weighted average net assets for the period.

<sup>(2)</sup> Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load.

<sup>(4)</sup> Interim periods are annualized.

<sup>(5)</sup> Calculated based upon the weighted average of principal debt outstanding for the period.

<sup>(6)</sup> Based on outstanding senior securities of \$1,395.0 million and \$1,114.1 million as of June 30, 2022 and 2021, respectively.

# Note 12. Derivative Instruments

The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company's investments denominated in foreign currencies. In order to better define its contractual rights and to secure rights that will help the Company mitigate its counterparty risk, the Company entered into an International Swaps and Derivatives Association, Inc. Master Agreement (the "ISDA Master Agreement") with its derivative counterparty, JPMorgan Chase Bank, N.A. The ISDA Master Agreement permits a single net payment in the event of a default or similar event. As of June 30, 2022, no cash collateral has been pledged to cover obligations and no cash collateral has been received from the counterparty with respect to the Company's forward currency contracts.

In connection with the issuance of the 2027 Notes, the Company entered into an interest rate swap agreement with the Royal Bank of Canada pursuant to an ISDA Master Agreement. As of June 30, 2022, the Company paid \$36.3 million to the Royal Bank of Canada to cover collateral obligations under the terms of the interest swap agreement, which is included in due from broker on the Consolidated Statement of Assets and Liabilities.

Certain information related to the Company's foreign currency forward contracts is presented below as of June 30, 2022.

Description	Amo	otional ount to be rchased		Notional mount to be Sold	Maturity Date	Gross mount of ecognized Assets	An Rec	Gross tount of cognized abilities	Balance Sheet Location of Net Amounts
Foreign currency forward contract	\$	46,196	€	43,643	8/11/2022	\$ 440	\$	_	Derivative asset
Foreign currency forward contract	\$	49,442	£	40,109	8/11/2022	\$ 694	\$	_	Derivative asset
						\$ 1,134	\$		

Certain information related to the Company's foreign currency forward contracts is presented below as of September 30, 2021.

Description	Am	otional ount to be irchased		Notional nount to be Sold	Maturity Date	Gross mount of ecognized Assets	An Re	Gross nount of cognized abilities	Balance Sheet Location of Net Amounts
Foreign currency forward contract	\$	52,186	£	37,709	11/12/2021	\$ 1,339	\$	_	Derivative asset
Foreign currency forward contract	\$	46,663	€	39,736	11/12/2021	\$ 573	\$		Derivative asset
						\$ 1,912	\$		

Certain information related to the Company's interest rate swap is presented below as of June 30, 2022.

Description	Notional Amount	Maturity Date	Gross mount of ecognized Assets	Re	Gross nount of cognized iabilities	Balance Sheet Location of Net Amounts
Interest rate swap	\$ 350,000	1/15/2027	\$ 	\$	30,866	Derivative liability
			\$ 	\$	30,866	

Certain information related to the Company's interest rate swap is presented below as of September 30, 2021.

Description	Notional Amount	Maturity Date	Gross mount of cognized Assets	An Re	Gross nount of cognized abilities	Balance Sheet Location of Net Amounts
Interest rate swap	\$ 350,000	1/15/2027	\$ _	\$	2,108	Derivative liability
			\$ 	\$	2,108	

# Note 13. Commitments and Contingencies

# **Off-Balance Sheet Arrangements**

The Company may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of its portfolio companies. As of June 30, 2022, the Company's only off-balance sheet arrangements consisted of \$232.1 million of unfunded commitments, which was comprised of \$183.1 million to provide debt and equity financing to certain of its portfolio companies and \$49.0 million to provide financing to the JVs. As of September 30, 2021, the

Company's only off-balance sheet arrangements consisted of \$264.9 million of unfunded commitments, which was comprised of \$212.4 million to provide debt and equity financing to certain of its portfolio companies, \$49.0 million to provide financing to the JVs and \$3.5 million related to unfunded limited partnership interests. Such commitments are subject to the portfolio companies' satisfaction of certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in the Consolidated Statements of Assets and Liabilities.

A list of unfunded commitments by investment (consisting of revolvers, term loans with delayed draw components, subordinated notes and LLC equity interests in the JVs, preferred stock and limited partnership interests) as of June 30, 2022 and September 30, 2021 is shown in the table below:

	June 30, 2022	September 30, 2021
Senior Loan Fund JV I, LLC	\$ 35,000	\$ 35,00
Fairbridge Strategic Capital Funding LLC	32,250	-
Athenex, Inc.	21,072	21,07
BioXcel Therapeutics, Inc.	14,066	-
OCSI Glick JV LLC	13,998	13,99
Dominion Diagnostics, LLC	11,148	11,14
BAART Programs, Inc.	9,562	3,58
MRI Software LLC	6,800	2,69
Innocoll Pharmaceuticals Limited	6,292	-
Marinus Pharmaceuticals, Inc.	5,734	18,34
Establishment Labs Holdings Inc.	5,075	-
Accupac, Inc.	5,014	3,26
RumbleOn, Inc.	4,822	16,30
Assembled Brands Capital LLC	4,746	24,86
Ardonagh Midco 3 PLC	4,372	14,89
Grove Hotel Parcel Owner, LLC	4,293	-
Mindbody, Inc.	4,000	4,00
OTG Management, LLC	3,789	3,78
Mesoblast, Inc.	3,553	-
Pluralsight, LLC	3,532	3,53
Dialyze Holdings, LLC	3,431	3,43
Spanx, LLC	3,092	-
Thrasio, LLC	2,578	2,57
PRGX Global, Inc.	2,518	2,51
Liquid Environmental Solutions Corporation	2,324	-
Relativity ODA LLC	2,218	2,21
Acquia Inc.	1,971	2,06
Tahoe Bidco B.V.	1,741	-
PFNY Holdings, LLC	1,527	-
CorEvitas, LLC	1,526	3,23
MHE Intermediate Holdings, LLC	1,429	3,46
Apptio, Inc.	1,338	1,33
LSL Holdco, LLC	1,282	-
Kings Buyer, LLC	1,208	-
Berner Food & Beverage, LLC	1,114	2,47
Telestream Holdings Corporation	1,055	1,26
Coyote Buyer, LLC	933	1,33
Digital.AI Software Holdings, Inc.	826	89
109 Montgomery Owner LLC	513	93
GKD Index Partners, LLC	320	32
Gulf Operating, LLC	—	10,06
Coty Inc.	-	9,88
Latam Airlines Group S.A.	—	7,20
Sunland Asphalt & Construction, LLC	-	6,49
NeuAG, LLC	-	5,44
Olaplex, Inc.	—	4,80
Pingora MSR Opportunity Fund I-A, LP	—	3,50
SIO2 Medical Products, Inc.		3,4
SumUp Holdings Luxembourg S.À.R.L.	—	3,33
4 Over International, LLC		2,3
The Avery	—	1,8
Ministry Brands, LLC		1,1
Thermacell Repellents, Inc.	—	83
CircusTrix Holdings, LLC		
Total	\$ 232,062	\$ 264,9

# Note 14. Subsequent Events

The Company's management evaluated subsequent events through the date of issuance of the Consolidated Financial Statements. There have been no subsequent events that occurred during such period that would require disclosure in, or would be required to be recognized in the Consolidated Financial Statements as of and for the three and nine months ended June 30, 2022, except as discussed below.

# Distribution Declaration

On July 29, 2022, the Company's Board of Directors declared a quarterly distribution of \$0.17 per share, payable in cash on September 30, 2022 to stockholders of record on September 15, 2022.

#### Oaktree Specialty Lending Corporation

#### Schedule of Investments in and Advances to Affiliates

(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Nine months ended June 30, 2022

(unaudited)

Portfolio Company/Type of Investment (1)	Cash Interest Rate	Industry	Principal	Net Realized Gain (Loss)	I C	Amount of Interest, Fees or Dividends Fredited in ncome (2)	air Value as October 1, 2021	Gross Additions (3)	Re	Gross eductions (4)	Fair V as of Ju 20	une 30,	% of Total Net Assets
Control Investments													
C5 Technology Holdings, LLC		Data Processing & Outsourced Services											
829 Common Units				\$ —	\$	_	\$ _	\$ —	\$	_	\$	_	— %
34,984,460.37 Preferred Units				_		_	27,638	_		_		27,638	2.2 %
Dominion Diagnostics, LLC		Health Care Services											
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	7.26 %		\$ 16,074	_		1,078	27,381	_		(11,307)		16,074	1.3 %
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			_	_		42	_	_		_		_	— %
30,030.8 Common Units in DD Healthcare Services Holdings, LLC						3,308	18,065			(8,798)		9,267	0.7 %
First Star Speir Aviation Limited (5)		Airlines											
First Lien Term Loan, 9.00% cash due 12/15/2025			_	7,500		_	7,500	_		(7,500)		—	— %
100% equity interest				(5,632)	)	158	698	_		(698)		_	— %
OCSI Glick JV LLC (6)		Multi-Sector Holdings											
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	4.94 %		60,274			3,292	55,582	1,123		(6,099)		50,606	4.0 %
87.5% equity interest				-		-	-	-		—		—	— %
Senior Loan Fund JV I, LLC (7)		Multi-Sector Holdings											
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	8.00 %		96,250	_		5,839	96,250	_		_		96,250	7.6 %
87.5% LLC equity interest						2,026	 37,651			(14,628)		23,023	1.8 %
Total Control Investments			\$172,598	\$ 1,868	\$	15,743	\$ 270,765	\$ 1,123	\$	(49,030)	\$	222,858	17.6 %
Affiliate Investments													
Assembled Brands Capital LLC		Specialized Finance											
First Lien Revolver, LIBOR+6.75% cash due 10/17/2023	9.00 %		\$ 21,754	\$ —	\$	1,185	\$ 15,712	\$ 11,585	\$	(6,037)	\$	21,260	1.7 %
1,609,201 Class A Units				_		_	587	_		(24)		563	— %
1,019,168.80 Preferred Units, 6%				_		—	1,152	51		_		1,203	0.1 %
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029				_		_	_	_		_		_	— %
Caregiver Services, Inc.		Health Care Services											
1,080,399 shares of Series A Preferred Stock, 10%							838			(437)		401	— %
Total Affiliate Investments			\$ 21,754	s —	\$	1,185	\$ 18,289	\$ 11,636	\$	(6,498)	\$	23,427	1.9 %
Total Control & Affiliate Investments			\$194,352	\$ 1,868	\$	16,928	\$ 289,054	\$ 12,759	\$	(55,528)	\$	246,285	19.5 %

This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements.

(1) The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments.

- (2) Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the Control or Affiliate categories.
- (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-accrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation as well as the movement of an existing portfolio company into this category or out of a different category.

- (4) Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation as well as the movement of an existing portfolio company out of this category and into a different category.
- (5) First Star Speir Aviation Limited is a wholly-owned holding company formed by the Company in order to facilitate its investment strategy. In accordance with ASU 2013-08, the Company has deemed the holding company to be an investment company under GAAP and therefore deemed it appropriate to consolidate the financial results and financial position of the holding company and to recognize dividend income versus a combination of interest income and dividend income. Accordingly, the debt and equity investments in the wholly-owned holding company are disregarded for accounting purposes since the economic substance of these instruments are equity investments in the operating entities.
- (6) Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required).
- (7) Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required).

# **Oaktree Specialty Lending Corporation**

#### Schedule of Investments in and Advances to Affiliates

(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Nine months ended June 30, 2021

(unaudited)

	Cash Interest			Net Realiz Gair	zed	In F Div	nount of aterest, ees or vidends edited in		air Value as October 1,	Gross Addition	; I	Gross Reductions	Fair Value as of June 30,	% of Total Net
Portfolio Company/Type of Investment (1) Control Investments	Rate	Industry	Principal	(Los	is)	Inc	come (2)		2020	(3)		(4)	2021	Assets
Control Investments		Data Processing & Outsourced Services												
829 Common Units				\$	—	\$	_	\$	_	\$ -	- \$	s —	\$ —	— %
34,984,460.37 Preferred Units					—		_		27,638	_	-	—	27,638	2.1 %
Dominion Diagnostics, LLC		Health Care Services												
First Lien Term Loan, LIBOR+5.00% cash due 2/28/2024	6.00 %		\$ 27,451		_		1,293		27,660	_	-	(209)	27,451	2.1 %
First Lien Revolver, LIBOR+5.00% cash due 2/28/2024			_		_		261		5,260	2,439	,	(7,699)	_	— %
30,030.8 Common Units in DD Healthcare Services Holdings, LLC					_		358		7,667	10,398	:		18,065	1.4 %
First Stor Spain Ariation Limited (5)														
First Star Speir Aviation Limited (5) First Lien Term Loan, 9.00% cash due 12/15/2025		Airlines	7.500						11 510			(4.010)	7.500	0 ( 0)
100% equity interest			7,500		_		 550		11,510	1,02		(4,010)	7,500 482	0.6 %
New IPT, Inc.		Oil & Gas Equipment & Services					550		1,622	1,02		(2,161)	402	70
First Lien Term Loan, LIBOR+5.00% cash due 3/17/2021		Services	_		_		42		1,800	504	Ļ	(2,304)	_	— %
First Lien Revolver, LIBOR+5.00% cash due 3/17/2021			_		_		17		788	22		(1,009)	_	— %
50.087 Class A Common Units in New IPT Holdings, LLC					_		_		_	_	-	_	_	— %
OCSI Glick JV LLC (6)		Multi-Sector Holdings												
Subordinated Debt, LIBOR+4.50% cash due 10/20/2028	4.70 %		62,296		_		1,134		_	55,923		(526)	55,397	4.3 %
87.5% equity interest					—		—		—	_	-		—	— %
Senior Loan Fund JV I, LLC (7)		Multi-Sector Holdings												
Subordinated Debt, LIBOR+7.00% cash due 12/29/2028	8.00 %		96,250		_		5,420		96,250	-	-	_	96,250	7.4 %
87.5% LLC equity interest					_		451		21,190	15,505			36,695	2.8 %
Total Control Investments			\$193,497	\$	_	\$	9,526	\$	201,385	\$ 86,011		\$ (17,918)	\$ 269,478	20.7 %
LOCIT A T A														
Affiliate Investments Assembled Brands Capital LLC		Specialized Finance												
First Lien Revolver, LIBOR+6.00% cash due 10/17/2023	7.00 %	- manoe	\$ 11,924	\$		\$	452	\$	4,194	\$ 7,990	5 \$	6 (510)	\$ 11,680	0.9 %
1,609,201 Class A Units	1.00 /0		φ 11, <i>j</i> 2 .	Ψ	_	Ψ		Ψ	483	9(			579	- %
1,019,168.80 Preferred Units, 6%					_		_		1,091	40		_	1,131	0.1 %
70,424.5641 Class A Warrants (exercise price \$3.3778) expiration date 9/9/2029					_		_			_	_	_		— %
Caregiver Services, Inc.		Health Care Services												
1,080,399 shares of Series A Preferred Stock, 10%			_		_		_		741	_		(172)	569	— %
Total Affiliate Investments			\$ 11,924	\$	_	\$	452	\$	6,509	\$ 8,132	\$		\$ 13,959	1.1 %
Total Control & Affiliate Investments			\$205,421	\$	_	\$	9,978	\$	207,894	\$ 94,143	\$	\$ (18,600)	\$ 283,437	21.8 %

This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements.

- (1) The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments, included in the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2021.
- (2) Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the Control or Affiliate categories.
- (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-accrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross additions also include net increases in unrealized appreciation or net decreases in unrealized depreciation as well as the movement of an existing portfolio company into this category or out of a different category.
- (4) Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in unrealized depreciation or net decreases in unrealized appreciation as well as the movement of an existing portfolio company out of this category and into a different category.
- (5) First Star Speir Aviation Limited is a wholly-owned holding company formed by the Company in order to facilitate its investment strategy. In accordance with ASU 2013-08, the Company has deemed the holding company to be an investment company under GAAP and therefore deemed it appropriate to consolidate the financial results and financial position of the holding company and to recognize dividend income versus a combination of interest income and dividend income. Accordingly, the debt and equity investments in the wholly-owned holding company are disregarded for accounting purposes since the economic substance of these instruments are equity investments in the operating entities.
- (6) Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required).
- (7) Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required).

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in connection with our Consolidated Financial Statements and the notes thereto included elsewhere in this quarterly report on Form 10-Q.

Some of the statements in this quarterly report on Form 10-Q constitute forward-looking statements because they relate to future events or our future performance or financial condition. The forward-looking statements contained in this quarterly report on Form 10-Q may include statements as to:

- our future operating results and distribution projections;
- the ability of Oaktree Fund Advisors, LLC, or Oaktree, to reposition our portfolio and to implement Oaktree's future plans with respect to our business;
- the ability of Oaktree and its affiliates to attract and retain highly talented professionals;
- our business prospects and the prospects of our portfolio companies;
- the impact of the investments that we expect to make;
- the ability of our portfolio companies to achieve their objectives;
- our expected financings and investments and additional leverage we may seek to incur in the future;
- the adequacy of our cash resources and working capital;
- the timing of cash flows, if any, from the operations of our portfolio companies; and
- the cost or potential outcome of any litigation to which we may be a party.

In addition, words such as "anticipate," "believe," "expect," "seek," "plan," "should," "estimate," "project" and "intend" indicate forward-looking statements, although not all forward-looking statements include these words. The forward-looking statements contained in this quarterly report on Form 10-Q involve risks and uncertainties. Our actual results could differ materially from those implied or expressed in the forward-looking statements for any reason, including the factors set forth in *"Item 1A. Risk Factors*" in our annual report on Form 10-K for the year ended September 30, 2021 and elsewhere in this quarterly report on Form 10-Q.

Other factors that could cause actual results to differ materially include:

- changes or potential disruptions in our operations, the economy, financial markets or political environment, including the impacts of inflation and rising interest rates;
- risks associated with possible disruption in our operations or the economy generally due to terrorism, war or other geopolitical conflict (including the current conflict between Russia and Ukraine), natural disasters or the COVID-19 pandemic;
- future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities) and conditions in our operating areas, particularly with respect to Business Development Companies or regulated investment companies, or RICs;
- general considerations associated with the COVID-19 pandemic;
- the ability to realize the anticipated benefits of the Mergers (as defined below); and
- other considerations that may be disclosed from time to time in our publicly disseminated documents and filings.

We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the Securities and Exchange Commission, or the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.

All dollar amounts in tables are in thousands, except share and per share amounts and as otherwise indicated.

## **Business Overview**

We are a specialty finance company dedicated to providing customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. We are a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act of 1940, as amended, or the Investment Company Act. In addition, we have qualified and elected to be treated as a RIC under the Internal Revenue Code of 1986, as amended, or the Code, for U.S. federal income tax purposes.

We are externally managed by Oaktree pursuant to an investment advisory agreement, as amended from time to time, or the Investment Advisory Agreement. Oaktree Administrator, an affiliate of Oaktree, provides certain administrative and other services necessary for us to operate pursuant to an administration agreement, as amended from time to time, or the Administration Agreement.

Our investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. We may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions. Our portfolio may also include certain structured finance and other non-traditional structures. We invest in companies that typically possess resilient business models with strong underlying fundamentals. We intend to deploy capital across credit and economic cycles with a focus on long-term results, which we believe will enable us to build lasting partnerships with financial sponsors and management teams, and we may seek to opportunistically take advantage of dislocations in the financial markets and other situations that may benefit from Oaktree's credit and structuring expertise. Sponsors may include financial sponsors, such as an institutional investor or a private equity firm, or a strategic entity seeking to invest in a portfolio company. Oaktree is generally focused on middle-market companies, which we define as companies with enterprise values of between \$100 million and \$750 million. We generally invest in securities that are rated below investment grade by rating agencies or that would be rated below investment grade if they were rated. Below investment grade securities, which are often referred to as "high yield" and "junk," have predominantly speculative characteristics with respect to the issuer's capacity to pay interest and repay principal.

In the current market environment, Oaktree intends to focus on the following areas, in which Oaktree believes there is less competition and thus potential for greater returns, for our new investment opportunities: (1) situational lending, which we define to include directly originated loans to non-sponsor companies that are hard to understand and value using traditional underwriting techniques, (2) select sponsor lending, which we define to include financing to support leveraged buyouts of companies with specialized sponsors that have expertise in certain industries, and (3) stressed sector and rescue lending, which we define to include opportunistic private loans in industries experiencing stress or limited access to capital.

Oaktree intends to continue to rotate our portfolio into investments that are better aligned with Oaktree's overall approach to credit investing and that it believes have the potential to generate attractive returns across market cycles (which we call "core investments"). Oaktree has performed a comprehensive review of our portfolio and categorized our portfolio into core investments, non-core performing investments and underperforming investments. Certain additional information on such categorization and our portfolio composition is included in investor presentations that we file with the SEC. Since an Oaktree affiliate became our investment adviser in October 2017, Oaktree and its affiliates have reduced the investments identified as non-core by approximately \$800 million at fair value. Over time, Oaktree intends to rotate us out of the remaining non-core investments, which were approximately \$77 million at fair value as of June 30, 2022. Oaktree periodically reviews designations of investments as core and non-core and may change such designations over time.

On March 19, 2021, we acquired Oaktree Strategic Income Corporation, or OCSI, pursuant to the Merger Agreement, dated as of October 28, 2020, by and among OCSI, us, Lion Merger Sub, Inc., our wholly-owned subsidiary, or Merger Sub, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the Merger Agreement, Merger Sub was first merged with and into OCSI as the surviving corporation, or the Merger, and, immediately following the Merger, OCSI was then merged with and into us, with us as the surviving company or together with the Merger, or the Mergers. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of OCSI's common stock was converted into the right to receive 1.3371 shares of our common stock (with OCSI's stockholders receiving cash in lieu of fractional shares of our common stock). As a result of the Mergers, we issued an aggregate of 39,400,011 shares of our common stock to former OCSI stockholders.

## **Business Environment and Developments**

Global financial markets have experienced an increase in volatility as concerns about the impact of higher inflation, rising interest rates, a potential recession, the current conflict in Ukraine and the ongoing uncertainty related to the COVID-19 pandemic have weighed on market participants. These factors have created disruptions in supply chains and economic activity and have had a particularly adverse impact on certain companies in the energy, raw materials and transportation sectors, among others. These uncertainties can ultimately impact the overall supply and demand of the market through changing spreads, deal terms and structures and equity purchase price multiples.

We are unable to predict the full effects of these macroeconomic events or how long any further market disruptions or volatility might last. We continue to closely monitor the impact these events have on our business, industry and portfolio companies and will provide constructive solutions where necessary.

Against this uncertain macroeconomic backdrop, we believe attractive risk-adjusted returns can be achieved by making loans to middle market companies that typically possess resilient business models with strong underlying fundamentals. Given the breadth of the investment platform and decades of credit investing experience of Oaktree and its affiliates, we believe that

we have the resources and experience to source, diligence and structure investments in these companies and are well placed to generate attractive returns for investors.

As of June 30, 2022, 87.8% of our debt investment portfolio (at fair value) and 87.6% of our debt investment portfolio (at cost) bore interest at floating rates. Most of our floating rate loans are indexed to the LIBOR and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly or monthly at the borrower's option. Certain loans may also be indexed to the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities, or the Sterling Overnight Index Average, or SONIA, an alternative reference rate that is based on transactions. In July 2017, the head of the United Kingdom Financial Conduct Authority, or the FCA, announced the desire to phase out the use of LIBOR by the end of 2021. However, in March 2021 the FCA announced that most U.S. dollar LIBOR would continue to be published through June 30, 2023 effectively extending the LIBOR transition period to June 30, 2023. However, the FCA no longer compels panel banks to contribute to LIBOR and the Federal Reserve Board, the Office of the Comptroller of the Currency, and the Federal Deposit Insurance Corporation have encouraged banks to cease entering into new contracts that use U.S. dollar LIBOR as a reference rate no later than December 31, 2021. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, supports replacing U.S.-dollar LIBOR with SOFR. Although there have been issuances utilizing SOFR or SONIA, it is unknown whether these alternative reference rates will attain market acceptance as replacements for LIBOR. In anticipation of the cessation of LIBOR, we may need to renegotiate any credit agreements extending beyond the applicable phase out date with our prospective portfolio companies that utilize LIBOR as a factor in determining the interest rate. Certain of the loan agreements with our portfolio companies have included fallback language in the event that LIBOR becomes unavailable. This language generally provides that the administrative agent may identify a replacement reference rate, typically with the consent of (or prior consultation with) the borrower. In certain cases, the administrative agent will be required to obtain the consent of either a majority of the lenders under the facility, or the consent of each lender, prior to identifying a replacement reference rate. Certain of the loan agreements with our portfolio companies do not include any fallback language providing a mechanism for the parties to negotiate a new reference interest rate and will instead revert to the base rate in the event LIBOR ceases to exist.

## **Critical Accounting Estimates**

#### **Investment** Valuation

We value our investments in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 820, *Fair Value Measurements and Disclosures*, or ASC 820, which defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.

Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

- Level 1 Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.
- Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.
- Level 3 Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.

Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily

available market quotations provided by pricing vendors and brokers for all of our investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.

We seek to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If we are unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within our set threshold, we seek to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, we do not adjust any of the prices received from these sources.

If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, we value such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value, or EV, of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that we are deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. We may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. Under the EV technique, the significant unobservable input used in the fair value measurement of our investments in debt or equity securities is the EBITDA, revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and we consider the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by us are substantially illiquid with no active transaction market, we depend on primary market data, including newly funded transactions and industry-specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. Under the market yield technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively.

In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.

We estimate the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk-free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.

The fair value of our investments as of June 30, 2022 and September 30, 2021 was determined in good faith by our Board of Directors. We have and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of our portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter, and the Board of Directors may reasonably rely on that assistance. As of June 30, 2022, 89.0% of our portfolio at fair value was valued either based on market quotations, the transactions precedent approach or corroborated by independent valuation firms. However, our Board of Directors is responsible for the ultimate valuation of the portfolio investments at fair value as determined in good faith pursuant to our valuation policy and a consistently applied valuation process.

Certain factors that may be considered in determining the fair value of our investments include the nature and realizable value of any collateral, the portfolio company's earnings and its ability to make payments on its indebtedness, the markets in which the portfolio company does business, comparison to comparable publicly-traded companies, discounted cash flow and other relevant factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, our determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. Due to these uncertainties, our fair value determinations may cause our net asset value on a given date to materially understate or overstate the value that we may ultimately realize upon the sale of one or more of our investments.

As of June 30, 2022, we held \$2,565.4 million of investments at fair value, up from \$2,556.6 million held at September 30, 2021, primarily driven by new originations and partially offset by unrealized losses related to credit spread widening. As of June 30, 2022 and September 30, 2021, approximately 95.4% and 97.0%, respectively, of our total assets represented investments at fair value.

## **Revenue Recognition**

#### Interest Income

Interest income, adjusted for accretion of original issue discount, or OID, is recorded on an accrual basis to the extent that such amounts are expected to be collected. We stop accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash, and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of each of June 30, 2022 and September 30, 2021, there were no investments on non-accrual status.

In connection with our investment in a portfolio company, we sometimes receive nominal cost equity that is valued as part of the negotiation process with the portfolio company. When we receive nominal cost equity, we allocate our cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.

#### PIK Interest Income

Our investments in debt securities may contain payment-in-kind, or PIK, interest provisions. PIK interest, which typically represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We generally cease accruing PIK interest if there is insufficient value to support the accrual or if we do not expect the portfolio company to be able to pay all principal and interest due. Our decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; our assessment of the portfolio company's business development success; information obtained by us in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. Our determination to cease accruing PIK interest is generally made well before our full write-down of a loan or debt security. In addition, if it is subsequently determined that we will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on our debt investments increases the recorded cost bases of these investments in our Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by us to Oaktree. To maintain our status as a RIC, certain income from PIK interest may be required to be distributed to our stockholders, even though we have not yet collected the cash and may never do so.

## **Portfolio Composition**

Our investments principally consist of loans, common and preferred equity and warrants in privately-held companies, Senior Loan Fund JV I, LLC, or SLF JV I, a joint venture through which we and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation, or Kemper, co-invest in senior secured loans of middle-market companies and other corporate debt securities, and OCSI Glick JV LLC, or the Glick JV, a joint venture through which we and GF Equity Funding 2014 LLC, or GF Equity Funding, co-invest primarily in senior secured loans of middle-market companies. We refer to SLF JV I and the Glick JV collectively as the JVs. Our loans are typically secured by a first, second or subordinated lien on the assets of the portfolio company and generally have terms of up to ten years (but an expected average life of between three and four years).

During the nine months ended June 30, 2022, we originated \$659.7 million of investment commitments in 40 new and 34 existing portfolio companies and funded \$607.0 million of investments.

During the nine months ended June 30, 2022, we received \$545.0 million of proceeds from prepayments, exits, other paydowns and sales and exited 27 portfolio companies.

A summary of the composition of our investment portfolio at cost and fair value as a percentage of total investments is shown in the following tables:

	June 30, 2022	September 30, 2021
Cost:		
Senior secured debt	85.14 %	85.85 %
Debt investments in the JVs	5.50	5.79
Preferred equity	3.18	2.60
Subordinated debt	2.76	1.67
LLC equity interests of the JVs	1.85	1.94
Common equity and warrants	1.57	2.15
Total	100.00 %	100.00 %

	June 30, 2022	September 30, 2021
Fair value:		
Senior secured debt	86.60 %	86.72 %
Debt investments in the JVs	5.72	5.94
Preferred equity	3.18	2.49
Subordinated debt	2.49	1.67
LLC equity interests of the JVs	1.11	1.47
Common equity and warrants	0.90	1.71
Total	100.00 %	100.00 %

The industry composition of our portfolio at cost and fair value as a percentage of total investments was as follows:

	June 30, 2022	September 30, 2021
Cost: Application Software	15.30 %	14.40.0
Multi-Sector Holdings (1)	7.35	14.49 9
Pharmaceuticals	4.84	5.44
Data Processing & Outsourced Services	4.52	4.74
Biotechnology	3.85	4.74
Health Care Technology	3.69	0.55
Industrial Machinery	2.94	3.47
Aerospace & Defense	2.80	2.66
Specialized Finance	2.77	2.70
Internet & Direct Marketing Retail	2.55	2.45
Fertilizers & Agricultural Chemicals	2.42	2.63
Construction & Engineering	2.30	2.44
Health Care Services	2.23	3.34
Automotive Retail	2.22	1.65
Internet Services & Infrastructure	2.02	1.85
Personal Products	1.99	4.08
Metal & Glass Containers	1.75	0.69
Health Care Distributors	1.74	0.78
Home Improvement Retail	1.73	1.83
Leisure Facilities	1.61	0.99
Airport Services	1.61	1.64
Real Estate Services	1.51	1.59
Real Estate Operating Companies	1.48	1.08
Diversified Support Services	1.43	1.60
Specialty Chemicals	1.42	1.84
Health Care Supplies	1.36	1.17
Insurance Brokers	1.34	1.00
Integrated Telecommunication Services	1.30	1.85
Soft Drinks	1.30	1.32
Electrical Components & Equipment	1.27	1.27
Oil & Gas Storage & Transportation	1.18	1.44
Advertising	1.12	1.13
Other Diversified Financial Services	1.10	0.63
Oil & Gas Refining & Marketing	1.04	1.42
Movies & Entertainment	0.98	1.02
Distributors	0.95	
Health Care Equipment	0.91	0.93
Environmental & Facilities Services	0.73	_
Home Furnishings	0.73	0.77
Cable & Satellite	0.72	1.05
Systems Software	0.56	0.26
Consumer Finance	0.54	
Hotels, Resorts & Cruise Lines	0.52	_
Auto Parts & Equipment	0.47	0.49
IT Consulting & Other Services	0.44	0.30
Research & Consulting Services	0.38	0.29
Air Freight & Logistics	0.36	0.19
Restaurants	0.35	0.37
Education Services	0.34	0.04
Trading Companies & Distributors	0.29	
Apparel, Accessories & Luxury Goods	0.19	0.20
Integrated Oil & Gas	0.18	0.19
Food Distributors	0.17	0.19
Apparel Retail	0.17	
Specialized REITs	0.16	_
Communications Equipment	0.14	_
Housewares & Specialties	0.14	0.07
Diversified Banks	0.13	0.14
Technology Distributors	0.12	0.14
Construction Materials	0.09	0.09
Alternative Carriers	0.08	0.26
Electronic Components	0.08	0.40
Independent Power Producers & Energy Traders		0.40
Airlines		0.88
Commercial Printing		0.78
Managed Health Care	—	0.78
Thrifts & Mortgage Finance	_	0.73
Property & Casualty Insurance	—	0.63
Leisure Products	_	0.39
Food Retail		
	100.00.0/	0.15
Total	100.00 %	100.00 %

Fair value:         Application Software         Multi-Sector Holdings (1)         Pharmaceuticals         Data Processing & Outsourced Services         Biotechnology         Health Care Technology         Industrial Machinery         Internet & Direct Marketing Retail         Acrospace & Defense         Specialized Finance         Fertilizers & Agricultural Chemicals         Construction & Engineering         Automotive Retail         Internet Services & Infrastructure	15.69 % 6.62 4.73 4.38 3.97 3.76 3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11 2.05	14.58 7.41 5.56 4.46 4.44 0.55 3.53 2.68 2.72 2.69 2.64 2.47 1.65
Multi-Sector Holdings (1) Pharmaceuticals Data Processing & Outsourced Services Biotechnology Health Care Technology Health Care Technology Industrial Machinery Industrial Machinery Internet & Direct Marketing Retail Aerospace & Defense Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail Internet Services & Infrastructure	6.62 4.73 4.38 3.97 3.76 3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11	7.41 5.56 4.46 4.44 0.55 3.53 2.68 2.72 2.69 2.64 2.47 1.65
Pharmaceuticals Data Processing & Outsourced Services Biotechnology Health Care Technology Industrial Machinery Internet & Direct Marketing Retail Aerospace & Defense Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail Internet Services & Infrastructure	4.73 4.38 3.97 3.76 3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11	5.56 4.46 4.44 0.55 3.53 2.68 2.72 2.69 2.64 2.47 1.65
Data Processing & Outsourced Services Biotechnology Health Care Technology Industrial Machinery Internet & Direct Marketing Retail Aerospace & Defense Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail Internet Services & Infrastructure	4.38 3.97 3.76 3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11	4.46 4.44 0.55 3.53 2.68 2.72 2.69 2.64 2.47 1.65
Biotechnology Health Care Technology ndustrial Machinery nternet & Direct Marketing Retail Aerospace & Defense Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail nternet Services & Infrastructure	3.97 3.76 3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11	4.44 0.55 3.53 2.68 2.72 2.69 2.64 2.47 1.65
Health Care Technology         ndustrial Machinery         nternet & Direct Marketing Retail         Aerospace & Defense         Specialized Finance         "ertilizers & Agricultural Chemicals         Construction & Engineering         Nutomotive Retail         nternet Services & Infrastructure	3.76 3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11	0.55 3.53 2.68 2.72 2.69 2.64 2.47 1.65
ndustrial Machinery nternet & Direct Marketing Retail Aerospace & Defense Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail nternet Services & Infrastructure	3.02 2.84 2.81 2.68 2.52 2.40 2.27 2.11	3.53 2.68 2.72 2.69 2.64 2.47 1.65
nternet & Direct Marketing Retail Aerospace & Defense Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail nternet Services & Infrastructure	2.84 2.81 2.68 2.52 2.40 2.27 2.11	2.68 2.72 2.69 2.64 2.47 1.65
Specialized Finance Fertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail nternet Services & Infrastructure	2.81 2.68 2.52 2.40 2.27 2.11	2.72 2.69 2.64 2.47 1.65
ertilizers & Agricultural Chemicals Construction & Engineering Automotive Retail nternet Services & Infrastructure	2.68 2.52 2.40 2.27 2.11	2.69 2.64 2.47 1.65
Construction & Engineering Automotive Retail nternet Services & Infrastructure	2.40 2.27 2.11	2.47 1.65
Automotive Retail nternet Services & Infrastructure	2.27 2.11	1.65
nternet Services & Infrastructure	2.11	
	2.05	1.87
Iealth Care Services Personal Products		3.31
Actal & Glass Containers	2.03	4.13
Iome Improvement Retail	1.82	0.68
Health Care Distributors	1.79	1.82
irport Services	1.75	0.77
eisure Facilities	1.64	1.59 0.90
Leal Estate Services	1.62	1.61
Leal Estate Operating Companies	1.56	1.01
Diversified Support Services	1.45	1.60
lealth Care Supplies	1.41	1.18
pecialty Chemicals	1.38	1.82
isurance Brokers	1.36	1.02
oft Drinks	1.32	1.31
ntegrated Telecommunication Services	1.30	1.94
lectrical Components & Equipment	1.28	1.26
dvertising	1.11	1.19
il & Gas Storage & Transportation	1.09	1.35
il & Gas Refining & Marketing	1.07	1.43
fovies & Entertainment	1.05	1.06
ther Diversified Financial Services	1.00	0.62
istributors	0.96	_
ealth Care Equipment nvironmental & Facilities Services	0.93	0.93
Invironmental & Facilities Services	0.75	
able & Satellite	0.73	0.77
onsumer Finance	0.70 0.56	1.06
lotels, Resorts & Cruise Lines	0.56	
ystems Software	0.50	0.26
uto Parts & Equipment	0.46	0.20
Consulting & Other Services	0.40	0.29
esearch & Consulting Services	0.37	0.30
ir Freight & Logistics	0.35	0.19
estaurants	0.35	0.37
ducation Services	0.33	0.04
rading Companies & Distributors	0.23	_
ntegrated Oil & Gas	0.19	0.19
pparel Retail	0.17	_
ousewares & Specialties	0.15	0.08
ommunications Equipment	0.14	
pecialized REITs	0.14	_
ood Distributors	0.14	0.18
iversified Banks	0.13	0.14
echnology Distributors	0.12	0.12
lectronic Components	0.08	0.40
onstruction Materials Iternative Carriers	0.07	0.09
irlines	0.07	0.27
Independent Power Producers & Energy Traders	-	0.96
ommercial Printing		0.92
Ianaged Health Care	—	0.79
hrifts & Mortgage Finance		0.74
roperty & Casualty Insurance		0.62
eisure Products		0.39
ood Retail		0.26
Total	100.00 %	100.00

(1) This industry includes our investments in the JVs and certain limited partnership interests.

# **The Joint Ventures**

#### Senior Loan Fund JV I, LLC

In May 2014, we entered into a limited liability company, or LLC, agreement with Kemper to form SLF JV I. We coinvest in senior secured loans of middle-market companies and other corporate debt securities with Kemper through our investment in SLF JV I. SLF JV I is managed by a four person Board of Directors, two of whom are selected by us and two of whom are selected by Kemper. All portfolio decisions and investment decisions in respect of SLF JV I must be approved by the SLF JV I investment committee, which consists of one representative selected by us and one representative selected by Kemper (with approval from a representative of each required). Since we do not have a controlling financial interest in SLF JV I, we do not consolidate SLF JV I. SLF JV I is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act. SLF JV I is capitalized pro rata with LLC equity interests as transactions are completed and may be capitalized with additional subordinated notes issued to us and Kemper by SLF JV I. The subordinated notes issued by SLF JV I are referred to as the SLF JV I Notes. The SLF JV I Notes are senior in right of payment to SLF JV I LLC equity interests and subordinated in right of payment to SLF JV I's secured debt.

As of June 30, 2022 and September 30, 2021, we and Kemper owned, in the aggregate, 87.5% and 12.5%, respectively, of the LLC equity interests of SLF JV I and the outstanding SLF JV I Notes. As of each of June 30, 2022 and September 30, 2021, we and Kemper had funded approximately \$165.5 million to SLF JV I, of which \$144.8 million was from us. As of each of June 30, 2022 and September 30, 2021, we had aggregate commitments to fund SLF JV I of \$35.0 million, of which approximately \$26.2 million was to fund additional SLF JV I Notes and approximately \$8.8 million was to fund LLC equity interests in SLF JV I.

Both the cost and fair value of our SLF JV I Notes were \$96.3 million as of each of June 30, 2022 and September 30, 2021. We earned interest income of \$1.9 million and \$5.8 million on the SLF JV I Notes for the three and nine months ended June 30, 2022, respectively. We earned interest income of \$1.9 million and \$5.4 million on the SLF JV I Notes for the three and nine months ended June 30, 2021, respectively. As of June 30, 2022, the SLF JV I Notes bore interest at a rate of one-month LIBOR plus 7.00% per annum with a LIBOR floor of 1.00% and will mature on December 29, 2028.

The cost and fair value of the LLC equity interests in SLF JV I held by us was \$49.3 million and \$23.0 million, respectively, as of June 30, 2022, and \$49.3 million and \$37.7 million, respectively, as of September 30, 2021. We earned \$0.9 million and \$2.0 million in dividend income for the three and nine months ended June 30, 2022, respectively, with respect to our investment in the LLC equity interests of SLF JV I. We earned \$0.5 million in dividend income for the three and nine months ended June 30, 2021 with respect to our investment in the LLC equity interests of SLF JV I. The LLC equity interests of SLF JV I are dividend producing to the extent SLF JV I has residual cash to be distributed on a quarterly basis.

Below is a summary of SLF JV I's portfolio as of June 30, 2022 and September 30, 2021:

	June 30, 2022	September 30, 2021
Senior secured loans (1)	\$357,198	\$344,196
Weighted average interest rate on senior secured loans (2)	6.79%	5.60%
Number of borrowers in SLF JV I	56	55
Largest exposure to a single borrower (1)	\$9,650	\$9,875
Total of five largest loan exposures to borrowers (1)	\$47,298	\$46,984

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

See "*Note 3. Portfolio Investments*" in the notes to the accompanying financial statements for more information on SLF JV I and its portfolio.

# OCSI Glick JV LLC

On March 19, 2021, as a result of the consummation of the Mergers, we became party to the LLC agreement of the Glick JV. The Glick JV invests primarily in senior secured loans of middle-market companies. We co-invest in these securities with GF Equity Funding through the Glick JV. The Glick JV is managed by a four person Board of Directors, two of whom are selected by GF Equity Funding. All portfolio decisions and investment decisions in respect of the Glick JV must be approved by the Glick JV investment committee, consisting of one representative selected by us and one representative selected by GF Equity Funding (with approval from a representative of each required). Since we do not have a controlling financial interest in the Glick JV, we do not consolidate the Glick JV. The Glick JV is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act. The Glick JV is capitalized as transactions are completed. The members provide capital to the Glick JV in exchange for LLC equity interests, and we and GF Debt Funding 2014 LLC, or GF Debt Funding, an entity advised by affiliates of GF Equity Funding, provide capital to the Glick JV in exchange for Subordinated notes issued by the Glick JV, or the Glick JV Notes. The Glick JV Notes are junior in right of payment to the repayment of temporary contributions made by us to fund investments of the Glick JV that are repaid when GF Equity Funding and GF Debt Funding make their capital contributions and fund their Glick JV Notes, respectively.

As of June 30, 2022 and September 30, 2021, we and GF Equity Funding owned 87.5% and 12.5%, respectively, of the outstanding LLC equity interests, and we and GF Debt Funding owned 87.5% and 12.5%, respectively, of the Glick JV Notes. Approximately \$84.0 million in aggregate commitments was funded as of each of June 30, 2022 and September 30, 2021, of which \$73.5 million was from us. As of June 30, 2022 and September 30, 2021, we had commitments to fund Glick JV Notes of \$78.8 million, of which \$12.4 million was unfunded. As of each of June 30, 2022 and September 30, 2021, we had commitments to fund LLC equity interests in the Glick JV of \$8.7 million, of which \$1.6 million was unfunded.

The cost and fair value of our aggregate investment in the Glick JV was \$50.4 million and \$50.6 million, respectively, as of June 30, 2022. The cost and fair value of our aggregate investment in the Glick JV was \$50.7 million and \$55.6 million, respectively, as of September 30, 2021. For the three and nine months ended June 30, 2022, our investment in the Glick JV Notes earned interest income of \$1.2 million and \$3.3 million, respectively. For the three months ended June 30, 2021, our investment in the Glick JV Notes earned interest income of \$1.0 million. For the period from March 19, 2021 to June 30, 2021, our investment in the Glick JV Notes earned interest income of \$1.1 million. We did not earn any dividend income for the three and nine months ended June 30, 2022 and for the period from March 19, 2021 to June 30, 2021 with respect to our investment in the LLC equity interests of the Glick JV. The LLC equity interests of the Glick JV are income producing to the extent there is residual cash to be distributed on a quarterly basis.

Below is a summary of the Glick JV's portfolio as of June 30, 2022 and September 30, 2021:

	June 30, 2022	September 30, 2021
Senior secured loans (1)	\$141,783	\$126,512
Weighted average current interest rate on senior secured loans (2)	6.85%	5.86%
Number of borrowers in the Glick JV	43	37
Largest loan exposure to a single borrower (1)	\$6,645	\$6,907
Total of five largest loan exposures to borrowers (1)	\$28,564	\$28,324

(1) At principal amount.

(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.

See "*Note 3. Portfolio Investments*" in the notes to the accompanying financial statements for more information on the Glick JV and its portfolio.

#### **Discussion and Analysis of Results and Operations**

## **Results of Operations**

Net increase (decrease) in net assets resulting from operations includes net investment income, net realized gains (losses) and net unrealized appreciation (depreciation). Net investment income is the difference between our income from interest, dividends and fees and net expenses. Net realized gains (losses) is the difference between the proceeds received from dispositions of investment related assets and liabilities and their stated costs. Net unrealized appreciation (depreciation) is the net change in the fair value of our investment related assets and liabilities carried at fair value during the reporting period, including the reversal of previously recorded unrealized appreciation (depreciation) when gains or losses are realized.

## Comparison of three and nine months ended June 30, 2022 and June 30, 2021

#### Total Investment Income

Total investment income includes interest on our investments, fee income and dividend income.

Total investment income for the three months ended June 30, 2022 and 2021 was \$63.1 million and \$65.4 million, respectively. For the three months ended June 30, 2022, this amount consisted of \$59.9 million of interest income from portfolio investments (which included \$5.2 million of PIK interest), \$2.3 million of fee income and \$1.0 million of dividend income. For the three months ended June 30, 2021, this amount consisted of \$56.6 million of interest income from portfolio investments (which included \$4.6 million of PIK interest), \$7.8 million of fee income and \$1.0 million of dividend income. The decrease of \$2.3 million, or 3.5%, in our total investment income for the three months ended June 30, 2021, was due primarily to a \$5.5 million decrease in fee income resulting from lower prepayment and amendment fees, partially offset by a \$3.3 million increase in interest income, primarily resulting from a larger investment portfolio and the impact of rising reference rates on interest income, partially offset by lower OID acceleration from exited investments.

Total investment income for the nine months ended June 30, 2022 and 2021 was \$192.4 million and \$145.6 million, respectively. For the nine months ended June 30, 2022, this amount consisted of \$181.7 million of interest income from portfolio investments (which included \$14.5 million of PIK interest), \$5.1 million of fee income and \$5.6 million of dividend income. For the nine months ended June 30, 2021, this amount consisted of \$130.8 million of interest income from portfolio investments (which included \$11.5 million of PIK interest), \$13.5 million of fee income and \$1.4 million of dividend income. The increase of \$46.8 million, or 32.1%, in our total investment income for the nine months ended June 30, 2021, was due primarily to (1) a \$50.9 million increase in interest income, which was primarily driven by a larger average investment portfolio as a result of the increase in assets resulting from the Mergers and new originations and the impact of rising reference rates on interest income and (2) a \$4.2 million increase in dividend income mainly driven by larger dividends received from two investments as compared with the prior year. This was partially offset by a \$8.4 million decrease in fee income primarily due to lower prepayment and amendment fees.

## Expenses

Net expenses (expenses net of fee waivers) for the three months ended June 30, 2022 and 2021 were \$22.8 million and \$29.1 million, respectively. Net expenses decreased for the three months ended June 30, 2022, as compared to the three months ended June 30, 2021, by \$6.4 million, or 21.9%, primarily due to (1) \$9.6 million of lower accrued Part II incentive fees as a result of a reversal of previously accrued capital gains incentive fees, (2) a \$0.5 million decrease in Part I incentive fees mainly due to higher interest expense and management fees and (3) a \$0.2 million decrease in professional fees, partially offset by a \$3.0 million increase in interest expense due to higher borrowings outstanding and the impact of rising reference rates and \$0.9 million of higher base management fees (net of management fee waivers) resulting from a larger investment portfolio.

Net expenses (expenses net of fee waivers) for the nine months ended June 30, 2022 and 2021 were \$76.3 million and \$81.2 million, respectively. Net expenses decreased for the nine months ended June 30, 2022, as compared to the nine months ended June 30, 2021, by \$4.9 million, or 6.0%, primarily due to \$24.8 million of lower accrued Part II incentive fees as a result of a reversal of previously accrued capital gains incentive fees driven by unrealized losses during the current period, partially offset by (1) a \$9.7 million increase in interest expense due to higher borrowings outstanding and the impact of rising reference rates, (2) \$5.9 million of higher base management fees (net of management fee waivers) primarily as a result of a larger investment portfolio and (3) a \$4.1 million increase in Part I incentive fees mainly due to higher total investment income, partially offset by higher interest expense and management fees.

## Net Investment Income

Primarily as a result of the \$2.3 million decrease in total investment income, the \$6.4 million decrease in net expenses and a \$0.4 million decrease in provision for taxes on net investment income, net investment income for the three months ended June 30, 2022 increased by \$4.4 million compared to the three months ended June 30, 2021.

Primarily as a result of the \$46.8 million increase in total investment income, the \$4.9 million decrease in net expenses and a \$3.0 million increase in the provision for taxes on net investment income, net investment income for the nine months ended June 30, 2022 increased by \$48.7 million compared to the nine months ended June 30, 2021.

#### Realized Gain (Loss)

Realized gains or losses are measured by the difference between the net proceeds from the sale or redemption of investments and foreign currency and the cost basis without regard to unrealized appreciation or depreciation previously recognized, and includes investments written-off during the period, net of recoveries. Realized losses may also be recorded in connection with our determination that certain investments are considered worthless securities and/or meet the conditions for loss recognition per the applicable tax rules.

During the three months ended June 30, 2022 and 2021, we recorded aggregate net realized gains of \$9.2 million and \$8.6 million, respectively, in connection with the exits of various investments and foreign currency forward contracts. During the nine months ended June 30, 2022 and 2021, we recorded aggregate net realized gains of \$19.9 million and \$22.7 million, respectively, in connection with the exits of various investments and foreign currency forward contracts. See "*Note 8. Realized Gains or Losses and Net Unrealized Appreciation or Depreciation*" in the notes to the accompanying Consolidated Financial Statements for more details regarding investment realization events for the three and nine months ended June 30, 2022 and 2021.

#### Net Unrealized Appreciation (Depreciation)

Net unrealized appreciation or depreciation is the net change in the fair value of our investments and foreign currency during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

During the three months ended June 30, 2022 and 2021, we recorded net unrealized appreciation (depreciation) of \$(86.8) million and \$3.9 million, respectively. For the three months ended June 30, 2022, this consisted of \$66.8 million of net unrealized depreciation on debt investments, \$17.9 million of net unrealized depreciation on equity investments, \$1.6 million of net unrealized depreciation of foreign currency forward contracts and \$0.4 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains). For the three months ended June 30, 2021, this consisted of \$12.3 million of net unrealized appreciation on debt investments, \$3.8 million of net unrealized appreciation on equity investments and \$1.1 million of net unrealized appreciation of foreign currency forward contracts, partially offset by \$13.3 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification related to exited investments (a portion of which resulted in a reclassification related to exited investments).

During the nine months ended June 30, 2022 and 2021, we recorded net unrealized appreciation (depreciation) of \$(118.4) million and \$116.6 million, respectively. For the nine months ended June 30, 2022, this consisted of \$84.6 million of net unrealized depreciation on debt investments, \$23.8 million of net unrealized depreciation on equity investments, \$9.2 million of net unrealized depreciation related to exited investments (a portion of which resulted in a reclassification to realized gains) and \$0.8 million of net unrealized depreciation of foreign currency forward contracts. For the nine months ended June 30, 2021, this consisted of \$79.7 million of net unrealized appreciation related to exited investments, \$30.7 million of net unrealized appreciation on equity investments, \$4.0 million of net unrealized appreciation related to exited in a reclassification to realized appreciation a reclassification to realized appreciation on equity investments, \$4.0 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized appreciation of net unrealized appreciation related to exited investments, \$4.0 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$2.2 million of net unrealized appreciation of foreign currency forward contracts.

## Financial Condition, Liquidity and Capital Resources

We have a number of alternatives available to fund our investment portfolio and our operations, including raising equity, increasing or refinancing debt and funding from operational cash flow. We generally expect to fund the growth of our investment portfolio through additional debt and equity capital, which may include securitizing a portion of our investments. We cannot assure you, however, that our efforts to grow our portfolio will be successful. For example, our common stock has generally traded at prices below net asset value for the past several years, and we may not be able to raise additional equity at prices below the then-current net asset value per share. We intend to continue to generate cash primarily from cash flows from operations, including interest earned, and future borrowings or equity offerings. We intend to fund our future distribution

obligations through operating cash flow or with funds obtained through future equity and debt offerings or credit facilities, as we deem appropriate.

Our primary uses of funds are investments in our targeted asset classes and cash distributions to holders of our common stock. We may also from time to time repurchase or redeem some or all of our outstanding notes. At a special meeting of our stockholders held on June 28, 2019, our stockholders approved the application of the reduced asset coverage requirements in Section 61(a)(2) of the Investment Company Act to us effective as of June 29, 2019. As a result of the reduced asset coverage requirement, we can incur \$2 of debt for each \$1 of equity as compared to \$1 of debt for each \$1 of equity. As of June 30, 2022, we had \$1,395.0 million in senior securities and our asset coverage ratio was 187.8%. During the quarter, the Company increased its target debt to equity ratio from 0.85x to 1.0x to 0.90x to 1.25x (i.e., one dollar of equity for each \$0.90 to \$1.25 of debt outstanding) to provide the Company with increased capacity to opportunistically deploy capital into the markets. As of June 30, 2022, our debt to equity ratio was 1.10x.

For the nine months ended June 30, 2022, we experienced a net increase in cash and cash equivalents (including restricted cash) of \$4.7 million. During that period, we used \$43.8 million of net cash from operating activities, primarily from funding \$620.8 million of investments and \$34.7 million of increase in due from broker (cash held at a broker to cover collateral obligations under the interest swap agreement), partially offset by \$554.9 million of principal payments and sale proceeds received, \$5.3 million of net decrease in receivables from unsettled transactions and the cash activities related to \$112.8 million of net investment income. During the same period, net cash provided by financing activities was \$49.4 million, primarily consisting of \$115.0 million of net borrowings under the credit facilities and \$20.6 million of proceeds (net of offering costs) from shares issued under the "at the market" offering, partially offset by \$85.1 million of cash distributions paid to our stockholders, \$0.9 million of repurchases of common stock under our dividend reinvestment plan, DRIP, and \$0.3 million of deferred financing costs paid.

For the nine months ended June 30, 2021, we experienced a net increase in cash and cash equivalents (including restricted cash) of \$48.4 million. During that period, we used \$35.9 million of net cash from operating activities, primarily from funding \$714.8 million of investments, partially offset by \$586.8 million of principal payments and sale proceeds received, \$20.9 million of cash acquired in the Mergers, the cash activities related to \$64.1 million of net investment income and \$18.3 million of net increase in payables from unsettled transactions. During the same period, net cash provided by financing activities was \$85.4 million, primarily consisting of \$349.0 million of borrowings of unsecured notes (net of OID), partially offset by \$190.5 million of net repayments under the credit facilities, \$54.3 million of cash distributions paid to our stockholders, \$9.3 million of repayments of secured borrowings, \$1.6 million of repurchases of common stock under our DRIP, and \$7.8 million of deferred financing costs paid.

As of June 30, 2022, we had \$36.3 million in cash and cash equivalents (including \$2.0 million of restricted cash), portfolio investments (at fair value) of \$2.6 billion, \$29.1 million of interest, dividends and fees receivable, \$455.0 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), \$5.3 million of net payables from unsettled transactions, \$745.0 million of borrowings outstanding under our credit facilities and \$611.6 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment).

As of September 30, 2021, we had \$31.6 million in cash and cash equivalents (including \$2.3 million of restricted cash), portfolio investments (at fair value) of \$2.6 billion, \$22.1 million of interest, dividends and fees receivable, \$470.0 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), \$0.1 million of net receivables from unsettled transactions, \$630.0 million of borrowings outstanding under our credit facilities and \$638.7 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment).

We may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of our portfolio companies. As of June 30, 2022, our only off-balance sheet arrangements consisted of \$232.1 million of unfunded commitments, which was comprised of \$183.1 million to provide debt and equity financing to certain of our portfolio companies and \$49.0 million to provide financing to the JVs. As of September 30, 2021, our only off-balance sheet arrangements consisted of \$264.9 million of unfunded commitments, which was comprised of \$212.4 million to provide debt and equity financing to certain of our portfolio companies, \$49.0 million to provide financing to the JVs and \$3.5 million related to unfunded limited partnership interests. Such commitments are subject to our portfolio companies' satisfaction of

certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in our Consolidated Statements of Assets and Liabilities.

As of June 30, 2022, we have analyzed cash and cash equivalents, availability under our credit facilities, the ability to rotate out of certain assets and amounts of unfunded commitments that could be drawn and believe our liquidity and capital resources are sufficient to take advantage of market opportunities in the current economic climate.

## **Contractual Obligations**

The following table reflects information pertaining to our principal debt outstanding under the Syndicated Facility (as defined below), Citibank Facility (as defined below), our 3.500% notes due 2025, or the 2025 Notes, and our 2.700% notes due 2027, or the 2027 Notes:

	Debt Outstandin as of September 30, 3		 Debt Outstanding as of June 30, 2022	eighted average debt outstanding for the nine months ended June 30, 2022	out nin	Aaximum debt tstanding for the ne months ended June 30, 2022
Syndicated Facility	\$ 495	5,000	\$ 575,000	\$ 548,846	\$	620,000
Citibank Facility	135	5,000	170,000	159,304		185,000
2025 Notes	300	0,000	300,000	300,000		300,000
2027 Notes	350	0,000	 350,000	 350,000		350,000
Total debt	\$ 1,280	0,000	\$ 1,395,000	\$ 1,358,150		

The following table reflects our contractual obligations arising from the Syndicated Facility, Citibank Facility, 2025 Notes and 2027 Notes:

		Payments due by per	iod as of June 30, 2022	
Contractual Obligations	Total	1-3 years	3-5 years	
Syndicated Facility	\$ 575,000	\$ —	\$	\$ 575,000
Interest due on Syndicated Facility	69,984	18,194	36,388	15,402
Citibank Facility	170,000	_	170,000	_
Interest due on Citibank Facility	16,900	7,074	9,826	_
2025 Notes	300,000	_	300,000	_
Interest due on 2025 Notes	27,933	10,500	17,433	_
2027 Notes	350,000	_	—	350,000
Interest due on 2027 Notes (a)	43,015	9,458	18,916	14,641
Total	\$ 1,552,832	\$ 45,226	\$ 552,563	\$ 955,043

20 2022

(a) The interest due on the 2027 Notes was calculated net of the interest rate swap.

## **Equity Issuances**

During the nine months ended June 30, 2022, we issued an aggregate of 212,382 shares of common stock as part of the DRIP.

On February 7, 2022, we entered into an equity distribution agreement by and among us, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by us of shares of common stock, having an aggregate offering price of up to \$125.0 million. Sales of the common stock, if any, may be made in negotiated transactions or transactions that are deemed to be "at the market," as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

In connection with the "at the market" offering, we issued and sold the following shares of common stock during the nine months ended June 30, 2022:

	Number of Shares Issued	Gros	ss Proceeds	Placement Agent Fees	Net	Proceeds (1)	erage Sales e per Share (2)
"At the market" offering	2,801,206	\$	21,049	\$ 210	\$	20,839	\$ 7.51

(1) Net proceeds excludes offering costs of \$0.2 million.

(2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses.

On March 19, 2021, in connection with the Mergers, we issued an aggregate of 39,400,011 shares of common stock to former OCSI stockholders. There were no other common stock issuances during the nine months ended June 30, 2021.

# Significant Capital Transactions

The following table reflects the distributions per share that we have paid, including shares issued under our DRIP, on our common stock since October 1, 2019:

Date Declared	Record Date	Payment Date	Amount per Share	Cash Distribution	DRIP Shares Issued (1)	DRIP Shares Value
November 12, 2019	December 13, 2019	December 31, 2019	\$ 0.095	\$ 12.9 million	87,747	\$ 0.5 million
January 31, 2020	March 13, 2020	March 31, 2020	0.095	12.9 million	157,523	0.5 million
April 30, 2020	June 15, 2020	June 30, 2020	0.095	13.0 million	87,351	0.4 million
July 31, 2020	September 15, 2020	September 30, 2020	0.105	14.3 million	102,404	0.5 million
November 13, 2020	December 15, 2020	December 31, 2020	0.11	15.0 million	93,964	0.5 million
January 29, 2021	March 15, 2021	March 31, 2021	0.12	16.4 million	81,702	0.5 million
April 30, 2021	June 15, 2021	June 30, 2021	0.13	22.9 million	76,979	0.5 million
July 30, 2021	September 15, 2021	September 30, 2021	0.145	25.5 million	85,075	0.6 million
October 13, 2021	December 15, 2021	December 31, 2021	0.155	27.2 million	107,971	0.8 million
January 28, 2022	March 15, 2022	March 31, 2022	0.16	28.5 million	104,411	0.8 million
April 29, 2022	June 15, 2022	June 30, 2022	0.165	29.4 million	131,028	0.9 million

 Shares were purchased on the open market and distributed other than with respect to the distributions paid on December 31, 2021 and March 31, 2022. New shares were issued and distributed during the quarters ended December 31, 2021 and March 31, 2022.

# Indebtedness

See "Note 6. Borrowings" in the Consolidated Financial Statements for more details regarding our indebtedness.

## Syndicated Facility

As of June 30, 2022, (i) the size of our senior secured revolving credit facility, or, as amended and/or restated from time to time, the Syndicated Facility, pursuant to a senior secured revolving credit agreement, with the lenders, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A. as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents, was \$1.0 billion (with an "accordion" feature that permits us, under certain circumstances, to increase the size of the facility to up to the greater of \$1.25 billion and our net worth (as defined in the Syndicated Facility) on the date of such increase), (ii) the period during which we may make drawings will expire on May 4, 2025 and the maturity date was May 4, 2026 and (iii) the interest rate margin for (a) LIBOR loans (which may be 1-, 2-, 3- or 6-month, at our option) was 2.00% and (b) alternate base rate loans was 1.00%.

Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. Borrowings under the Syndicated Facility are subject to the facility's various covenants and the leverage restrictions contained in the Investment Company Act. We cannot assure you that we will be able to borrow funds under the Syndicated Facility at any particular time or at all.

The following table describes significant financial covenants, as of June 30, 2022, with which we must comply under the Syndicated Facility on a quarterly basis:

<b>Financial</b> Covenant	Description	Target Value	March 31, 2022 Reported Value (1)
Minimum shareholders' equity	Net assets shall not be less than the sum of (x) $600$ million, plus (y) 50% of the aggregate net proceeds of all sales of equity interests after May 6, 2020	\$610 million	\$1,330 million
Asset coverage ratio	Asset coverage ratio shall not be less than the greater of 1.50:1 and the statutory test applicable to us	1.50:1	1.93:1
Interest coverage ratio	Interest coverage ratio shall not be less than 2.25:1	2.25:1	4.85:1
Minimum net worth	Net worth shall not be less than \$550 million	\$550 million	\$1,155 million

(1) As contractually required, we report financial covenants based on the last filed quarterly or annual report, in this case our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. We were in compliance with all financial covenants under the Syndicated Facility based on the financial information contained in this Quarterly Report on Form 10-Q.

As of June 30, 2022 and September 30, 2021, we had \$575.0 million and \$495.0 million of borrowings outstanding under the Syndicated Facility, respectively, which had a fair value of \$575.0 million and \$495.0 million, respectively. Our borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 2.406% and 2.202% for the nine months ended June 30, 2022 and 2021, respectively. For the three and nine months ended June 30, 2022, we recorded interest expense (inclusive of fees) of \$4.8 million and \$12.6 million, respectively, related to the Syndicated Facility. For the three and nine months ended June 30, 2021, we recorded interest expense (inclusive of fees) of \$4.0 million and \$10.5 million, respectively, related to the Syndicated Facility.

## Citibank Facility

On March 19, 2021, as a result of the consummation of the Mergers, we became party to a revolving credit facility, or, as amended and/or restated from time to time, the Citibank Facility, with OCSL Senior Funding II LLC, our wholly-owned, special purpose financing subsidiary, as the borrower, us, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. As of June 30, 2022, we were able to borrow up to \$200 million under the Citibank Facility (subject to borrowing base and other limitations). As of June 30, 2022, the reinvestment period under the Citibank Facility was scheduled to expire on November 18, 2023 and the maturity date for the Citibank Facility was November 18, 2024.

As of June 30, 2022, borrowings under the Citibank Facility are subject to certain customary advance rates and accrue interest at a rate equal to LIBOR plus between 1.25% and 2.20% per annum on broadly syndicated loans, subject to observable market depth and pricing, and LIBOR plus 2.25% per annum on all other eligible loans during the reinvestment period. In addition, as of June 30, 2022, for the duration of the reinvestment period there is a non-usage fee payable of 0.50% per annum on the undrawn amount under the Citibank Facility. The minimum asset coverage ratio applicable to us under the Citibank Facility is 150% as determined in accordance with the requirements of the Investment Company Act. Borrowings under the Citibank Facility are secured by all of the assets of OCSL Senior Funding II LLC and all of our equity interests in OCSL Senior Funding II LLC. We may use the Citibank Facility to fund a portion of our loan origination activities and for general corporate purposes. Each loan origination under the Citibank Facility is subject to the satisfaction of certain conditions.

As of June 30, 2022 and September 30, 2021, we had \$170.0 million and \$135.0 million outstanding under the Citibank Facility, respectively, which had a fair value of \$170.0 million and \$135.0 million, respectively. Our borrowings under the Citibank Facility bore interest at a weighted average interest rate of 2.563% and 2.198% for the nine months ended June 30, 2022 and the period from March 19, 2021 to June 30, 2021, respectively. For the three and nine months ended June 30, 2022, we recorded interest expense (inclusive of fees) of \$1.6 million and \$3.5 million, respectively, related to the Citibank Facility. For three months ended June 30, 2021 and the period from March 19, 2021 to June 30, 2021 to June 30, 2021, the Company recorded interest expense (inclusive of fees) of \$1.6 million, respectively, related to the Citibank Facility.

## 2025 Notes

On February 25, 2020, we issued \$300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the notes.

## 2027 Notes

On May 18, 2021, we issued \$350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8 million after deducting OID of \$1.0 million, underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the notes.

In connection with the 2027 Notes, we entered into an interest rate swap to more closely align the interest rates of our liabilities with our investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, we receive a fixed interest rate of 2.700% and pay a floating interest rate of the three-month LIBOR plus 1.658% on a notional amount of \$350 million. We designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship.

The below table presents the components of the carrying value of the 2025 Notes and the 2027 Notes as of June 30, 2022 and September 30, 2021:

	As of June 30, 2022				As of September 30, 2021			
(\$ in millions)	2	2025 Notes		2027 Notes		2025 Notes		2027 Notes
Principal	\$	300.0	\$	350.0	\$	300.0	\$	350.0
Unamortized financing costs		(2.0)		(3.4)		(2.6)		(4.0)
Unaccreted discount		(1.3)		(0.8)		(1.7)		(0.9)
Interest rate swap fair value adjustment				(30.9)		_		(2.1)
Net carrying value	\$	296.7	\$	314.9	\$	295.7	\$	343.0
Fair Value	\$	284.0	\$	301.1	\$	314.5	\$	351.1

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended June 30, 2022:

	2025 Notes				2027 Notes			
(\$ in millions)		nonths ended e 30, 2022		months ended ine 30, 2022		e months ended une 30, 2022		months ended ne 30, 2022
Coupon interest	\$	2.6	\$	7.9	\$	2.4	\$	7.1
Amortization of financing costs and discount		0.3		0.9		0.2		0.7
Effect of interest rate swap		—		_		(0.1)		(1.6)
Total interest expense	\$	2.9	\$	8.8	\$	2.5	\$	6.2
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)		3.500 %		3.500 %		2.572 %		2.069 %

The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended June 30, 2021:

	2025 Notes				2027 Notes			
(\$ in millions)		months ended ne 30, 2021		e months ended une 30, 2021		ee months ended June 30, 2021		months ended ine 30, 2021
Coupon interest	\$	2.6	\$	7.9	\$	1.1	\$	1.1
Amortization of financing costs and discount		0.3		0.9		0.1		0.1
Effect of interest rate swap		—				(0.3)		(0.3)
Total interest expense	\$	2.9	\$	8.8	\$	0.9	\$	0.9
Coupon interest rate (net of effect of interest rate swap for 2027 Notes)		3.500 %		3.500 %		1.813 %		1.813 %

## **Regulated Investment Company Status and Distributions**

We have qualified and elected to be treated as a RIC under Subchapter M of the Code for U.S. federal income tax purposes. As long as we continue to qualify as a RIC, we will not be subject to tax on our investment company taxable income

(determined without regard to any deduction for dividends paid) or realized net capital gains, to the extent that such taxable income or gains is distributed, or deemed to be distributed as dividends, to stockholders on a timely basis.

Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation. Distributions declared and paid by us in a taxable year may differ from taxable income for that taxable year as such distributions may include the distribution of taxable income derived from the current taxable year or the distributions also may include returns of capital.

To maintain RIC tax treatment, we must, among other things, distribute dividends, with respect to each taxable year, of an amount at least equal to 90% of our investment company taxable income (i.e., our net ordinary income and our realized net short-term capital gains in excess of realized net long-term capital losses, if any), determined without regard to any deduction for dividends paid. As a RIC, we are also subject to a federal excise tax, based on distribution requirements of our taxable income on a calendar year basis. We anticipate timely distribution of our taxable income in accordance with tax rules. We did not incur a U.S. federal excise tax for calendar years 2020 and 2021 and do not expect to incur a U.S. federal excise tax for calendar years.

We intend to distribute at least 90% of our annual taxable income (which includes our taxable interest and fee income) to our stockholders. The covenants contained in our credit facilities may prohibit us from making distributions to our stockholders, and, as a result, could hinder our ability to satisfy the distribution requirement associated with our ability to be subject to tax as a RIC. In addition, we may retain for investment some or all of our net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) and treat such amounts as deemed distributions to our stockholders. If we do this, our stockholders will be treated as if they received actual distributions of the capital gains we retained and then reinvested the net after-tax proceeds in our common stock. Our stockholders also may be eligible to claim tax credits (or, in certain circumstances, tax refunds) equal to their allocable share of the tax we paid on the capital gains deemed distributions for that fiscal and taxable year, a portion of those distributions may be deemed a return of capital to our stockholders.

We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, we may be limited in our ability to make distributions due to the asset coverage test for borrowings applicable to us as a Business Development Company under the Investment Company Act and due to provisions in our credit facilities and debt instruments. If we do not distribute a certain percentage of our taxable income annually, we will suffer adverse tax consequences, including possible loss of our ability to be subject to tax as a RIC. We cannot assure stockholders that they will receive any distributions or distributions at a particular level.

A RIC may treat a distribution of its own stock as fulfilling its RIC distribution requirements if each stockholder elects to receive his or her entire distribution in either cash or stock of the RIC, subject to certain limitations regarding the aggregate amount of cash to be distributed to all stockholders. If these and certain other requirements are met, for U.S federal income tax purposes, the amount of the dividend paid in stock will be equal to the amount of cash that could have been received instead of stock.

We may generate qualified net interest income or qualified net short-term capital gains that may be exempt from U.S. withholding tax when distributed to foreign stockholders. A RIC is permitted to designate distributions of qualified net interest income and qualified short-term capital gains as exempt from U.S. withholding tax when paid to non-U.S. shareholders with proper documentation. The following table, which may be subject to change as we finalize our annual tax filings, lists the percentage of qualified net interest income and qualified short-term capital gains for the year ended September 30, 2021.

Year Ended	Qualified Net Interest Income	Qualified Short-Term Capital Gains
September 30, 2021	89.8 %	

We have adopted a DRIP that provides for the reinvestment of any distributions that we declare in cash on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board of Directors declares a cash distribution, then our stockholders who have not "opted out" of the DRIP will have their cash distributions automatically reinvested in additional shares of our common stock, rather than receiving a cash distribution. If our shares are trading at a premium to net asset value, we typically issue new shares to implement the DRIP, with such shares issued at the greater of the most recently computed net asset value per share of our common stock or 95% of the current market value per share of our common stock on the payment date for such distribution. If our shares are trading at a discount to net asset value, we typically purchase shares in the open market in connection with our obligations under the DRIP.

## **Related Party Transactions**

We have entered into the Investment Advisory Agreement with Oaktree and the Administration Agreement with Oaktree Administrator, an affiliate of Oaktree. Mr. John B. Frank, an interested member of our Board of Directors, has an indirect pecuniary interest in Oaktree. Oaktree is a registered investment adviser under the Investment Advisers Act of 1940, as amended, that is partially and indirectly owned by Oaktree Capital Group, LLC. See "*Note 10. Related Party Transactions – Investment Advisory Agreement*" and "*– Administrative Services*" in the notes to the accompanying Consolidated Financial Statements.

## **Recent Developments**

#### Distribution Declaration

On July 29, 2022, our Board of Directors declared a quarterly distribution of \$0.17 per share, payable in cash on September 30, 2022 to stockholders of record on September 15, 2022.

## Rule 2a-5

On July 29, 2022, the Board of Directors appointed Oaktree as the valuation designee under Rule 2a-5 of the Investment Company Act effective September 8, 2022 for purposes of determining the fair value of our investments.

## Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are subject to financial market risks, including changes in the valuations of our investment portfolio and interest rates.

## Valuation Risk

Our investments may not have a readily available market price, and we value these investments at fair value as determined in good faith by our Board of Directors, with the assistance of the Audit Committee and Oaktree. There is no single standard for determining fair value in good faith and valuation methodologies involve a significant degree of management judgment. In addition, our valuation methodology utilizes discount rates in part in valuing our investments, and changes in those discount rates may have an impact on the valuation of our investments. Accordingly, valuations by us do not necessarily represent the amounts which may eventually be realized from sales or other dispositions of investments. Estimated fair values may differ from the values that would have been used had a ready market for the investment existed, and the differences could be material to the financial statements.

# Interest Rate Risk

We are subject to financial market risks, including changes in interest rates. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our risk management procedures are designed to identify and analyze our risk, to set appropriate policies and to continually monitor these risks. Our investment income will be affected by changes in various interest rates, including LIBOR, SOFR, SONIA and prime rates, to the extent our debt investments include floating interest rates.

As of June 30, 2022, 87.8% of our debt investment portfolio (at fair value) and 87.6% of our debt investment portfolio (at cost) bore interest at floating rates. As of September 30, 2021, 91.5% of our debt investment portfolio (at fair value) and 91.8% of our debt investment portfolio (at cost) bore interest at floating rates. The composition of our floating rate debt investments by interest rate floor as of June 30, 2022 and September 30, 2021, was as follows:

		June 30, 2022 September 30, 2021					
(\$ in thousands)	]	Fair Value	% of Floating Rate Portfolio	Fair Value	% of Floating Rate Portfolio		
0%	\$	256,910	11.9 %	\$ 322,222	14.6 %		
>0% and <1%		362,178	17.0 %	283,065	12.8 %		
1%		1,452,203	68.0 %	1,507,977	68.4 %		
>1%		65,328	3.1 %	92,384	4.2 %		
<b>Total Floating Rate Investments</b>	\$	2,136,619	100.0 %	\$ 2,205,648	100.0 %		

Based on our Consolidated Statement of Assets and Liabilities as of June 30, 2022, the following table shows the approximate annualized net increase (decrease) in net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investment and capital structure. However, there can be no assurances our portfolio companies will be able to meet their contractual obligations at any or all levels on increases in interest rates.

(\$ in thousands) Basis point increase	Increase in Interest Income		(Increase) in Interest Expense	Net increase in net assets resulting from operations	
250	\$ 54	4,812 9	\$ (27,375)	\$ 27,437	
200	43	3,780	(21,900)	21,880	
150	32	2,802	(16,425)	16,377	
100	21	1,866	(10,950)	10,916	
50	1(	0,933	(5,475)	5,458	

(\$ in thousands) Basis point decrease	ecrease) in erest Income	Decrease in Interest Expense		Net (decrease) in net assets resulting from operations	
50	\$ (10,789)	\$	5,475	\$	(5,314)
100	(19,446)		10,950		(8,496)
150	(24,552)		12,892		(11,660)
200	(26,628)		13,742		(12,886)

We regularly measure exposure to interest rate risk. We assess interest rate risk and manage our interest rate exposure on an ongoing basis by comparing our interest rate sensitive assets to our interest rate sensitive liabilities. Based on this review, we determine whether or not any hedging transactions are necessary to mitigate exposure to changes in interest rates. The following table shows a comparison of the interest rate base for our interest-bearing cash and outstanding investments, at principal, and our outstanding borrowings as of June 30, 2022 and September 30, 2021:

		June 30, 2022			September 30, 2021			
(\$ in thousands)	(	erest Bearing Cash and ivestments		Borrowings	Iı	nterest Bearing Cash and Investments		Borrowings
Money market rate	\$	8,657	\$		\$	23,600	\$	
Prime rate		2,285				305		10,000
LIBOR								
30 day		797,277		575,000		674,613		485,000
90 day (a)		831,103		520,000		1,037,019		485,000
180 day		300,499				323,869		_
360 day		33,861		_		96,095		_
EURIBOR								
30 day		25,967		_		28,786		_
90 day		17,680				19,599		_
180 day		2,053		_		18,516		_
SOFR								
30 day		82,763		_		_		_
90 day		88,208						_
SONIA								
30 day		26,112						_
180 day		22,633		_				_
Fixed rate		318,859		300,000		200,599		300,000
Total	\$	2,557,957	\$	1,395,000	\$	2,423,001	\$	1,280,000

(a) Borrowings include the 2027 Notes, which pay interest at a floating rate under the terms of the interest rate swap.

## Item 4. Controls and Procedures

#### (a) Evaluation of Disclosure Controls and Procedures

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2022. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of June 30, 2022, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in timely identifying, recording, processing, summarizing and reporting any material information relating to us that is required to be disclosed in the reports we file or submit under the Exchange Act.

There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### PART II

## Item 1. Legal Proceedings

We are currently not a party to any pending material legal proceedings.

#### Item 1A. Risk Factors

Except as set forth below, there have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended September 30, 2021.

# Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine.

The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the U.S., United Kingdom, and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia. We do not currently have investments in companies headquartered or that operate primarily in Russia or Ukraine. However, businesses in the United States and globally have experienced shortages in materials and increased costs for transportation, energy, and raw material due in part to the negative impact of the Russia-Ukraine military conflict on the global economy, all of which could have an indirect impact on our portfolio companies. Further escalation of geopolitical tensions related to the military conflict, including increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, supply disruptions, lower consumer demand, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business, financial condition and results of operations and that of our portfolio companies. In addition, the effects of the ongoing conflict could heighten many of our known risks described in the Company's Annual Report on Form 10-K for the year ended September 30, 2021.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

#### Item 3. Defaults Upon Senior Securities

None.

#### Item 4. Mine Safety Disclosures

Not applicable.

## Item 5. Other Information

None.

# Item 6. Exhibits

- <u>31.1\*</u> Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
- <u>31.2\*</u> Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
- <u>32.1\*</u> Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
- <u>32.2\*</u> Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
- \* Filed herewith.

# SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

# OAKTREE SPECIALTY LENDING CORPORATION

By:	/s/

Armen Panossian Chief Executive Officer

Armen Panossian

By: /s/ Christopher McKown

Christopher McKown Chief Financial Officer and Treasurer

Date: August 3, 2022

I, Armen Panossian, Chief Executive Officer of Oaktree Specialty Lending Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2022 of Oaktree Specialty Lending Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 3<sup>rd</sup> day of August, 2022.

By: /s/ Armen Panossian

Armen Panossian Chief Executive Officer I, Christopher McKown, Chief Financial Officer of Oaktree Specialty Lending Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2022 of Oaktree Specialty Lending Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated this 3<sup>rd</sup> day of August, 2022.

By: /s/ Christopher McKown

Christopher McKown Chief Financial Officer

#### Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)

In connection with the quarterly report on Form 10-Q for the quarter ended **June 30, 2022** (the "Report") of **Oaktree Specialty Lending Corporation** (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, **Armen Panossian**, the Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ Armen Panossian

Name: Armen Panossian

Date: August 3, 2022

#### Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)

In connection with the quarterly report on Form 10-Q for the quarter ended **June 30**, **2022** (the "Report") of **Oaktree Specialty Lending Corporation** (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, **Christopher McKown**, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

/s/ Christopher McKown

Name: Christopher McKown

Date: August 3, 2022